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Once you set out for Ithaka 
hope your road to be long, 
full of adventures, full of knowledge. 
  
Don't be afraid of the Laistrygonians and the Cyclops, 
the angry Poseidon 
you'll never find them on your way 
if you keep your thoughts high, 
if rare excitement touches your spirit and your body. 
  
You won't meet the Laistrygonians and the Cyclops, 
the wild Poseidon 
unless you bring them along inside your soul, 
unless your soul puts them in front of you. 
  
Hope your road to be long 
may there be many summer mornings 
when you'll enter with pleasure, with joy, 
the harbours you've seen for the first time 
  
Stop in Phoenician trading stations 
and get the good wares 
pearls and corals, ambers and ebony, 
and sensual herbs of every kind 
as many sensual herbs as you can 
  
Go to many Egyptian cities 
to study and learn from the educated ones 
keep Ithaka always in your mind 
your arrival there is your destiny 
  
But don't rush the journey at all 
it better lasts for many years, 
and then when you're old to stay on the island, 
wealthy with all you've gained on the way 
without expecting Ithaka to make you rich. 
  
Ithaka gave you the beautiful journey. 
without her you wouldn't have set out 
there's nothing else to give you anymore 
  
And if you find her poor, Ithaka hasn't fooled you. 
now that you became wise with so much experience 
you should have already understood what Ithakas mean 
 
 
Kostantinos Kavafis 
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Abstract 
Intestinal epithelial cells (IECs) lining the surface of our gastrointestinal tract tolerate the 
presence of the commensal microbiota, while maintaining responsiveness against enteric 
pathogens. How IECs regulate their innate immune response to maintain this finely tuned 
balance and establish an immune-homeostatic state in the gut remains unclear. Interferons 
(IFNs) are cytokines produced upon viral infection. While type I IFN receptors are 
ubiquitously expressed, type III IFN receptors are preferentially expressed on epithelial cells. 
This epithelium specificity strongly suggests exclusive functions at epithelial surfaces, but 
the relative roles of type I and type III IFNs in the establishment of an antiviral response in 
human IECs are not clearly defined.  
Here, we utilized human mini-gut organoid cultures and human colon cell lines to delve into 
the antiviral properties of type I versus type III IFNs in the gut. We could show that although 
primary human IECs, produce transcript levels for both IFNs, they secrete only type III IFNs 
in the supernatant upon viral challenge. However, using genetic ablation of either type I or 
type III IFN receptors, we revealed that human IECs respond to both IFNs, by independently 
establishing an antiviral state, responsible for combating enteric viral infection. Importantly, 
we could identify differences in the establishment of each IFN antiviral activity. Contrary to 
type I IFN, the antiviral activity induced by type III IFN is strongly dependent on the mitogen-
activated protein kinases signaling pathway, suggesting a pathway used by type III IFNs that 
non-redundantly contributes to the antiviral state. In addition, we showed that while type I 
IFN signaling is characterized by an acute strong induction of ISGs and confers fast antiviral 
protection, type III IFN mediated antiviral protection is characterized by a slow weak 
induction of ISGs. Combining data-driven mathematical modeling with experimental 
validation, we demonstrated that these kinetic differences are intrinsic to each signaling 
pathway and not due to different expression levels of the corresponding IFN receptors.  
In conclusion, our results strongly suggest that type III IFN is specifically tailored to act on 
epithelial cells not only due to the restriction of its receptor but also by providing IECs with a 
distinct antiviral environment compared to type I IFN, which allows for efficient protection 
against pathogens without producing excessive inflammatory signals. We propose that this 
specific antiviral environment is key for mucosal surfaces, which are often challenged with 
the extracellular environment, to maintain gut homeostasis. 
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Zusammenfassung 
Intestinale Epithelzellen, welche den gastointestinalen Trakt auskleiden, tolerieren die 
kommensale Darmflora während sie gleichzeitig gegen Darmpathogene reagieren. Es ist 
nicht klar, wie intestinale Epithelzellen ihre angeborene Immunabwehr regulieren, um im 
Darm das feinabgestimmte Gleichgewicht aufrecht zu erhalten und die Immunhomöostasis 
zu erreichen. Interferone sind Zytokine, welche bei viralen Infektionen produziert werden. 
Typ-I Interferonrezeptoren werden ubiquitär exprimiert, wohingegen Typ-III 
Interferonrezeptoren hauptsächlich auf Epithelzellen exprimiert werden. Diese Spezifität für 
Epithelien suggeriert eine Funktion ausschließlich in epithelialen Oberflächen, aber die 
jeweilige Rolle von Typ-I und Typ-III Interferonen bei der Etablierung einer antiviralen 
Immunantwort in humanen Epithelzellen ist nicht klar definiert.  
Wir benutzten humane Miniatur-Darm Organoidkulturen und humane Dickdarmzelllinien, um 
die antiviralen Eigenschaften von Typ-I im Vergleich zu Typ-III Interferonen zu untersuchen. 
Wir konnten zeigen, dass bei viraler Infektion nur Typ-III Interferone von primären humanen 
Epithelzellen in den Zellkulturüberstand sekretiert werden, obwohl beide Interferone auf 
Transkriptebene produzieren werden. Jedoch konnten wir mit genetischer Entfernung von 
Typ-I oder Typ-III Interferonrezeptoren zeigen, dass intestinale Epithelzellen auf beide 
Interferone reagieren, indem diese unabhängig von einander einen antiviralen Zustand 
erzeugen, der für die Bekämpfung von viralen Darminfektionen verantwortlich ist. Wir 
konnten wichtige Unterschiede in der Herbeiführung der antiviralen Aktivität der einzelnen 
Interferone identifizieren. Im Unterschied zu Typ-I Interferonen ist die antivirale Aktivität, 
welche von Typ-III Interferonen herbeigerufen wird, stark abhängig vom „mitogen-activated 
protein kinases“-Signalweg, was darauf hindeutet, dass ein nicht redundanter Signalweg 
zum Typ-III interferoninduzierten antiviralen Zustand beiträgt. Außerdem war es uns möglich 
zu zeigen, dass die durch Typ-I Interferone ausgelöste Signaltransduktion zu eine 
charakteristischen starken und akuten Induktion von interferonstimulierten Genen führt und 
einen schnellen antivirale Schutz gewährleistet, im Gegensatz zum antiviralen Schutz, 
welcher durch Typ-III Interferone erzeugt wird, der sich durch eine langsame Induktion von 
interferonstimulierten Genen auszeichnet. Die Verknüpfung von datengetriebener 
mathematischer Modellierung mit experimenteller Validierung zeigte, dass diese kinetischen 
Unterschiede intrinsisch für den jeweiligen Signalweg sind und nicht durch unterschiedliche 
Expressionsniveaus der zugehörigen Interferonrezeptoren hervorgerufen wird. 
Zusammenfassend betrachtet lassen unsere Daten darauf schließen, dass im Vergleich zu 
Typ-I Interferone, Typ-III Interferone spezifisch dafür produziert werden, auf Epithelzellen zu 
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wirken, nicht nur durch Beschränkung der Rezeptorexpression sondern auch durch das 
Bereitstellen einer eigenen antiviralen Umgebung für intestinale Epithelzellen, welche einen 
effizienten Schutz gegen Pathogene ohne übermäßige Entzündungsreaktion gewährleistet. 
Wir glauben, dass diese spezifische antivirale Umgebung sehr wichtig für die 
Aufrechterhaltung des Darmgleichgewichts durch die Oberflächen von Schleimhäuten ist, da 
diese der extrazellulären Umgebung ausgesetzt sind. 
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1 Introduction 
1.1 Gastrointestinal tract: cellular composition and immune response 
Mucosal tissue, strategically lining the surface of the respiratory, gastrointestinal and 
reproductive tract, constitutes the physical, chemical and immunological barrier that 
separates the inner milieu of multicellular complex organisms from their external 
environments. The gastrointestinal (GI) tract, being the largest of these mucosal surfaces, 
acts as the site of continuous contact with a diverse range of dietary antigens and the 
trillions of microorganisms living in the intestinal lumen1,2. Thus together with its overall 
function in digestion, absorption and excretion, the GI tract is adapted to prevent the entry of 
undesired foreign antigens and luminal pathogens, while enabling the colonization by 
commensal microorganisms that contribute to the digestion and significantly impact the 
development of intestinal mucosal immunity3,4 
 
1.1.1 Cellular components of the intestinal mucosal epithelium 
To be able to function as a physical and immunological barrier with a primary role in 
digestion and absorption, the monolayer of the intestinal epithelium is composed of six 
differentiated cell types: the enterocytes, goblet cells, enteroendocrine cells, tuft cells, 
Microfold cells and Paneth cells  
Figure 1. Schematic of the human 
intestinal epithelium. The surface 
of the epithelium is organized in 
finger-like protrusions known as villi 
and gland-like invaginations into the 
underlying connective tissue called 
crypts. A number of different highly 
specialized cell types (enterocytes, 
goblet cells, enteroendocrine cells, 
tuft cells, M cells and Paneth cells) 
create the continuous monolayer of 
the epithelium, which separates the 
lumen of the gut from the lamina 
propria, consisting mainly of 
myofibroblasts and immune cells.  
The epithelium is renewing every 
three days and the crypts harbor the 
stem cell niche Adapted from Abreu, 
(2010)
27
. 
  Introduction 
 
 2 
Enterocytes or enteroabsorptive cells are the most abundant cell population of the 
intestinal epithelium. They are covering approximately the 80% of the epithelium both along 
the proximal-distal axis and the crypt-villus axis and they present phenotypic differences 
regarding their position and their interaction with the other cell types5,6. Enterocytes are 
highly polarized with an apical brush border covered with microvilli, which protects against 
unwanted antigens, produces digestive enzymes and contributes to nutrient absorption3,4. 
Apart from their primary functions, they further contribute to the immune response of the 
epithelium by expressing a number of innate immune receptors4,7. In addition to this, they 
also support the adaptive immune system in the gut by promoting the transcytosis of the 
secretory IgA (SIgA) into the lumen8. Goblet cells are scattered through the intestinal 
epithelium with their percentage increasing from the small to the large intestine9. They 
function as secretory cells, and are responsible for the production of the major components 
of the mucus matrix such as the Mucin A family of proteins. This semisolid heavily 
glycosylated mucus layer covers the intestinal mucosal surface and serves as a protective 
barrier which prevents the direct contact of large particles and pathogenic microorganisms 
with the intestinal epithelial cells10–12. In addition, by acting as a trap also for commensal 
bacteria, Goblet cells regulate the localization of the intestinal microflora by generating the 
mucus matrix6.  
Enteroendocrine cells are a rare population of secretory cells residing along the crypt-villus 
axis of the epithelium6. In response to different stimulus such as dietary substances or 
harmful signals, they produce a diverse range of neuropeptides and hormones, which they 
secrete into the bloodstream, transfer to the enteric nervous system or diffuse over a short 
distance13. Thus, they contribute to regulating the digestive activity of the intestine and to 
mucosal protection. Another rare secretory cell subset of the intestinal epithelium are the 
tuft cells14,15. Tuft cells act as chemosensory cells, which produce and release endogenous 
opioids and inflammatory mediators such as prostanoids. Furthermore, they are believed to 
serve as the only source of interleukin-25 (IL-25) in the gut and to play a crucial role against 
parasitic infections and allergic responses16. 
Microfold cells (M cells) are specialized epithelial cells, which are located at specific 
positions of the intestinal epithelium. In particular, they reside in the follicle-associated 
epithelium (FAE), which covers the secondary mucosa-associated lymphoid tissue (MALT) 
of the gut such as the Peyer’s Patches6. In addition to the FAE sites, cells refereed to as 
villous M cells can be found in the villi compartment. M cells’ primary role is to transfer 
antigens from the intestinal lumen to intraepithelial antigen-presenting cells in the 
subepithelial lymphoid tissues6. Thus, they function as antigen-sampling cells responsible for 
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controlling the lumen content and are able to initiate an immune response in the presence of 
danger signals from pathogenic microoorganisms17,18. M cells are characterized by a unique 
morphology, which facilitates their antigen-sampling role. First of all, in contrast to the typical 
enterocytes, their apical side is covered with a short microvilli which enables close contact 
with microorganisms. Secondly, at their basal side, they are characterized by a pocket-like 
structure occupied by lymphocytes, macrophages or dendritic cells6. In addition, they 
present a unique glycosylation pattern by expressing the α-(1,2)-fucose and the glycoprotein 
2 (GP2) on their surface, which facilitates bacteria binding and transcytosis19.  
Paneth cells are situated at the base of the crypts exclusively in the region of the small 
intestine. They are secretory cells that produce and release a diverse array of antimicrobial 
substances such as lysozymes, cathelicidins, defensins and C-type lectins20,21. In addition to 
this, they have an essential role in development, homeostasis and maintenance of the stem 
cell niche by providing a range of different growth factors to the Lgr5+ stem cells22. To be 
able to release high amounts of antimicrobial peptides and growth factors, Paneth cells are 
characterized by an extensive endoplasmic reticulum and Golgi system, which creates a lot 
of granules. Contrary to the other short-lived intestinal cell populations, Paneth cells are 
retained at the bottom of the crypts after their differentiation and live approximately six to 
eight weeks14,22.  
Intermingled with the Paneth cells, around ten to fifteen pluripotent stem cells are found at 
the very base of each crypt, which fuel the continuous self-renewal of the intestinal 
epithelium throughout life23,24. These Lgr5+ stem cells, known also as crypt base columnar 
(CBC) cells, are dividing approximately once per day, giving rise to one stem cell and one 
transient amplifying (TA) cell9,25. TA cells are rapidly proliferating, migrating upwards the 
crypt-villus axis and differentiate into one of the five specialized intestinal cell lineages: 
enterocytes, Goblet cells, enteroendocrinocytes, tuft cells and M cells14. The identity of each 
lineage is specified through a complex network of transcription factors, which are expressed 
in the presence of specific growth factors, cytokines, mitogenic stimuli and differentiation 
signals provided from the Paneth cells and the surrounding stroma cells.  
1.1.2 Immune response at the intestinal epithelium 
Numerous professional subepithelial immune cells such as T and B lymphocytes, 
macrophages, dendritic cells and intraepithelial lymphocytes (IELs) cohabit with the 
intestinal epithelium4. In particular, they are scattered through the lamina propria layer or 
they are collected in Peyer’s Patches or other sites of the mucosa-associated lymphoid 
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tissue (MALT). From these sites squeezed between the epithelial cells, the immune cells 
extend protrusions (transepithelial dendrites) to sample the content of the intestinal lumen 
and to elicit an adaptive immune response upon the recognition of foreign antigens or 
components of pathogenic microorganisms.  
However, multiple studies have demonstrated that the central mediator between the 
subepithelial immune cells and the luminal content is the intestinal epithelium. Being in a 
constant interplay with these professional immune cells, the intestinal epithelial cells (IECs) 
function as antigen presenting cells, which sample the external environment, decode the 
information and shift their gene expression profile to shape the epithelial host defense and to 
orchestrate the response of the adaptive immune branch5,7. Together with their primary role 
in the development of anti-pathogenic responses, IECs have the unique ability to direct a 
tolerogenic and immunoregulatory response by being in continuous interaction with 
symbiotic commensals. How IECs manage to tolerate the microbiota, while maintaining full 
responsiveness against enteric pathogens remains unclear. However, taking into account 
the importance of this finely tailored response in regulation of gut development, 
homeostasis, disease and inflammation, specific strategies of IECs have been proposed and 
discussed recently to explain how this subtly tuned balance is generated. 
IECs express a diverse variety of pattern-recognition receptors (PRRs) such as Toll-like 
receptors (TLRs), RIG-I-like receptors (RLRs) and NOD-like receptor (NLRs), which 
recognize a wide range of pathogen-associated molecular patterns (PAMPs), associated 
with pathogenic bacteria, parasites and viruses as well as with the commensal flora, 
nutrient-derived stimuli and self antigens4,26–28. Upon infection, PRRs’ stimulation initiates 
several signaling cascades to protect IECs against pathogens. Interestingly, in homeostatic 
conditions PRRs are also stimulated by several microbial stimuli present in the gut lumen but 
without causing a pro-inflammatory response. This constant homeostatic epithelial signaling 
has been proposed to be essential for the development of immune tolerance in IECs and for 
the maintenance of intestinal epithelial barrier integrity26,29.  
A second important feature of IECs that contributes to their altered responsiveness is their 
polarized organization. IECs are highly polarized cells with their apical side facing the lumen 
of the gut and their basolateral side attached to the lamina propria. Interestingly, taking into 
account that only the apical side of IECs is exposed to environmental stimuli and luminal 
microbes, it has been demonstrated that the localization of innate immune receptors in IECs 
is also influenced by the polarized nature of the cells18,26,30,31.  
Additionally, IECs posses the property of horizontal communication by lateral diffusion of 
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small molecules and signaling messengers or through gapjunctional intracellular pathways4. 
This form of cell-to-cell communication allows transferring of immune signals to neighboring 
cells and may also facilitate a well-orchestrated response on infection or tolerance to 
commensals32–34. 
Taken all together, homeostatic stimulation of innate immune receptors in combination with 
their functional compartmentalization and horizontal cell-to-cell communication are strategies 
that IECs have developed to tolerate the presence of the commensal microbiota while 
maintaining responsiveness against enteric pathogens. 
1.2 Interferons 
1.2.1 Interferons: Roles and classification 
Over fifty years have passed since interferons (IFNs) have been discovered by Isaacs and 
Lindemann for their ability to ‘’interfere’’ with influenza virus replication35. Since then it has 
been shown that animals can be protected against invading viruses and a diverse range of 
different pathogens via IFN-mediated innate immune responses36. When cells sense viral 
products, IFNs are produced and released, which in turn act in an autocrine or paracrine 
manner inducing the transcription of hundreds of antiviral molecules responsible for 
restriction of viral infection in target cells37. However, it is only the past decade that the 
complicated network of IFN family members, from their expression and signaling to their 
pleiotropic functions and therapeutic potential, has begun to be unraveled38–40. The IFN 
family of cytokines is divided into three types: I, II and III, based on common features in gene 
sequence, protein structure, expression pattern, receptor engagement and biological roles 
(Table 1).  
 
Type I IFNs 
Type I is the first group of IFNs discovered35. It is the largest and most thoroughly studied 
group within this cytokine family. In humans, type I IFNs consist of five subtypes: IFN-α, IFN-
β, IFN-ε, IFN-κ, and IFN-ω41–43 (Table 1). The human genome possesses 13 IFN-α genes 
(IFN-α1-13), with IFN-α1 and IFN-α13 encoding for identical protein sequences44. Type I IFN 
genes are syntenic in a single locus on chromosome 9 and show sequence homology, which 
suggests that their origin may have been from a common ancestor gene and the subtypes 
arose from duplication and diversification events45. Additionally, in mammals, all type I IFN 
genes lack introns, apart from IFN-κ gene, which has an intron in the 3’-UTR43,44. 
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Table 1: Members of  the human interferon (IFN) family.  
Adapted from Takaoka and Yanai, (2006)31. 
 
Type Subtype Receptors Gene locus 
Amino acid 
residues 
Molecular 
Weight (kDa) 
I IFN-α IFNAR1/IFNAR2 9p21 165-166
a
 15-23 
I IFN-β IFNAR1/IFNAR2 9p21 166
a
 15-23 
I IFN-ε IFNAR1/IFNAR2 9p21 208 24.4 
I IFN-κ IFNAR1/IFNAR2 9p21 180
a
 24.5 
I IFN-ω IFNAR1/IFNAR2 9p21 172
a
 20-23 
II IFN-γ
b
 IFNGR1/IFNGR2 12q24.1 146
a
 34 
III IFN-λ1 IFNLR1/IL10Rb 19q1 200 20-33
c
 
III IFN-λ2 IFNLR1/IL10Rb 19q1 200 22 
III IFN-λ3 IFNLR1/IL10Rb 19q1 196 22 
III IFN-λ4 IFNLR1/IL10Rb 19q1 179 20 
a
: signal peptides are not included 
b
: acts as a homodimer 
c
: due to its glycosylation 
 
Type I IFNs are pleiotropic cytokines, which exhibit a wide diversity of biological functions 
including antiviral, anti-proliferative and immunomodulatory activities in innate and adaptive 
immune responses. Since their pharmaceutical approval, type I IFNs, have also been used 
as potential anticancer agents and as treatment against several microbial infections46. 
Although type I IFNs are produced by almost all cell types, the different subtypes present 
some degree of cell type-specific expression. In particular, IFN-α is primarily expressed by 
leukocytes47, with plasmacytoid dendritic cells (pDCs) to serve as the main source upon viral 
infection48,49. IFN-β is produced by most cell types, especially fibroblasts50. Similar to IFN-α, 
IFN-ω is mainly produced by leukocytes and shows similar biological functions51, whereas 
IFN-κ expression is limited to keratinocytes and IFN-ε is mainly associated with the antiviral 
protection of the female reproductive tract43,52. Interestingly, apart from their limited structural 
similarity, all 17 subtypes signal through a common ubiquitously expressed heterodimeric 
receptor complex, composed of a single chain of IFN-α receptor 1 (IFNAR1) and IFN-α 
receptor 2 (IFNAR2)41,53. 
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Type II IFNs  
Contrary to type I IFNs, the type II IFN family consists of a sole member (IFN-γ), which 
signals as a homodimer and shows low sequence similarity with the other IFNs54 (Table 1). 
IFN-γ is mainly expressed by immune cells and especially by macrophages, natural killer 
cells and activated T cells and although its production is not directly induced by viral 
infection, it shows response against viruses, as well as against intracellular bacteria and 
parasites55. In addition to this, while type I and type III IFNs are perceived as the main 
antiviral mediators, IFN-γ is frequently considered as an immunomodulatory cytokine. IFN-γ 
interacts with a tetrameric complex, including two subunits of IFN-γ receptor 1 (IFNGR1) and 
two subunits of IFN-γ receptor 2 (IFNGR2)54. IFNGR ternary complex presents a broad 
tissue expression pattern, giving the potential that all cell types can respond to IFN-γ56.  
 
Type III IFNs  
More recently in 2003, the first members of type III IFN family, also termed as IFN-λs were 
discovered by two independent research groups. These novel cytokines, were initially 
characterized to exert antiviral activity similar to those of type I IFNs38,39. Initially, they were 
named interleukin-28 (IL-28) and IL-29 and grouped together with IL-10 family members 
based on their interaction with the IL-10 receptor subunit 2 (IL-10R2). However, subsequent 
studies have provided increasing evidence for their functional similarity with type I IFNs and 
for this they were considered as ‘’interferon-like cytokines’’57,58.  
 
Figure 2. Human type III IFNs. (A) Schematic of the genomic organization of IFNL genes in human 
chromosome 19. (B) Phylogenetic tree of type I, II and III IFNs together with members of the IL-10 
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family of cytokines. (C) Protein sequence alignment of type III IFNs. Adapted from Kotenko and 
Durbin, (2017)
44
. 
 
In humans, the type III IFN family consists of four members: IFN-λ1 (IL-29), IFN-λ2 (IL-28A), 
IFN-λ3 (IL-28B) and IFN-λ444 (Table 1). All type III IFN genes are clustered on human 
chromosome 19 (Figure 2A). Whereas in mice, two functional orthologs exist encoding IFN-
λ1 and IFN-λ2 and two pseudogenes IFNL1-P1 and IFNL1-P2, clustered on chromosome 
759. All different subtypes of type III IFNs are closely related. For example IFN-λ1 shares a 
high degree of similarity (around 80%) in amino acid sequence with IFN-λ2 and IFN-λ339,60 
(Figure 2B and 2C). Interestingly, IFN-λ2 and IFN-λ3 have almost indistinguishable amino 
acid sequences, 96% homology, which suggests that the evolution of type III IFNs has been 
subjected to positive selection via recent duplication events39,60. This might also reflect 
important and unique biological functions for type III IFNs, independently from the members 
of type I IFN family61.  
IFN-λ4 is the most recently described member of the family. It was identified in 2013 from 
genetic data in primary hepatocytes based on its 28% amino acid identity with the other type 
III IFNs40. This low similarity with the other type III IFN genes might suggest that IFN-λ4 has 
been introduced through a distinct duplication event58. The IFN-λ4 gene is located upstream 
of IFN-λ3 (Figure 2A) and is expressed only in a fraction of the human population, as in the 
most of individuals is out of frame and non-functional40,62. Due to a genetic polymorphism, in 
some individuals a 5’-proximal frameshift mutation is introduced which restores transcription 
of IFN-λ4 gene and the functional version of IFN-λ4 protein is produced, which shows 
antiviral potency similar to the other type III IFNs63. Notably, chronic hepatitis C virus (HCV) 
patients who express a functional IFN-λ4 version have been associated with poor 
spontaneous or IFN-α-induced clearance of HCV64,65. Thus it remains a paradox, how IFN-
λ4 can block viral replication on one hand and on the other hand leads to HCV resistance to 
IFN-α treatment65,66. 
Contrary to their common functional characteristics, type III IFNs share limited homology 
with type I IFNs, such as 15-19% of similarity in their amino acid sequence with IFN-α39,60. 
However, type III IFNs have been shown to share homology also with members of the IL-10 
family of cytokines, showing similarity of 11-13% in amino acid sequence with IL-10 and of 
15-19% with IL-2239,60 (Figure 2B). Despite this poor sequence conservation, type III IFNs 
have been shown to be closely associated in structure with the IL-10 superfamily 
cytokines67–69, which is related also with the fact that both type III IFNs and the cytokines of 
the IL-10 family signal through a common receptor subunit (IL-10R2). In addition to this, it 
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has been shown that the complex structures of IFN-λ1/IFNLR1, IL-10/IL-10R1 and IL-22/IL-
22LR1 present high similarity in their ligand-receptor docking topology68–71. 
Type III IFNs signal via a distinct heterodimeric receptor complex, composed of two chains: 
a unique alpha chain, the IFNLR1 (also known as IL-28Ra) and the IL-10Rb chain, which 
serves as a common receptor subunit for all the members of the IL-10 family (IL-10, IL-22 
and IL-26)41,72. Whereas the IL-10Rb subunit is broadly distributed in various cell types, the 
expression of IFNLR1 chain is predominately restricted to epithelial cells73–80. In addition to 
this preferential expression of IFNLR1 in epithelial cells of the lung, skin, gastrointestinal 
tract, reproductive tract and liver, also some immune cell populations, such as specific 
subsets of conventional dendritic cells (cDCs), plasmacytoid dendritic cells (pDCs), human 
monocyte-derived macrophages and neutrophils have been demonstrated to express 
IFNLR1 and in turn, it has been shown that type III IFN stimulation can significantly affect 
their immune properties74,81–89. Of note, in recent years, further investigation of type III IFN 
responses in immune cells has resulted in some controversial results about which immune 
cells express IFNLR1 or respond to type III IFNs90,91.  
Therefore, the limited distribution of IFNLR1 and cellular responsiveness to type III IFNs 
might reflect unique properties of these cytokines for the epithelium of mucosal surfaces. 
This hypothesis is further supported by the fact that epithelial cells are able to generate high 
amounts of type III IFNs upon viral infection74,79,80,92–100. Although, it has been also shown 
that similarly to type I IFNs, a range of primary human cell types of the hematopoietic 
lineage can produce type III IFNs, with cDCs and pDCs to serve as the main source among 
them83,85,101–103. 
1.2.2 Induction of type I and type III IFN production  
Apart from the central role of IFNs in controlling viral infections in all the different stages of 
viral lifecycle, there is an ever expanding set of functions discovered for type I and type III 
IFNs ranging from effects on cellular physiology such as regulation of cell survival, 
differentiation and proliferation, protein translation and metabolism to regulation of non-viral 
pathogenic infections and non-infectious diseases such as auto-immune and auto-
inflammatory conditions and cancer45,46,89,104–109. Therefore, it is not surprising that the 
expression of type I and type III IFNs is the result of an intricate network of different signaling 
pathways, molecular elements and transcriptional factors tightly regulated and well-
coordinated in all the different stages of IFN production. Additionally, the expression and 
action of many of these elements, responsible for IFN production, are themselves subjected 
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to both type I and III IFN control, leading to an even more complicated network of 
overlapping feed-forward and feedback loops45,110. 
 
Induction of type I and type III IFN production by PRRs 
Upon invasion of viruses, type I and type III IFN production is mediated by PRRs located on 
the cell surface or the endosomes, which sense a broad range of PAMPs including viral 
ligands, such as nucleic acids51,111 (Figure 3). On the endosomes, viral nucleic acids are 
sensed by the membrane-bound Toll-like receptors (TLRs), including TLR3, TLR7, TLR8 
and TLR947,58,74,101,112,113. Whereas, in the cytosol pathogen-derived RNA is recognized by 
the three members of the retinoic acid-inducible gene 1-(RIG-I)-like family of receptors 
(RLRs): the RIG-I, melanoma differentiation-associated protein 5 (MDA5), and laboratory of 
genetics and physiology 2 (LGP2)47,114. In addition, cytoplasmic DNA is recognized by the 
recently identified receptor cyclic GMP-AMP (cGAMP) synthase (cGAS), leading to IFN 
induction47,115 (Figure 3). While the PRRs responsible for type I and type III IFN production 
predominantly overlap, there is one exception of the cytosolic DNA sensor Ku70, which has 
been demonstrated to cause induction of type III IFNs but not type I116,117. 
 
Toll-like receptors (TLRs) 
TLRs are type I transmembrane proteins, acting as predominant PRRs that recognize a 
broad range of pathogenic ligands and DAMPs. Up to now, ten TLRs (TLR1-10) have been 
identified in human and mice and three more (TLR11-13) have been described only in 
mice111,118. Of the human TLRs, TLR3, TLR7, TLR8 and TLR9, act in endosomes, and are 
the most relevant to virus infection and IFN production, as they specialize in detecting viral 
genome or intermediates of virus replication (Figure 3). In particular, TLR3 binds to double 
stranded RNA and can recognize dsRNA viruses such as reoviruses119,120. TLR7 and TLR8 
are functionally related and can bind to single-stranded RNA of viruses. TLR9 binds to 
unmethylated CpG DNA on bacteria genome and viral DNA118. TLR7, TLR8 and TLR9 are 
expressed in a cell-specific manner and are mainly produced by innate immune cells, with 
pDCs to serve as the main cell type related to virus recognition and IFN production 
downstream of these TLRs50,111. While TLR3 is present in a range of different cell types 
including epithelial cells, endothelial cells, fibroblasts and astrocytes111. Interestingly, apart 
from its endosomal localization, the presence of TLR3 has been reported at the basolateral 
cell membrane of ileal and colonic epithelium27  and mainly at the apical surface of tracheal 
epithelium, leading to type III IFN production upon stimulation94. 
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Figure 3. Induction of type I and type III IFN upon viral infection. Viral products are sensed by 
intracellular pattern recognition receptors (PRRs), localized on the endosomes such as TLR3, 7, 8, 
and 9 or in the cytoplasm like RLRs (RIG-1 or MDA5), which in turn mediate IFN production through a 
range of different signaling pathways involving the IRFs, the NF-kB and the MAPKs. Adapted from 
Garcia-Sastre and Biron, (2006)
356
. 
 
All TLRs share a common structure consisting of an ectodomain with multiple leucine-rich 
repeats, responsible for ligand binding, a transmembrane domain and a cytoplasmic Toll-
interleukin (IL)-1 receptor (TIR) domain111,118. Ligand binding to TLR3, TLR7, TLR8 and 
TLR9 results in TLR dimerization and recruitment of TIR containing adaptor molecules such 
as the myeloid differentiation factor 88 (MyD88) and TIR-domain-containing adaptor-
molecule 1 (TRIF)57,111. Downstream of MyD88 and TRIF, a number of other signaling 
elements are recruited leading to the activation of three distinct pathways involving the IkB 
kinases (IKK) complex, TANK-binding kinase 1 (TBK1)/IKKe complex and the MAPK 
pathway121. In turn the IKKs promote downstream activation and nuclear translocation of 
nuclear factor kB (NF-kB)57,122, while TBK1 and IKKe phosphorylate and activate members 
of the interferon regulatory factor (IRF) family of transcriptional factors123. All together these 
pathways lead to the transcription of IFNs and other pro-inflammatory cytokines and 
chemokines.  
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RIG-I like receptors (RLRs) 
RLRs belong to the DExD/H box RNA helicase family. They function as cytoplasmic 
helicases, present in all cell types, and are responsible for the recognition of RNA derived 
from viruses and in some cases bacteria124 (Figure 3). The different RLRs present ligand-
dependent specificity. RIG-1 typically signals the presence of short 5′-triphosphate uncapped 
double or single- stranded RNA125,126. MDA5 recognizes longer and branched double-
stranded RNA molecules125, while LGP2 serves as an auxiliary receptor in fine-tuning the 
innate immune response upon RNA sensing127. As far as the recognition of enteric viruses 
by RLRs is concerned, it has been shown that MRV is recognized by both RIG-I and 
MDA5128, while other enteric viruses such as members of the picornavirus family, are 
recognized by MDA5129.  
In the absence of their ligands, RLRs are in an inactivated state. Upon binding of dsRNA or 
5’ppp-RNA to the central cleft in their C-terminal domain (CTD), a conformational change is 
induced, which uncovers their N-terminal caspase activation and recruitment domain 
(CARD)130. In turn, through their CARD domain, RLRs associate with the CARD domain of 
the membrane bound mitochondrial antiviral-signaling protein (MAVS), also known as IPS-1, 
VISA and Cardif131 and induce the aggregation of MAVS to a prion-like structure on the outer 
surface of mitochondrial membrane132. Following aggregation, MAVS promotes the 
recruitment of the kinases IKKs and TBK1, as well as members of the MAPKinase pathway, 
leading to the expression of type I and III IFNs and inflammatory cytokines via activation of 
the transcriptional factors NF-kB, IRFs and AP-1133.  
1.2.3 Transcriptional regulation of type I and III IFN gene expression: shared 
and distinct mechanisms 
The general paradigm of type I and type III IFN gene activation, involves the recruitment of 
specific transcription factors including NF-kB, IRFs and AP-1, which are activated 
downstream of the PRRs (Figure 4). In particular, the promoter of IFN-β gene consists of 
four positive regulatory domains (PRDI-IV), localized in close proximity. PRDI and PRDIII, 
serve as the binding sites for IRF3 and IRF7, respectively, while the p50/RelA NF-kB 
complex interacts with PRDII and the ATF-2/c-Jun AP-1 complex is recruited in the PRDIV 
site of the IFN-β gene promoter134. Notably, it has been shown that upon viral infection, 
expression of the IFN-β gene requires the well orchestrated and cooperative binding of all 
these transcriptional factors in a complex known as the “enhanceosome”134–136. While IRF3 
and IRF7 play a universal role in the induction of type I IFNs, the temporal sequence of their 
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engagement in the promoter of the IFN genes varies. Specifically, IRF3, being ubiquitously 
and constitutively expressed in cells, functions as the early activator upon viral infection, 
whereas IRF7 requires an IFN positive feedback loop for its expression and acts with 
delayed kinetics45,110,137.  
In contrast with IFN-β, the IFN-α gene expression requires the binding only of the members 
of the IRF transcription factor family138 and is preferentially expressed by IRF7139 (Figure 4). 
Except for IRF3 and IRF7, IRF1, IRF4, IRF5 and IRF8 have been described to be involved in 
the expression of the different IFN-α subtypes in a cell type-dependent manner138. This 
diversity of different IRF transcriptional factors may reflect a degree of gene specific 
regulation for the different type I IFN subtypes, as their promoters may present differential 
affinities for each IRF element45,139.  
The expression of type III IFN genes has been shown to be mediated by either the IRF or 
the NF-kB signaling pathway114,140,141, without AP-1 being involved114 (Figure 4). Again, 
contrary to type I IFNs, IRF3, IRF7 and NF-kB can act independently on type III IFN 
promoters, without the need of acting in concert for type III IFN synthesis142,143. However, 
there are also similarities in the regulation of type III and type I IFN genes. Specifically, it has 
been described that the early expression of IFNL1 displays similar regulation as the IFN-β 
gene, induced by NF-kB, IRF3 and IRF7. While similarly to IFN-α gene, the IFNL2 and 
IFNL3 expression depends more on IRF7 and seems to be delayed141,144. Based on this, a 
positive feedback mechanism between type I and III IFN production has been described, 
with both IFN-λ1 and IFN-β being able to prime IFN-α, IFN-λ2 and IFN-λ3 gene expression 
through IRF7 upregulation upon viral infection110,137,145. 
 
Figure 4. Promoter and enhancer regions involved in type I and type III IFN expression. A 
similar set of transcriptional factors regulates type I and type III IFN production with distinct 
mechanisms. IFN-β promoter activation requires coordinated binding of IRFs, NF-kB and AP1, while 
IFN-α transcription is mainly dependent on IRFs. IFN-λ1 gene can be activated by either IRFs or NF-
kB and IFN-λ2,3 expression is largely IRF7 dependent Adapted from Durbin et al., (2013)
51
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1.3 Type I and type III IFN signaling and the effector mediators from the 
IFN receptor to the nucleus 
Upon secretion, type I and type III IFNs act in an autocrine, paracrine, or systemic manner to 
induce different cellular responses, with their antiviral activity through the expression of 
antiviral genes to be the best characterized. IFN-induced assembly of the receptor ternary 
complex happens sequentially in a two-step binding event, which induces a conformational 
change in the intracellular part of the receptor subunits. The IFN receptor does not contain 
any catalytic activity. Upon IFN-induced receptor activation, members of the receptor-
associated janus kinases (JAK) family, which are constitutively associated with the IFN 
receptor, are activated and in turn phosphorylate receptor tyrosine residues. This 
phosphorylation mediates the recruitment of signal transducer and activator of transcription 
(STAT) proteins, which are then phosphorylated by JAKs. STAT activation results in homo- 
or heterodimerization of STATs and the formation of the IFN-stimulated gene factor 3 
(ISGF3) complex, consisting of STAT1, STAT2, and IRF9. Translocation of ISGF3 or dimers 
of STATS to the nucleus regulates the expression of ISGs (Figure 5). 
 
Figure 5. Classical type I and type III IFN signaling pathway. Type I and type III IFNs signal 
through distinct complexes of heterodimeric receptors, which lead to the activation of the same 
JAK/STAT signaling cascade. Downstream of receptor activation, phosphorylated STAT1/STAT2 
together with IRF9 form the ISGF3 complex, which translocates into the nucleus and induces the 
upregulation of hundreds of interferon-stimulated genes (ISGs) Adapted from Galani et al., (2015)
60
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1.3.1.1 Type I and III IFN receptor system 
All the IFN receptors belong to the class II helical cytokine receptors (hCRs) family, which 
includes the receptors also for tissue factor (TF), IL-10, IL-20 and IL-22, and are 
characterized by a type III fibronectin (FBN-III) domain in their extracellular region72,146. In 
the type I IFN receptor complex, IFNAR1 is considered the low affinity binding chain, while 
IFNAR2 serves as the high affinity one147–151. Remarkably, IFNAR1 is also required for the 
recognition of the different type I IFN subtypes152,153. It has been shown that the binding 
affinity to the IFNAR complex varies toward the different type I IFNs, correlating with the 
differences in the biological activities of type I IFN subtypes150,154. While all IFN-αs present 
similar low affinity for IFNAR1, IFN-β binds IFNAR1 more tightly149,151. This difference is in 
turn reflected in a stronger antiviral, anti-proliferative and transcriptional activity of IFN-β 
compared to IFN-α154,155. In addition to this, binding of the different type I IFN subtypes to 
their receptor might cause a different conformational assembly of the receptor ternary 
complex leading to differential activities156. Interestingly, it has also been reported that IFN-β 
is able to signal only by binding to the IFNAR1 subunit52.  
Although, two splice variants of IFNAR1 have been identified, further bioinformatic analysis 
confirmed the presence of only one variant, suggesting cell type specific expression of the 
former or an experimental artifact157,158. Unlike IFNAR1, IFNAR2 exists as three isoforms: 
IFNAR2c, IFNAR2b and the soluble form sIFNAR2a152,153. They are all generated from the 
same gene by alternative splicing and possible protease processing. Among them, IFNAR2c 
is the productive ‘’long’’ transmembrane form of IFNAR2, containing all the crucial signaling 
domains and thereby being responsible for the antiviral function of type I IFNs147. IFNAR2b 
is a short transmembrane form lacking the intracellular domain and suggested to serve as a 
decoy receptor blocking the IFN signaling159. sIFNAR2a is truncated before the 
transmembrane region and shown to circulate in the blood acting as either an agonist or 
antagonist. An alterative role suggested to be ascribed to sIFNAR2a is to mediate IFN 
biological effects by a mechanism known as ‘’trans-signaling’’, whereby sIFNAR2a can bind 
IFN-α or IFN-β and present them to IFNAR1, resulting in the induction of the IFN signal160,161. 
In type III IFN receptor complex, IFNLR1 (IL28RA) exists in three different isoforms 
generated from alternative splicing: IFNLR1v1, IFNLR1v2 and IFNLR1v3. IFNLR1v1 and 
IFNLR1v2 differ in their intracellular region, where IL28RAv3 is lacking a region of 29 amino 
acids. IFNLR1v3 is a truncated form predicted to serve as a non-functional soluble IFNLR1 
form, as it is missing the transmembrane and the extracellular domains39. Expression of a 
non-functional splice variant has been reported in pDCs162. Unlike type I IFNs, which signal 
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through their own unique receptor complex, the second chain of the type III IFN receptor 
complex, IL10RB is engaged also in the signaling cascade of IL-10, IL-22 and IL-26. 
Interestingly, a functional crosstalk of type III IFNs with IL-22 and IL-10 has been shown. In 
particular, in the presence of IL-10, inhibition of the type III IFN activity has been reported, 
suggesting a competition of type III IFNs with IL-10 for the IL10RB receptor163. Conversely, 
in a recent study, enhancement of the signaling activity and the antiviral properties of type III 
IFNs was shown in the presence of IL-2296. 
 In type III IFN receptor ternary complex, the IFNLR1 chain binds type III IFNs with high 
affinity, while IL10RB is the low affinity subunit. However, in comparison with type I IFNs, the 
binding affinity of type III IFNs for their receptor complex is much lower67,68. Even though all 
subtypes of type III IFN family bind to the same receptor complex, differences in their 
biological activities have been described. In particular, it has been shown that IFN-λ3 
exhibits the highest potency among the different human type III IFNs, which is reflected in 
their signaling and biological activity164,165.  
1.3.1.2 Regulation of type I and III IFN receptor cell surface levels  
Regulation of the IFN receptor cell surface levels by internalization and degradation, is 
considered to be the most specific and rapid step to limit IFN responses166. In a ligand 
dependent manner, the ternary IFNAR complex is internalized by clathrin-mediated 
endocytosis167,168 (Figure 6). Several differences have been noted in the downregulation 
mechanisms of IFNAR1 and IFNAR2153. Remarkably, upon type I IFN stimulation, IFNAR1 is 
rapidly endocytosed and routed for lysosomal degradation, whereas after endocytosis, 
IFNAR2 can be recycled back to the cell surface or degraded169,170. 
Based on these studies, the mechanism of internalization and degradation of the ternary 
IFNAR complex is mainly determined by the endocytosis of IFNAR1 chain. In particular, a 
linear tyrosine based sequence in IFNAR1 serves as an endocytic motif, which is recognized 
by the AP2 endocytic complex. In basal levels, this motif is constitutively associated with 
TYK2 and remains masked from AP2167,168. Upon stimulation, phosphorylation of this motif 
decreases its binding with TYK2 and facilitates its exposure to AP2. This mechanism 
explains the importance of TYK2 for IFNAR1 cell surface stability171,172. In addition, several 
ubiquitination sites within the cytoplasmic region of IFNAR1 have been described to facilitate 
its degradation167,173–175. Notably, the cell surface levels of IFNAR2 seems not to be 
regulated through ubiquitination dependent degradation176. Unlike the various mechanisms 
proposed to regulate the IFNAR cell surface levels, there is no literature available 
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concerning the molecular mechanisms underpinning the IFNLR internalization and recycling. 
1.3.1.3 Regulation of JAK activation 
The next step in the regulatory network of IFN responses, targets the interaction of IFNAR 
and IFNLR with downstream signaling elements. This step includes the interactions of IFN 
receptor with the members of the JAK family. In particular, in the course of the canonical 
type I and type III IFN pathway TYK2 pre-associates with IFNAR1 and IL10RB, while JAK1 
binds constitutively IFNAR2 and IL28RA. Interestingly, in two recent studies it was shown 
that JAK2 can be phosphorylated and activated downstream of the IFNLR and plays a 
specific role in the antiviral activity of type III IFNs114,177.  
Binding of the IFN, changes the proximity of the IFNAR1 and IFNAR2 and subsequently of 
the two kinases, leading to their activation via trans-phosphorylation at tyrosine residues 
Y1022 and Y1023 for JAK1 and Y1054 and Y1055 for TYK251. Activated JAKs 
phosphorylate IFN receptor chains at multiple sites, creating docking sites for STAT1 and 
STAT2 via their SH2 domain. Within the intracellular region of IFNAR2 tyrosine 
phosphorylation at residues Y337 and Y512 have been shown to be crucial for STAT1 and 
STAT2 recruitment178, while Y466 on IFNAR1 is also considered important for STAT2 
activation179. Multiple other sites have been reported to play a role in IFNAR signaling in 
different human or mouse cell lines51.  
Although the IFNLR activation has not been investigated in such a detail, two tyrosine 
residues on IFNLR1 Y343 and Y517 have been shown to mediate STAT2 activation. 
Notably, the Y343 based motif of IFNLR1 resembles the sequence surrounding the Y466 of 
IFNAR1 and the C-terminal sequence including the Y517 of IFNLR1 shows some similarity 
with the C-terminal sequence containing the Y512 of IFNAR251,180. Although these motifs 
reflect a degree of similarity in the STAT2 docking sites between IFNAR and IFNLR, the 
intracellular regions of IFNAR2 and IFNLR1 are dramatically different145. Interestingly, a 
recent study has reported striking differences also in the formation of the ligand-receptor 
complex between type I and III IFNs, suggesting the involvement of different signaling 
cascades activated downstream of IFNLR or IFNAR complex181. 
1.3.1.4 Negative regulation of JAK activation 
As activation of IFN receptors and JAKs is mainly based on sequential phosphorylation 
events, a number of phosphatases have been shown to negatively modulate these 
components of IFN signaling cascade. In particular downstream of IFNAR, the protein-
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tyrosine phosphatase 1B (PTPB1)182 and T cell protein-tyrosine phosphatase (TCPTP)183 
have been shown to target TYK2, JAK2 and JAK1 for de-phosphorylation. The 
transmembrane PTPase CD45 has also been shown to serve as a JAK phosphatase in type 
I IFN dependent manner184.  
Apart from the reversal of JAKs’ activation, another negative regulation in the receptor levels 
includes the blockade of the binding of IFNR with JAKs. The ubiquitin-specific protease 
USP18, despite its role in ISGylation of certain substrates, binds IFNAR2 and prevents the 
interaction with JAK1185 (Figure 6). This association seems to be ligand dependent, as it 
inhibits specific signaling from IFN-α subtypes, which bind IFNAR2 with lower affinity in 
comparison with IFN-β186–188. USP18 dependent inhibition of IFN-α responses, can explain 
the shorter duration of IFN-α responses compared to IFN-β165,189. For type III IFNs, there is 
only one recent study showing a negative impact of USP18 on type III IFN induction of a 
subset of ISGs in the mouse system190.  
 
Figure 6. Negative regulation of type I IFN signaling at the receptor level. Upon IFN binding and 
activation of the JAK/STAT signaling cascade, the IFNAR complex is internalized by clathrin-mediated 
endocytosis, which is initiated by phosphorylation of IFNAR1 by Tyk2, leading to its ubiquitination. 
Another layer of IFNAR negative regulation is mediated by members of the SOCs family, which bind 
to TYK2, or by USP18, which interacts with IFNAR2 and suppresses IFNAR complex formation. 
These negative regulators are ISGs, which are expressed upon IFN signaling, promoting the negative 
feedback and ensuring IFNAR receptor inactivation. Adapted from Schreiber et al., (2017)
357
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In addition, members of the suppressor of cytokine signaling (SOCS) family such as SOCS1 
and SOCS3 can interact with TYK2 and thereby negatively regulating the activation status of 
TYK2191 (Figure 6). Among SOCS, SOCS1 is considered the more potent negative regulator. 
Recently, it has been shown that a SOCS1 dependent TYK2 destabilization, through 
ubiquitination, drives IFNAR1 downregulation192,193. Interestingly, it has also been described 
that type III IFNs up-regulate the expression levels of SOCS-1 and SOCS-3, suggesting a 
possible role of SOCS as negative regulators of type III IFNs signal transduction194,195. In 
addition, it should also be take into account that USP18 and SOCS are ISGs and might 
serve as a negative feedback loop in type I and type III IFN signaling cascades153.  
1.3.2 Regulation of type I vs type III IFN signaling from the receptor to the 
nucleus: 
1.3.2.1 Regulation of STAT induction 
In the canonical type I and type III IFN signaling pathway the next players downstream the 
IFN receptors and JAKs are STAT1, STAT2 and IRF9, which are regulated at the level of 
expression and activation. A major layer of control of these factors, which are themselves 
ISGs, relies on transcriptional regulation. For type I IFN it has been shown, that under 
homeostatic conditions low quantities of IFN-β are secreted and lead to physiological 
significant levels of STAT1, STAT2 and IRF9 through an autocrine loop196. Interestingly, it 
has been reported that commensal pathogens can serve as the trigger for this constitutive 
production of IFN by epithelial and immune cells197,198. The maintenance of this pool of 
STATs and IRF9 in uninfected cells has been shown to be important not only for priming 
cells for a fast response upon infection but also by regulating the hematopoietic stem cells, 
activation of immune cells, and for anti-tumor responses. Lack of this constitutive expression 
has also been reported in autoimmune and inflammatory syndromes199.  
Apart from basal levels of expression in homeostatic conditions, in the presence of a 
stimulus such as elevated levels of type I, II IFNs or other cytokines such as TNF-α and IL-6, 
high expression levels of STAT1 and IRF9 lead to prolonged ISG expression and sustained 
antiviral protection200–202. For type I IFN, together with STAT1 and STAT2, STAT3, STAT4, 
STAT5 and STAT6 have been shown to be induced in certain cell types and participate in 
the antiviral and anti-proliferative actions of IFNs203–205. Similar to type I IFNs, STATs 1-5 can 
be induced downstream of IFNLR180,206,207. However, given that STAT 3, 4, 5 activation by 
type III IFN has been observed only in few cultured cell lines, these results have to be 
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explored in a wider range of cells and tissues where the antiviral effects of type III IFN have 
been reported. 
1.3.2.2 Regulation of STAT dimerization 
The availability of the different STATs is the crucial determinant in the next step of STAT 
dependent regulation, which involves the activation of STATs and the formation of homo and 
heterodimeric STAT complexes. Apart from the STAT1:STAT2 heterodimer, which together 
with IRF9 forms the ISGF3 transcriptional complex in the canonical type I and III IFN 
cascade, a wide range of almost all the possible combinations of STATs, including 
STAT1:STAT1, STAT3:STAT3, STAT4:STAT4, STAT5:STAT5, STAT6:STAT6, 
STAT1:STAT2, STAT1:STAT3, STAT1:STAT4, STAT1:STAT5, STAT2:STAT3 
STAT5:STAT6 have been reported in response to type I IFNs203,208,209 (Figure 7). The ISGF3 
transcriptional complex, binds a specific element in the promoter of ISGs denoted as IFN-
stimulated response element (ISRE). However, the rest of the STAT homo and hetero 
dimers, upon their formation, translocate to the nucleus and show a binding affinity for 
another element in the promoter of ISGs known as IFN-γ activated site (GAS) element. 
Interestingly, in the promoter region of ISGs there are multiple STAT binding sites, which 
can contain only ISREs, only GAS elements or both. In this way, different subsets of ISGs 
can be activated by differential induction of STAT-containing complexes203,208–210. Taken all 
together, it has become clear that the multiplicity of STAT complexes reflects a degree of 
ISG specificity.  
1.3.2.3 Alternative mechanisms of positive and negative regulation of STAT 
complexes 
 
Positive regulation of STATs complexes 
According to the classical signaling cascade of type I and type III IFNs, JAK dependent 
phosphorylation of STAT1 and STAT2 on tyrosines Y701 and Y609, respectively, drives 
their activation, dimerization and translocation to the nucleus. Nonetheless, a number of 
other modifications have been shown to positively regulate STATs action. For example, 
upon type I IFN stimulation, phosphorylation of STAT1 and STAT3 on serine S727 by cell 
specific kinases have been shown to enhance the transcriptional activity of STATs without 
being required for nuclear translocation211,212. Cyclin-dependent kinase 8213,214, protein 
kinase C (PKC) family members like PKC-delta (PKC-δ) and PKC-epsilon (PKC-ε)165,215  and 
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p38-MAPK pathway216 have been documented to mediate phosphorylation of STAT1 on 
S727. In addition, IκB kinase epsilon (IKKε)-mediated serine phosphorylation of STAT1 at 
residue S708 has been positively related with ISGF3 formation and enhancement of 
transcriptional activity and antiviral response of type I IFN123,217. Interestingly, Bolen et al, 
have observed serine phosphorylation of STAT1 on residue S727 downstream of type III IFN 
signaling in hepatocytes165. 
 
Negative regulation of STATs complexes 
In addition, a number of modulators have been demonstrated to negatively modify the 
functions of STATs and increase the complexity of IFNAR signaling.  This is mainly 
accomplished by members of the protein tryrosine phosphatase family218. For instance, Src 
Homology phosphatase 2 (SHP-2) has been shown to be constitutively associated with 
IFNAR. Upon type I IFN stimulation, SHP-2 is activated and blocks JAK1, STAT1 and 
STAT2 phosphorylation219,220. In addition, SH2 domain-containing tyrosine phosphatase, 
SHPTP1, which is mainly expressed by hematopoietic cells, can also inhibit type I IFN 
induced JAK1 and STAT1 activation in macrophages221. Furthermore, nuclear STAT1 
tyrosine phosphatases, such as TC45, a nuclear isoform of TCPTB, can target STAT1 and 
STAT3 phosphorylation downstream IFNAR222. Apart from phosphatase-dependent STAT 
deactivation, phosphorylation of STAT on residue S287 and T387 negatively regulates the 
transcriptional, antiviral and anti-proliferative actions of type I IFNs223,224.  
STAT1 is also negatively regulated by protein inhibitors of activated STAT (PIAS) family 
members. Recent studies have shown that PIAS1 and PIASy can bind STAT1 and block its 
transcriptional activity. In addition, STAT1 is also sumolylated by PIAS1225,226, but the 
functional importance of this modification for IFNAR-induced gene activation needs to be 
further elucidated. Notably, acetylation and methylation sites on STATs have been reported 
and are proposed as sites for further important post-translational modifications in their 
regulated architecture227,228. 
1.3.2.4 Un-phosphorylated STAT complexes 
In addition to the formation of the canonical ISGF3 complex, in certain milieu, the formation 
of alternative ISGF3 complexes containing unphosphorylates STATs have been reported. In 
addition, the ISGF3II complex, including phosphorylated STAT1, unphosporylated STAT2 
and IRF9, and the ISGF3-like complex formed by STAT2 and IRF9 have been shown to be 
assembled mainly upon type I and II IFN treatment229–231. 
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1.3.2.5 JAK-STAT independent pathways triggered by type I and III IFNs 
Apart from the above-mentioned canonical and non-canonical pathways involving the JAK-
STAT axis, there is accumulating evidence that link the ISG transcription upon IFN treatment 
with a plethora of JAK-STAT independent cascades such as the Crk-like protein (CrkL)–Ras 
related protein 1 (RAP1) pathway232–235 the mitogen-activated protein kinase (MAPK) 
pathway209,236–238 and the phosphatidyl-inositol 3-kinase (PI3K)-signalling pathway209 (Figure 
7). We focus here on the role of members of the members of the MAP kinase family in type I 
and type III IFN-mediated signaling. 
1.3.2.6 MAP Kinases in type I and type III IFN-mediated signaling 
Type I IFN has been shown to signal through the MAP kinases pathway, including p38 
mitogen-activated protein kinase (MAPK), the extracellular signal-regulated kinase (ERK) 
and the c-Jun N-terminal kinase (JNK) pathway in several IFN sensitive cell lines209,236–238. 
Among them, the p38 kinase is the best characterized and has been shown to be important 
for both the growth inhibitory and the antiviral functions of type I IFN in specific cell 
lines236,239–242.  
Although, p38 signaling pathway has been clearly shown to be activated downstream 
IFNAR, type I IFN dependent activation of ERK and JNK has not been investigated 
Figure 7. Alternative pathways activated 
downstream type I IFN receptor. 
Downstream the IFNAR complex, apart from 
the STAT1:STAT2 heterodimer, which 
together with IRF9 forms the ISGF3 
complex, other STAT homo and 
heterodimers are formed or alternative 
pathways including the MAPKs and the PI3K 
are activated downstream IFNAR complex 
and lead to the upregulation of ISGs through 
the same or different promoter elements. 
Adapted from McNab et al., (2015)
358
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thoroughly. Few studies have shown a cell specific activation of ERK and its involvement in 
IFN-α mediated antiviral activity against HCV and myxoma virus243,244. For JNK even more 
limited information is available. Li et al., have demonstrated JNK involvement in type I IFN 
antiviral responses by elimination of infected cells through apoptosis245.  
Similar to type I IFNs, activation of p38, ERK and JNK has been shown upon type III IFN 
treatment in a cell dependent manner104,207,237. However, in contrast to type I IFN, there is no 
conclusive information regarding the precise mode of action of these kinases in IFNLR 
signaling. Interestingly, although initially fibroblasts were considered as not sensitive to type 
III IFN treatment, Alase et al., showed that epidermal fibroblasts respond to type III IFN in a 
MAP Kinase dependent manner which leads to ISG induction and TGF-β induced collagen 
production. This recent study indicates a specific role of IFNLR-dependent MAP kinase 
activation in antiviral protection and repair processes of epidermal tissue104.  
1.3.3 Regulation of type I versus type III IFN signaling in the nucleus 
The next step downstream, in the formation of the canonical ISGF3 complex or the 
activation of the above-described alternative signaling events takes place in the nucleus and 
drives the transcription of ISGs. Recent studies have described several regulatory 
mechanisms in the nucleus after type I IFN treatment, which can be mainly assessed in two 
layers: first, at the level of IFN-dependent chromatin remodeling at the target gene loci of 
ISGs and secondly, at the layer of interactions of STATs with other transcriptional factors, 
which are induced by the IFN pathway or by heterologous signaling cascades.  
1.3.3.1 Epigenetic regulation of IFN responses 
An emerging field in the regulation of IFN responses involves epigenetic modification. 
Epigenetic modifications are mediated by chromatin modulators such as histone 
acetyltransferases (HATs), which induce transcription by transforming chromatin into a more 
relaxed state or by histone deacetylases (HDACs), which inhibit gene induction by keeping 
chromatin into a highly organized condensed state. In addition, co-activators and co-
repressors play an important role by facilitating interactions of specific transcriptional 
complexes (for instance, ISGF3 in the case of IFN responses) with the general 
transcriptional machinery and with chromatin modulators246. 
The focus on IFN-dependent epigenetic regulation is driven by recent studies, which show a 
high degree of nucleosome occupancy in the promoter region of ISGs, suggesting chromatin 
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remodeling as an indispensable step in the induction of ISG transcription upon IFN 
stimulation247,248. As type III IFN mediated chromatin remodeling has not yet been 
investigated we focus on type I dependent remodeling mediated through interactions of 
chromosomal modifiers with components of the ISGF3 complex. STAT2 is the most crucial 
mediator of these interactions, as STAT2 has an essential transactivation domain (TAD) that 
provides the fundamental transcriptional function of ISGF3 complex, while STAT1 and IRF9 
are responsible for DNA sequence specificity249. 
1.3.3.2 Modifiers of ISG chromatin structure 
The ATP-dependent nucleosome remodeling complexes SWI\SNF-A (BAF) and SWI\SNF-B 
(PBAF) are known chromatin modulators, which facilitate ISG promoter remodeling247,250–252. 
Upon type I IFN treatment, STAT2-dependent recruitment of BAF increases the accessibility 
of ISG promoter regions allowing expression of ISGs253. Furthermore, members of the HAT 
family such as binding protein p300254, cAMP-responsive-element-binding protein (CREB)-
binding protein (CBP)255 and general control non-depressible 5 (GCN5) protein256 have been 
shown to be recruited by direct interaction with STAT1 and STAT2 to the promoters of ISGs 
and facilitate their transcription. Unexpectedly, although HATs are considered positive 
modulators and HDACs negative regulators of general transcription, it has become clear that 
the histone-deacetylase activity (HDAC) is essential for type I IFN-dependent ISG 
transcription257–259. Although, these studies provide the basis for better understanding of 
HDAC mediated ISG regulation, HDACs have been also reported in co-repressor complexes 
to negatively target ISG transcription260.  
1.3.3.3 Co-activators and co-repressors of ISGs transcription 
Apart from chromatin modifiers, interactions of the ISGF3 complex with co-activators such 
as minichromosome maintenance deficient 5 (MCM5) and minichromosome maintenance 
deficient 3 (MCM3)261,262, N-Myc interactor (NMI)263, glucocorticoid receptor-interacting 
protein 1 (GRIP1)264, Vitamin D receptor-interacting protein complex component 150 
(DRIP150)265, the cyclin-dependent kinase 8 (CDK8) module of the Mediator co-activator 
complex214 and the AAA+ ATP binding proteins RVB1 and RVB2266 have been reported to 
enhance the transcriptional activation of ISGs upon IFN stimulation. On the other hand, for 
the fine-tuning of epigenetic regulation, involvement of co-repressors in the controlling of 
ISG activation has been observed with PIAS1, PIASy, TAF-1 and FOXO3 to serve as 
characteristic examples267,268.  
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1.3.3.4 Cooperation with other transcriptional factors  
Apart from epigenetic mechanisms, the control of IFN responses in the nucleus involves the 
coordinated activity of multiple other transcriptional factors, which cooperate with 
STATs224,269,270. Upon IFN stimulation, members of the interferon regulatory factor (IRF) 
family, such as IRF-1, are expressed and in turn induce the transcription of a subset of ISGs 
by recognizing specific DNA sequences (IRF-E site), which overlap with the ISRE 
sequence138,271–273. In this way, the cooperative action of IRFs and ISGF3 leads to an 
enhancement of ISG activation. In contrast, IRF-2 has been shown to operate as a 
suppressor of type I IFN responses, by competing with IRF-1 or IRF-9 for the same DNA 
binding sites268,274,275. Nonetheless, IRFs, by themselves can activate certain target genes 
independently of STATs269. Examples of genes activated by IRFs, without the help of 
STATs, upon type I IFN stimulation are MxA, GBP, MHC class I and B2M in immune cells276. 
In addition, upon IFN or virus stimulation IRF-7 expression amplifies various genes. Among 
them, IFN-α-mediated transcription serves as a positive feedback loop, which further 
enhances IFN responses277,278. Furthermore, independently of the ISGF3 action, upon virus 
infection, IRF-3 can directly bind the ISRE sequence and activate a subset of ISGs279–282. 
1.4 Functional significance of type I versus type III IFNs  
After the discovery of type III IFNs, the last 15 years the research in the IFN field has 
predominantly focused on understanding whether the induction, the signaling and the 
function of these powerful cytokines are regulated differently than type I IFNs. Initially, 
despite the fact that type I and type III IFNs are structurally unrelated and engage different 
receptor complexes, it was largely accepted that the signaling pathways emanating from 
type I and type III IFN receptors exhibit remarkable similarity leading to the induction of 
common biological responses, especially antiviral protection, via the expression of nearly an 
identical pool of more than 300 interferon stimulated genes (ISGs).  
However, a broad range of recent studies have shown not only overlapping but also distinct 
roles of type I and type III IFNs in viral infections. Thus, apart from the differences in the 
transcriptional regulation of type I versus type III IFN expression, which has been detailed 
above, crucial differences have begun to be unraveled regarding the cellular tropism of IFN 
production upon viral infection and expression of type I versus type III IFN receptor 
complexes 
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1.4.1 Type I versus type III IFN mediated antiviral responses at mucosal 
tissues 
The antiviral activity of type I and type III IFNs has been shown in vitro and in vivo by 
exogenous administration of IFNs or with the use of IFN receptor deficient mice38,39,73–
77,79,80,99. The type of infected tissue and the cellular tropism of the different viral pathogens 
are the two crucial factors, which could potentially give rise to specificity in type I versus type 
III IFN response. Type I IFN contributes to the antiviral response of many tissues including 
liver, kidney and spleen, while the type III IFN based defenses protect predominantly organs 
with mucosal surfaces73–80. 
Upon invading the mucosal lumen, a virus is able to infect the epithelial cells, the 
predominant cell type lining the mucosal surface, or the immune cells, residing in the sub-
mucosa or the lymphoid associated mucosal tissues and from there spread to other tissues. 
Taking into account the predominant induction of type III IFNs by epithelial cells or the 
largely limited expression of type III IFN receptor complex on epithelial tissues73–80,93,97,99,283, 
it becomes more and more apparent that type III IFNs are the preferential agents to combat 
viruses which infect epithelial cells of the respiratory tract, gastrointestinal tract, urogenital 
tract and the liver. While type I IFNs, produced mainly by immune cells, fibroblasts and 
endothelial cells of the epithelial sub-mucosa (lamina propria), contribute mainly to induce 
more systemic responses responsible for inhibiting viral dissemination beyond the mucosal 
barrier78–80,96,97,99,283.  
1.4.1.1 Type I versus type III IFNs in the gastrointestinal tract  
Intestinal epithelial cells preferentially produce type III IFN rather than type I IFN and 
express high levels of IFNLR175,77,79,80,96–98. Studies focusing on the mouse gastrointestinal 
tract have shown that type III IFNs may play a restricted role in gut epithelial cells 
irrespectively of type I IFNs. In particular, it has been demonstrated that mouse intestinal 
epithelial cells show a more compartmentalized response to IFNs in adult animals, with type 
III IFNs to act on epithelial cells, whereas type I IFNs have a significant effect on non-
epithelial cells such as lamina propria cells, and only a minimal effect on intestinal epithelial 
cells78–80,96,97,284 (Figure 8).  
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Figure 8. Epithelial specific responsiveness to type III IFNs in the mouse gastrointestinal tract. 
Mice were injected with type I or type IIII IFN and immunostaining of intestinal sections against the 
ISG IFIT3 was conducted. Upon type I IFN treatment, IFIT3 is mainly detected in the cells of the 
lamina propria, while type III IFN injection induces IFIT3 expression predominately on epithelial cells. 
(B) Schematic representation of the IFN induction and response in murine intestinal mucosa tissue 
upon viral challenge. IECs: intestinal epithelial cells, DC: Dendritic cells, T: T lymphocytes, MΦ: 
Macrophages. Adapted from Pott and Stockinger, (2017)
344
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This compartmentalization of type I versus type III IFN response in the mouse gut is also 
reflected in the restriction of enteric viruses with different cell tropism. For instance, rotavirus 
displays strong epithelial cell tropism and predominantly replicates in the epithelium of the 
small intestine285. Although both IFNs are induced following rotavirus infection in the 
gastrointestinal tract of adult mice, type III IFN based defense is predominantly responsible 
for the restriction of rotavirus replication in gut mucosal surface79,96,97. In line, rotavirus 
replication in mouse gut was inhibited only by parenteral administration of type III and not 
type I IFN79. However, in the case of reovirus, which replicates in both epithelial and non-
epithelial cells, both type I and III IFNs are required in a non-redundant fashion for viral 
inhibition in the mouse gastrointestinal tract80. Specifically, type III IFN restricts replication of 
reovirus in epithelial cells80,286, while type I IFN prevents systemic infection80. Recently, an 
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age-restricted dependence on IFNs in the mouse intestinal barrier has been shown with 
neonatal mice showing a response of epithelial cells to both IFNs, while adult mice are 
insensitive to type I IFNs97. In addition, it has been shown that reovirus infection induces 
mainly type III IFN production and lower levels of type I IFN in epithelial cells80,114,286.  
Similarly to reovirus, it has been shown that both IFNs act cooperatively for controlling 
norovirus infection, with type III IFNs inhibiting persistent shedding of virus in feces and type 
I IFN to prevent systemic spread286–288. In particular, using as a model, murine norovirus 
(MNoV), with acute and persistent strains, this differential sensitivity of type I and type III 
IFNs has been observed108. Acute MNoV, which exhibits cellular tropism to DCs, 
macrophages, B and T cells in the gut, reflects the importance of type I IFNs for elimination 
of viral infection288,289. Whereas, in the case of persistent MNoV strains type I IFN contributes 
to prevent systemic viral spread and type III IFNs are responsible for controlling viral load in 
the intestine286–288,290. Increased viral load has been shown in the gut and stool samples of 
IFNLR-/- mice and exogenous administration of type III IFNs inhibits persistent MNoV 
infection in intestinal tissue286,287,290. Tightening of the gastrointestinal epithelial barrier might 
be an explanation for the beneficial action of type III IFNs on reducing viral shedding. 
Interestingly, in the blood brain barrier, a similar action for type III IFNs has been described 
upon West Nile Virus infection, where type III IFN induction enhances the tight junction 
integrity of endothelial cells44,105. Notably, it has been reported that the protective effect of 
type III IFN system in norovirus infection is hampered by intestinal commensal bacteria, 
providing a possible explanation for why mice with functional type III IFN receptors are still 
susceptible to persistent norovirus infection291. Use of antibiotic treatment to deplete gut 
commensals, diminishes fecal shedding of norovirus in a type III IFN receptor dependent 
manner.  
1.4.2 Differential pattern of type I versus type III IFN activity  
Apart from the above described differences in the induction, response and antiviral 
protection under the prism of cellular and viral tropism mainly in mouse mucosal surfaces, 
type I and type III IFNs have also been shown to display significant subtle differences in their 
signal propagation in some recent in vitro studies utilizing different human cell lines. 
Interestingly, it has been shown that these differences are more quantitative than qualitative 
and related to the magnitude and the kinetics in type I versus type III IFN mediated cellular 
responses. 
First of all, although type I and type III IFN antiviral response is less black and white and 
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there is a degree of redundancy between the two IFN systems, in vitro studies utilizing 
human lung epithelial cell lines and hepatocytes have demonstrated that type I IFNs confer a 
more potent antiviral protection39,292–295. In line with this, the magnitude of the gene 
expression promoted by type I IFNs has been described to be higher than the response 
triggered by type III IFNs, even though it has been reported that an overlapping pool of ISGs 
is induced with both IFN39,93,97,165,189,237,292–294. Moreover, in vitro work performed in 
hepatocytes revealed a differential kinetic pattern of ISGs induction between type I and type 
III IFN stimulation, with type I IFN promoting a significantly faster transcriptional 
response165,189,293,294.  
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1.5 Objectives 
Intestinal epithelial cells constitute the primary barrier that enteric viruses have to face. Viral 
infection of epithelial surfaces triggers the production of type I IFNs, which signal through the 
IFNAR complex to up regulate hundreds of ISGs, that inhibit viral replication and induce viral 
resistance to neighboring cells. Type III IFNs constitute a newer class of interferons that 
share low homology with type I IFNs. Type III IFNs are abundantly expressed at mucosal 
layers such as the respiratory and gastrointestinal tracts following viral infection and bind to 
cells using the IFNLR complex. Interestingly, while the type I IFN receptor is ubiquitously 
expressed, the type III IFN receptor is expressed mainly in epithelial cells. 
Although type III IFNs signal through a unique receptor complex, they induce downstream 
signaling that appears remarkably similar to that of type I IFNs, driving the expression of a 
comparable set of ISGs. This has prompted speculation that type III IFNs are functionally 
redundant to type I IFNs. However, this model has been challenged more and more in 
recent studies   which highlight that the cell type specific compartmentalization of 
IFNLR   and the ligand availability provide type III IFNs a unique potential for targeting local 
infections at mucosal surfaces. However, up to now the epithelium specificity of type III IFNs 
has been supported mainly by in vivo studies focusing on murine epithelial surfaces, leaving 
unanswered questions about how and whether these two IFNs act differently in the human 
epithelium. Traditional experimental approaches utilizing human cell lines are limited to a 
comparative analysis of the response induced by type I versus type III IFN at the primary 
human intestinal epithelium. Here, we combined human IEC lines with human mini-gut 
organoids to study the relative role of type I and type III IFNs in protecting the human gut 
against viral infection.  
In addition, differences in the antiviral activity conferred by both IFNs appear to be not only 
driven by the spatial restriction of their receptors but also by intrinsic subtle differences in 
signal propagation. As these differences in the kinetics and the magnitude of type I versus 
type III IFN mediated cellular responses could not be directly explained by their signaling 
cascade, an alternative explanation was proposed where type III IFN receptor is expressed 
at lower levels at the cell surface. Here, we combined mathematical modeling with 
experimental time-resolved data to elucidate whether the observed differences between type 
I and type III IFNs are intrinsic to each IFN specific signal transduction pathway.  
Thus the presented work addresses the following, major objectives: 
1. Characterize the functional differences in type I versus type III IFN mediated innate 
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immune responses in human intestinal epithelial cells 
 
2. Determine the molecular mechanisms which are responsible for these differences 
Taken together, by combining the most up to date in vitro culture conditions of primary non-
transformed intestinal epithelial cells, with mathematical modeling and quantitative 
experimental data, this study aimed at providing molecular cues allowing us to determine 
how and why type III IFNs induce a distinct cellular response compared to type I IFNs in 
human epithelial cells and unravel how these differences in type I and type III IFNs function 
to maintain gut immuno-homeostasis (efficient protection against pathogens while limiting 
pro-inflammatory signals). Understanding these mechanisms could contribute to the 
development of new more efficient IFN therapies for combating viral infection without 
inducing excessive side effects.  
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2 Results 
2.1 Type I and type III interferons display different dependency on 
mitogen-activated protein kinases to mount an antiviral state in the 
human gut 
The text and figures of part 2.1 have been adapted from Pervolaraki et al. (2017)100. This 
corresponds to a co-first author published manuscript resulting directly from my PhD 
research project.  
Intestinal epithelial cells (IECs) are constantly exposed to commensal flora and pathogen 
challenges. How IECs regulate their innate immune response to maintain gut homeostasis 
remains unclear. During viral infection of mucosal surfaces, IFNs are the predominant 
cytokines produced to combat viral replication and spread36-40. While type I IFN receptors are 
ubiquitously expressed, type III IFN receptors are mainly expressed on epithelial cells73-80. 
This epithelium specificity strongly suggests exclusive functions at epithelial surfaces, but 
the relative roles of type I and III IFNs in the establishment of an antiviral innate immune 
response in human IECs are not clearly defined. Here, we use human mini-gut organoids 
and human IEC lines in combination with genetic ablation of either type I or type III IFN 
receptors, to investigate the relative roles of type I and type III IFNs in protecting the human 
gut against viral infection. These studies will allow us to refine our understanding of the 
evolutionary benefit of possessing multiple antiviral IFNs. 
2.1.1 Human Mini-Gut Organoids as a representative ex vivo model of human 
gastrointestinal epithelium 
To unravel the antiviral activity of type I versus type III IFNs in human primary intestinal cells, 
we established human colon and intestinal mini-gut organoid cultures. Here we isolated 
intestinal crypts from human colon or small intestine resections. Human samples were 
derived from multiple donors undergoing biopsy or surgery and from different parts of the 
small intestine including duodenum, jejunum and ileum. After isolation, single crypts 
containing the stem cell niche were embedded into matrigel and cultured ex vivo in media 
supplemented with intestinal growth factors such as Wnt3a, Noggin, R-Spondin1 and 
epidermal growth factor (EGF). 24 hours post-isolation, open crypts started to re-seal 
resulting in 3-dimensional structures called mini-gut organoids. Over a course of 
approximately 3 to 5 days of culture, human colon and intestinal organoids present a 
characteristic cystic or multi-lobular morphology, respectively, with a single continuous 
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lumen surrounded by a monolayer of epithelial cells. At 7-10 days post-isolation the 
organoids grew significantly in size (Figure 9A).  
 
Figure 9. Characterization of differentiated human mini-gut organoids. (A) Human colon 
organoids were prepared according to methods. Representative images of human colon organoids 
grown over 10 days from intestinal crypts. (B) Electron microscopy pictures of organoids at day five 
post-differentiation. (C) Five days post-differentiation, organoids were fixed, cryosectioned and 
immunostained for tight junctions (ZO-1), adherent junctions E-cadherin (E-cad), Goblet cells (Mucin-
2), and Enteroendocrine cells (synaptophysin, Syn). The data of panel (A) has been produced by 
Megan Stanifer, Heidelberg University. The data of panel (B) has been produced by Pranav Shah, 
Heidelberg University. Panels (A) and (C) were adapted from Pervolaraki et al., 2017. 
 
After culture in differentiation medium, we noticed the typical organization of the human 
colon organoids with the presence of a clear and developed lumen, the brush boarder on the 
apical side of enterocytes and the tight junctions, which seal the paracellular space between 
the epithelial cells (Figure 9B). In addition, we were able to observe all the different cell 
types present in the human gastrointestinal epithelium based on the expression of specific 
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cellular markers by immunofluorescence. These included the adhesion junction protein E-
cadherin (E-cad) for enterocytes, mucin (Mucin-2) for secreting Goblet cells, synaptophysin 
(Syn) for enteroendocrine cells (Figure 9C) and lysozyme for Paneth cells (data not shown). 
Furthermore, some physiological characteristics of organoids were demonstrated such as 
the polarized nature of the intestinal epithelium by the localization of E-cadherin at the 
basolateral side of cells and the detection of tight junctions at the apical side by staining of 
the zonula occludens-1 (ZO-1) protein (Figure 9C).  
2.1.2 Preferential induction of type III IFN production in human mini-gut 
organoids upon viral infection 
To evaluate the protective role of type I and/or type III IFNs in the human gut upon viral 
infection we utilized the mammalian reovirus (MRV). MRV is a well-known enteric virus 
model, which infects intestinal epithelial cells followed by induction of immune responses 
involving both type I and III IFNs114,296. In the rest of the thesis, the terms type I and type III 
IFNs refer to the use of IFN β1 and IFN λ1–3, respectively. Differentiated colon mini-gut 
organoids were removed from the matrigel in which they were embedded and inoculated 
with MRV with a low multiplicity of infection (MOI) of approximately 0.5. At 16 hours post-
inoculation (hpi), organoids were harvested, embedded into optimal-cutting-temperature 
(OCT) freezing compound and frozen to make blocks for sectioning and staining. 
Immunofluorescence analysis using antibodies against the reovirus non-structural protein 
μNS was used to identify infected cells. By using confocal microscopy, μNS staining was 
evident in MRV-infected organoids but not in mock-infected samples (Figure 10A). Notably, 
MRV infection resulted in a change in the morphology of human mini-gut organoids creating 
fragmented pieces of the epithelial layer, compared to mock infected organoids, which 
maintained an intact structure (Figure 10A). This observation was not sample dependent as 
the same results were obtained after infection of multiple donors with MRV (Figures 11B and 
12A). In addition to immunostaining, quantification of viral replication was assessed by 
quantitative real-time (qRT)-PCR. As shown in Figure 10B, MRV potently replicates over the 
course of infection. These results demonstrate that human mini-gut organoids are 
susceptible to MRV infection. 
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Figure 10. Infection of human mini-gut organoids with mammalian reovirus (MRV). Five days 
post-differentiation, organoids were mock or MRV infected (multiplicity of infection = 0.5). (A) 16 hpi, 
organoids were fixed, cryosectioned and immunostained. MRV-infected cells were detected using an 
antibody against the MRV non-structural protein μNS. Representative images are shown. White arrow 
indicates infected cells. (B-E) Quantitative real-time (qRT)-PCR and ELISA were used to detect (B) 
virus replication over a timecourse of 24 hours (C) time course of transcriptional upregulation of both 
type I interferons (IFNs) (β) and type III IFN (λ2/3) IFNs (D) 24 hpi the production and secretion of IFN 
proteins in the supernatant of infected organoids was determined by ELISA and (E) a time course of 
transcriptional upregulation of the IFN-stimulated genes Viperin and IFIT1. qRT-PCR data were 
normalized to TBP and HPRT1 (housekeeping genes) and are expressed relative to uninfected 
organoids at each time point. qRT-PCR data and ELISA data represent the mean values of three 
independent experiments. Error bars indicate the SD. The blue and red lines in  (D) demarcate the 
limit of detection of our ELISA for type   I and  type III IFNs, respectively. The data of this figure has 
been produced jointly with Megan Stanifer, Heidelberg University and was adapted from Pervolaraki 
et al., 2017. 
 
To assess the innate immune response generated by organoids upon viral infection, we 
monitored the upregulation of both type I (IFN-β) and type III (IFN-λ2–3) IFNs and the 
expression of ISGs over the course of MRV infection. Importantly, MRV infection triggered a 
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marked increase in type III IFN and to a lesser extent type I IFN expression as detected by 
interferon-specific qRT-PCR (Figure 10C). This was in line with the detection of only type III 
IFN in the supernatant of infected organoids (Figure 10D). The virus inhibitory 
protein, endoplasmic reticulum-associated, interferon-inducible (Viperin) and interferon-
induced protein with tetratricopeptide repeats 1 (IFIT1) were used as two representative 
ISGs induced upon viral infection and were both shown to be upregulated after MRV 
infection (Figure 10E). These results closely demonstrate that human primary IECs respond 
to viral infection by up-regulating both type I and type III IFNs, but only type III IFN can be 
detected in the supernatant of infected cells. 
2.1.3 Both type I and type III IFNs protect human mini-gut organoids against 
viral infection 
From our previous experiment, we found that viral infection of human organoids induces the 
induction of both type I and type III IFNs at the transcriptional level. To address whether both 
types of IFN are in turn able to induce an antiviral response by promoting ISGs production, 
mini-gut organoids were exogenously treated with a wide range of IFN concentrations. 
Results revealed that both type I and III IFNs induce the upregulation of ISGs in a dose-
dependent manner (Figure 11A). Interestingly, type I IFN appears to be more potent as it 
induces a higher expression of both the ISGs Viperin and IFIT1 compared to type III IFN 
(Figure 11A). These data were not dependent on specific ISGs, as similar results were 
obtained for multiple other ISGs including MXA, ISG15, ISG54 (data not shown). Of note, we 
also observed a continuous increase in ISG mRNA levels as the concentration of type I IFN 
increased, whereas ISG transcript levels quickly reached a plateau in type III IFN-treated 
cells.  
To evaluate whether type I and/or type III IFN could protect primary human IECs from viral 
infection, mini-gut organoid cultures were stimulated with 8 ng/mL of type I IFN (IFN-β) 
(equivalent 2,000 RU/mL, see Materials and methods) or 300 ng/mL of type III IFN (IFN-
λ1−3) prior to exposure to MRV. Organoids were harvested 16 hpi for analysis of viral 
infection/replication by immunostaining and immunoblotting against the reovirus non-
structural protein μNS as well as by quantification of viral replication using qRT-PCR. 
Compared to mock-treated cells, pre-treatment of colon organoids with either IFN 
significantly reduced both the number of MRV-infected cells (Figure 11B) and the viral 
antigen levels within these organoids, as assessed by the quantification of the total 
fluorescence intensity of the μNS protein per organoid (Figure 11C) or by western blot 
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analysis (Figure 11D). Complementarily, viral replication was severely impaired when 
organoids were treated with either IFNs as assayed by qRT-PCR (Figure 11E).  
 
 
Figure 11. Both type I and type III IFNs confer human mini-gut organoids protection against 
viral infection. (A) Colon organoids were treated with increasing concentrations of type I IFN (β) and 
type III IFN (λ1–3). Six hours post-treatment, organoids were harvested and the transcriptional 
upregulation of the IFN-stimulated genes Viperin (Vip) and IFIT1 was measured using qRT-PCR. 
Data were normalized to TBP and HPRT1. (B–E) Colon organoids were treated with type I IFN (β) 
(2,000 RU/mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) for 2.5 hours prior to infection 
with MRV (multiplicity of infection = 0.5) (B) 16 hpi MRV-infected organoids were analyzed by μNS-
specific immunofluorescence (green). The cells were stained against E-cadherin (red) and the nuclei 
were stained with DAPI (blue). Representative data from triplicate experiments are shown. (C) The 
fluorescence intensity of MRV μNS per organoid (panel B) was measured and expressed relative to 
untreated organoids (set as 100). (D) 16hpi MRV-infected organoids were analyzed for μNS 
production by Western blot. Actin was used as loading control. Production of μNS was quantified by 
densitometry. (E) The protective effect of type I or type III IFN was assayed by monitoring viral 
replication by qRT-PCR normalized to inoculum. Data represent the mean values of three 
independent experiments. Error bars indicate the SD. **P < 0.01, ***P < 0.001 (unpaired t-test). The 
data of this figure has been produced jointly with Megan Stanifer, Heidelberg University and was 
adapted from Pervolaraki et al., 2017. 
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To ensure that these findings were neither donor nor colon specific, colon organoids from 
different donors (colon D2–D3) and organoids derived from different parts of the small 
intestine such as the ileum or the jejunum were similarly treated with type I or type III IFNs 
prior to infection with MRV. Reduced viral infection characterized by the lower expression 
levels of the MRV μNS protein and the decreased MRV replication was detected in all the 
colon organoids generated from different donors (Figure 12A), as well as in the organoids 
derived from ileum (Figure 12B) and jejunum (Figure 12C). In addition, we confirmed that 
this inhibition was also true when using vesicular stomatitis virus (VSV), an unrelated model 
virus whose replication is also sensitive to both type I and type III IFNs114,296 (Figure 12D). All 
together, these results demonstrate the antiviral protective role of both type I and type III 
IFNs in primary IECs derived from different parts of the human intestine including colon, 
ileum, and jejunum. 
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Figure 12. Type I and type III IFNs confer protection against MRV infection to all sections of the 
gut. Organoids from multiple colon donors and multiple intestinal sections were treated with type I IFN 
(β) (2,000 RU/mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) for 2.5 hours prior to 
infection with MRV (multiplicity of infection = 0.5). Infection was assessed 16 hpi. (A) MRV-infected 
colon organoids (donor 2 and 3) were analyzed by μNS-specific immunofluorescence (green). The 
cells were stained against E-cadherin (red) and the nuclei were stained with DAPI (blue). 
Representative image of triplicate experiments are shown. The fluorescence intensity of MRV μNS 
per organoid was measured and expressed relative to untreated organoids (set to 100). (B, C) MRV-
infected organoids were analyzed for μNS production by Western blot. Actin was used as loading 
control. Production of μNS was quantified by densitometry. The protective effect of type I IFN (β) and 
III IFN (λ1−3) was assayed by monitoring the relative viral genome copies by quantitative real-time 
PCR normalized to inoculum. (B) Ileum. (C) Jejunum. (D) Colon organoids were treated with type I 
IFN (β) (2,000 RU/mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) for 2 hours prior to 
infection with VSV-expressing luciferase (multiplicity of infection = 1) Eight hpi VSV replication was 
assessed by measuring the luciferase activity. Data represent the mean values of three independent 
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experiments. Error bars indicate the SD. **P < 0.01, ***P < 0.001 (unpaired t-test). The data of this 
figure has been produced jointly with Megan Stanifer, Heidelberg University and was adapted from 
Pervolaraki et al., 2017. 
2.1.4 Human IEC lines express type I and type III IFN upon MRV infection 
Although the last years, human mini-gut organoids have been characterized as the best 
system to study ex vivo the properties of human primary intestinal epithelial cells, they are 
very difficult to genetically modify. Therefore, to better understand the functions and the 
mechanisms by which type I and type III IFNs confer hIECs an antiviral state, we used the 
human colon carcinoma-derived cell line T84. To test whether this cell line elicits a similar 
immune response as human mini-gut organoids, we infected T84 cells with MRV. 16 hpi, 
samples were harvested and the expression of 13 human type I and three type III IFNs were 
measured by qRT-PCR103. While T84 cells have low to non-detectable levels of IFNs under 
basal conditions, MRV infection induces the up-regulation of both type I (IFN-α and IFN-β) 
and type III IFNs (IFN-λ1, IFN-λ2 and IFN-λ3) (Figure 13A and 13B).  
Notably, similar to human mini-gut organoids (Figure 10C), viral infection induces a higher 
transcriptional up-regulation of type III IFNs compared to type I IFN (Figure 13A and 13B). 
To address whether both IFNs were made at the protein level and secreted by infected T84 
cells, we measure the amount of both IFNs in the supernatant of infected T84 cells using 
ELISA. Importantly, in agreement with the viral infection of mini-gut organoids (Figure 10D), 
only type III IFN was found in the supernatant (Figure 13C).  
 
Figure 13. Expression pattern of IFN mRNA and protein in human intestinal epithelial cells 
upon viral infection. T84 cells were infected with MRV (multiplicity of infection = 1). (A) 16 hpi, cells 
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were harvested and the copy numbers of the expression of 13 human type I and three type III IFNs 
were determined by qRT-PCR analysis. The geometric means of the peak responses in mock and 
infected intestinal epithelial cells are shown in a log10 scale as copy numbers per μg RNA. (B) 
Relative quantification of type I IFN (β) and type III IFN (λ2/3) transcripts during the course of MRV 
infection of T84 cells. Data are normalized to TBP and HPRT1 and are expressed relative to 
uninfected cells at each time point. (C) Quantification of type I (IFNβ) and type III (IFN λ2/3) prote in 
levels by ELISA  in supernatants of uninfected or MRV-infected T84 cells. The blue and red dashed 
lines demarcate the limit of detection of our ELISA for type I and type III IFNs, respectively. n.d., not 
detectable. Data represent the mean values of three independent experiments. Error bars indicate the 
SD. ****P < 0.0001 (unpaired t-test). The data of panel (A) have been produced jointly with Lynnsey 
A. Renn, Food and Drug Administration, Silver Spring, MD, USA (B) has been produced jointly with 
Megan Stanifer, Heidelberg University. This figure was adapted from Pervolaraki et al., 2017. 
 
To confirm whether T84 IECs respond to either type I and type III IFNs, we treated T84 IECs 
with type I or type III IFN and measured the expression levels of ISGs at different time points 
post-IFN treatment. Similar to human mini-gut organoids (Figure 11A), we found that type I 
IFN induces a higher expression of the ISGs Viperin and IFIT1 compared to type III IFN 
(Figure 14A). Transcriptome analysis of T84 cells 
 
Figure 14. T84 cells respond to both type I and III IFNs by upregulating IFN-stimulated genes 
(ISGs). (A) T84 cells were stimulated with indicated concentrations of type I (β) or III IFN (λ1−3) for 
different times and the transcript levels of the ISGs Viperin (Vip) and IFIT1 were analyzed by qRT-
PCR. Data are normalized to TBP and HPRT1 and are expressed relative to untreated cells at each 
time point. A representative experiment out of three independent experiments is shown. Mean values 
and SD are shown. (B) T84 cells were treated with type I IFN (β) (2,000 RU/mL equivalent 8 ng/mL) 
or type III IFN (λ1−3) (300 ng/mL) for 6 hours and identification of the IFN-induced ISGs was 
performed by transcript profiling using an Illumina microarray. The data of panel (B) has been 
produced jointly with Megan Stanifer, Heidelberg University. This figure was adapted from Pervolaraki 
et al., 2017. 
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treated with either type I or type III IFN revealed that type I IFN consistently induced higher 
expression level across all induced ISGs (Figure 14B).  
To determine the antiviral potency of type I and type III IFNs in T84 cells, we pre-treated T84 
cells with increasing concentrations of each IFN prior to infection with MRV. De novo 
production of viral proteins was monitored by immunoblotting against the MRV non-structural 
protein μNS. Figure 15A shows that both type I and type III IFNs limit viral infection in a 
dose-dependent manner. In addition, cells were fixed 16 hpi and the fraction of μNS-
expressing cells was determined by immunofluorescence. These results demonstrate that 
either type I or type III IFN decrease both the number of MRV-infected cells and the level of 
viral antigen per cell (Figure 15B). To confirm that this observation was not virus-specific, 
T84 cells were treated with increasing concentrations of either type I or type III IFNs and 
subsequently infected with VSV-Luc as a reporter of viral replication. Assessment of viral 
infection by bioluminescence showed that similar to MRV, either type I or type III IFNs are 
capable of inhibiting VSV infection in human IECs in a dose-dependent manner (Figure 
15C). In addition SKCO15, another colon cancer cell line, were used to exclude cell line-
specific effects. Consistent with T84 cells, a dose-dependent protective effect of both IFNs 
was observed in SKCO15 cells (Figure 15D). All together these results show that either type 
I or type III IFNs confer human intestinal cell lines an antiviral state and that T84 cells 
phenocopy the antiviral response generated by primary human IECs.  
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Figure 15. Both type I and type III IFNs mediate antiviral protection in human T84 cells. (A) T84 
cells were pre-treated for 2.5 hours with the indicated concentrations of type I IFN (β) and type III IFN 
(λ1–3) IFNs and then subsequently infected with MRV [multiplicity of infection (MOI) = 1]. 16 hpi, the 
protective effect of type I or III IFN was assayed by immunoblotting for the viral non-structural protein 
μNS. EF-2 is used as a loading control. A representative immunoblot out of three independent 
experiments is shown. (B) T84 cells were treated with type I IFN (β) (2,000 RU/mL equivalent 8 
ng/mL) or type III IFN (λ1−3) (300 ng/mL) for 2.5 hours prior to infection with MRV. 16 hpi MRV-
infected cells were analyzed by μNS-specific immunofluorescence. (Left panel) The number of 
infected cells was quantified and is expressed relative to untreated cells (set to 100). (Right panel) 
MRV uNS staining intensity was measured to obtain the average fluorescent intensity per cell and is 
expressed relative to untreated cells (set to 100). Data represent the mean values of three 
independent experiments. (C) T84 cells and (D) SKCO15 cells were pre-treated with the indicated 
concentrations of type I or III IFNs for 2 hours prior to infection with vesicular stomatis virus (VSV) 
expressing Firefly luciferase VSV expressing luciferase (MOI = 1). Viral replication was assayed by 
measuring the luciferase activity 8 hpi. For each sample luciferase activity was measured in triplicates 
and is expressed as the percentage of the activity present in VSV-infected cells without IFN treatment 
(set to 100). The mean value obtained from three independent experiments is plotted. Error bars 
indicate the SD. **P < 0.005, ****P < 0.0001 (unpaired t-test). Panels (A-C) were adapted from 
Pervolaraki et al., 2017. 
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2.1.5 Type I & III IFN mediated antiviral responses independently protect 
human IECs 
To understand whether type I and type III IFNs act in cooperation or independently in 
establishing the antiviral state of IECs, we generated T84 cell lines deficient for either the 
IFN alpha receptor 1 (IFNAR1) or the IFN lambda receptor 1 (IFNLR1) using CRISPR/Cas9 
technology. In the rest of this part of my thesis, the IFNAR-/- and IFNLR-/- are used to 
describe the disruption of the IFNAR1 and IFNLR1 specific chains of type I and type III IFN 
receptor complexes, respectively.  
 
Figure 16. Type I and type III IFNs independently confer intestinal epithelial cells antiviral 
protection. T84 IFNAR1 and IFNLR1 knockout cell lines were generated using the CRISPR/Cas9 
system. (A) T84 cell lines were treated with type I IFN (β) (2,000 RU/mL equivalent 8 ng/mL) or type 
III IFN (λ1−3) (300 ng/mL) for 1 hour and IFN signaling was measured by immunoblotting for pSTAT1 
Y701. EF-2 is used as a loading control. A representative immunoblot out of three independent 
experiments is shown. (B) Same as (A), except that induction of IFN-stimulated genes was monitored 
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by relative qRT-PCR quantification of Viperin at indicated times post-IFN treatment. Data were 
normalized to TBP and HPRT1 and are expressed relative to untreated cells of each time point. (C,D) 
T84 cell lines were infected with MRV for 16 hours (multiplicity of infection (MOI) = 1) and MRV-
infected cells were analyzed by μNS-specific immunofluorescence. (C) The number of infected cells is 
expressed relative to scramble control cells (set to 100). (D) MRV μNS staining intensity was 
measured to obtain the average fluorescence intensity per cell and expressed relative to scramble 
control cells (set to 100). (E) T84 cell lines were infected with VSV-GFP (MOI = 1) for 8 hours and the 
number of VSV-infected cells were analyzed by FACS. The percentage of infected cells is expressed 
relative to scramble control cells (set to 100). (F) Same as (E), except that T84 cell lines were infected 
with VSV expressing luciferase (VSV-Luc) (MOI = 1) and viral replication was assayed by measuring 
the luciferase activity. For each cell line luciferase activity was measured in triplicates and is 
expressed relative to scramble control cells (set to 100). (G) Same as (C), except that T84 cell lines 
were treated with type I IFN (β) (2,000 RU/mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) 
at indicated time points prior to infection with MRV. (H) Same as (F), except that T84 cell lines were 
treated with type I IFN (β) (2,000 RU/mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) for 2 
hours prior to infection with VSV-Luc. Data (B–H) represent the mean values of three independent 
experiments. Error bars indicate the SD. *P < 0.05, ***P < 0.001, ns, not significant (unpaired t-test). 
The data of this figure was adapted from Pervolaraki et al., 2017. 
 
Inactivation of these IFN receptors was confirmed by sequencing of the knockout (KO) cell 
lines, which revealed nucleotide deletions and changes of open reading frame in IFNAR1 
and IFNLR1 genes (data not shown). As shown in Figure 16A and 16B, IFNAR−/− cells were 
no longer able to phosphorylate pSTAT1 and induce ISGs after type I IFN treatment, but 
remained fully responsive to type III IFN, indicating a selective disruption of the type I IFN 
signaling pathway. Conversely, IFNLR−/− cells were insensitive to type III IFN but 
responded to type I IFN (Figure 16A and 16B). To exclude cell clone specific effect, multiple 
clones of T84 cells KO for IFNAR1 or IFNLR1 gene were generated. As shown in Figure 17, 
our findings were consistent across multiple IFNAR−/− and IFNLR−/− cell clones (Figure 
17A and 17B).  
To assess whether deletion of IFNAR1 or IFNLR1 renders human IECs more susceptible to 
viral infection, cells lacking functional receptors for type I or type III IFN were infected by 
either MRV or VSV and compared to wild-type or scrambled guide RNA-exposed cells. 
Immunofluorescence analysis revealed that loss of IFNAR1 slightly increased the number of 
MRV-infected cells compared to control cells (Figure 16C), but did not affect the average 
fluorescent intensity of MRV antigen per infected cell (Figure 16D). Interestingly, IFNLR−/− 
cells appeared to be more susceptible to VSV infection. The number of VSV-infected cells 
and the amount of viral antigens in each cell were significantly increased in IFNLR−/− cells 
compared to control cells (Figure 16E and 16F). To further verify the protective role of type I 
and type III IFN against viral infection in human IECs, IFNAR−/− and IFNLR−/− cells were 
pre-treated with either type I or III IFNs and subsequently infected with MRV or VSV. Type I 
or type III IFN could efficiently inhibit infection by both MRV and VSV in control cells (Figure 
16G and 16H). As expected, the protective effect of type I IFN against MRV (Figure 16G, left 
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panel) and VSV (Figure 16H) was no longer observed in IFNAR−/− cells, but was preserved 
in IFNLR−/− cells. Conversely, disruption of IFNLR1 specifically abolished the protective 
effect of type III IFN, but not of type I IFN. Similar results were obtained with several KO 
clones (Figure 17C). All together these data demonstrate that in human T84 cells, either 
type I or type III IFNs are capable of independently mediating antiviral protection.  
 
Figure 17. Characterization of different T84 IFNAR and IFNLR knockout (KO) cell clones 
generated using the CRISPR/Cas system. (A) IFNAR and IFNLR KO clones were treated with type 
I interferons (IFN) (β) (2,000 RU/mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) for 1 hour 
and IFN signaling was measured by immunoblotting for pSTAT1 Y701. EF-2 is used as a loading 
control. A representative immunoblot out of three independent experiments is shown. (B) Same as 
(A), except that IFN signaling was evaluated by monitoring induction of IFN-stimulated genes by 
relative quantification of Viperin at indicated times post-IFN treatment using qRT-PCR. Data are 
normalized to TBP and HPRT1 and are expressed relative to untreated control cells of each time 
point. A representative experiment, out of three independent experiments is shown. (C) T84 cell lines 
were treated with type I IFN (β) (2,000 RU/mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) 
  Results 
 
 47 
for 2 hours prior to infection with VSV-Luc (multiplicity of infection = 1) and viral replication was 
assayed by measuring the luciferase activity. Results are expressed relative to mock-IFN- treated 
control cells generated with a scrambled control gRNA (set to 100). The mean value obtained from 
two independent experiments is plotted. Error bars indicate the SD. The data of this figure was 
adapted from Pervolaraki et al., 2017. 
2.1.6 Role of MAP Kinase signaling pathways in type III IFN based antiviral 
activity in human IECs 
Type I and type III IFN signaling and antiviral activity are predominantly dependent on the 
JAK/STAT pathway, and inhibition of STAT1 phosphorylation blocks the production of ISGs 
and inhibits IFN-mediated antiviral protection209,297–299. In parallel, several MAPK signaling 
pathways, including the p38-mitogen activated protein kinase (p38-MAPK) pathway, the 
extracellular-signal regulated kinase (ERK) pathway and the c-Jun N-terminal kinases (JNK) 
pathway, have also been reported to be activated207 and contribute to ISG up-regulation in 
type I or type III IFN-stimulated cells104,237, but the role of the different MAPK pathways in the 
antiviral functions of type III IFNs remains unclear. We found that both type I or type III IFN 
treatment induced the phosphorylation of STAT1, STAT2, and STAT3 with similar kinetics in 
T84 cells (Figure 18). Type I or type III IFN treatment did not induce STAT5A, STAT5B, or 
STAT6 phosphorylation (data not shown).  
 
Figure 18. Type I and type III IFN mediated STAT1,2 and 3 phosphorylation. T84 cells were 
treated with 2000 RU/ml IFN or 300 ng/ml IFN for the indicated time points. The levels of 
phosphorylation of STAT1-6 was measured by Luminex technology. Only STAT1, 2 and 3 are shown 
as STAT5a, 5b and 6 were not activated upon type I or type III IFN treatment. 
 
We next addressed whether type I and type III IFNs activate the different MAPKs. We found 
that both IFNs induce the phosphorylation of the MAPKs, p38, ERK, and JNK to the same 
extent and with similar kinetics (Figure 19A western blot analysis and quantification). To 
determine the role of the STAT and MAPK pathways in the antiviral activity of IFNs, we used 
specific pharmacological inhibitors in combination with IFN treatment. These inhibitors were 
shown to be non-toxic in cell viability assay (Figure 19B) and specific by Western blot 
analysis (Figure 20).  
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Figure 19. Role of MAP kinase pathway in type I and III IFN antiviral activity. (A) T84 cells were 
treated with type I IFN (β) (2,000 RU/ mL equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) for 
the indicated time points. The levels of phosphorylation of MAPkinases p38, ERK, and JNK were 
assessed by Western blot analysis. p38, ERK, JNK, and EF-2 were used as loading control. The 
phosphorylation of the MAP kinases was quantified and expressed relative to untreated cells (right 
panel). Data represent the mean values of three independent experiments. Quantification was 
performed by densitometry. (B) T84 cells were treated with increasing concentrations of JAK and 
MAP kinase inhibitors. 24 hours post-inhibitor treatment the cell viability was assessed by MTT assay. 
The mean value obtained from three independent experiments is shown. Error bars indicate the SD. 
The data of this figure was adapted from Pervolaraki et al., 2017. 
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Figure 20. Specific inhibition of MAP kinases phosphorylation. T84 cells were pre-treated with 
JAK and MAPK inhibitors for  30 minutes prior to IFN treatment. Cells were harvested at different 
times post-treatment and the extent of JAK or MAPK inhibition was addressed by Western blot 
analysis. The specificity of each inhibitor was controlled by monitoring the phosphorylation status of 
JAK and all MAPKs. (A) 2 μM Pyridone 6 (pan-JAK inhibitor). (B) 10 μM U0126 (ERK inhibitor). (C) 10 
μM SB202190 (p38 inhibitor). A representative plot out of from three independent experiments is 
shown. The data of this figure was adapted from Pervolaraki et al., 2017. 
 
Inhibiting the JAK/STAT pathway with a pan-JAK inhibitor almost fully blocked 
phosphorylation of STAT1 (Figure 20A) and strongly impaired the antiviral activity of either 
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type I or III IFNs on both VSV and MRV (Figure 21A). Interestingly, inhibition of the MAPKs 
with specific inhibitors, had no effect on the phosphorylation kinetics of STAT1 (Figure 20B 
and 20C) but strongly affected the antiviral protection conferred by type III IFN only (Figure 
21A). This specific inhibition is seen across a range of different concentrations used for the 
inhibitors (Figure 21B). Of note, a partial inhibition of the antiviral activity of type I IFN was 
observed at high concentration of JNK inhibitor (Figure 21B) but at this concentration cell 
viability was severely affected (Figure 19B). This type III IFN restricted dependence on 
MAPKs was independent of IFN concentration (Figure 21C), verifying that the non-
dependence of type I IFN antiviral activity for MAPKs was not the result of differences in the 
IFN concentration used to stimulate the cells. Altogether, these results indicate the 
fundamental role of STAT-dependent signaling in conferring both type I and type III IFNs 
antiviral activity, and in addition demonstrate a unique role for MAPKs toward inducing the 
antiviral state induced by type III IFN but not type I IFN.  
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Figure 21. Type III IFNs require MAPKs for their antiviral response. (A) T84 cells were 
mock treated (black bar) or pre-incubated for 30 minutes with 2 μM Pyridone 6 (pan-JAK inhibitor), 10 
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μM U0126 (ERK inhibitor), 10 μM SB202190 (p38 inhibitor), or 100 μM SP600125 (JNK inhibitor). 
Subsequently, T84 cells were mock treated (black bar) or treated with type I IFN (β) (2,000 RU/mL 
equivalent 8 ng/mL) or type III IFN (λ1−3) (300 ng/mL) in the presence the inhibitor. 2 hours post-IFN 
treatment cells were infected with a MOI of 1 with VSV -Luc (left panel) or MRV (right panel). Viral 
replication was assayed by measuring the luciferase activity or by relative quantification of viral 
genome using qRT-PCR. Data were normalized to non-IFN-treated sample for each inhibitor (set to 
100). (B) Same as (A), except T84 cells were pre-incubated with increasing concentrations of JAK or 
MAP kinase inhibitors prior to treatment with IFNs. (C) T84 cells were pre-incubated for 30 minutes 
with 2 μM Pyridone 6 (pan-JAK inhibitor), 10 μM U0126 (ERK inhibitor), 10 μM SB202190 (p38 
inhibitor) and 100 μM SP600125 (JNK inhibitor). Then the indicative concentrations of type I or III IFN 
were added in parallel to the inhibitor. 2 hours post-IFN treatment cells were infected with VSV-Luc 
(MOI = 1) and viral replication was assayed by measuring the luciferase activity. Data were 
normalized to non-IFN-treated samples for each inhibitor. The mean value obtained from three 
independent experiments is shown. Error bars indicate the SD. ****P < 0.0001, **P < 0.005, ns, not 
significant (unpaired t-test). The data of this figure was adapted from Pervolaraki et al., 2017. 
 
Although it has been shown in multiple cell lines that IFNs can induce the activation of 
MAPKs104,207,237, the importance of these kinases in the IFN-mediated antiviral state has 
never been reported to our knowledge. This suggests that dependency on MAPKs might be 
cell type specific. To ensure that the antiviral activity of type III IFN in primary non-
transformed human IECs depends on MAPKs, we used our mini-gut organoid culture 
system. Colon organoids were treated with pharmacological inhibitors of the JAK/STAT or 
MAPKs signaling pathways. Following pre-treatment with type I or type III IFNs, organoids 
were infected with VSV. 8 hpi, organoids were harvested and the impact of the 
pharmacological inhibitors on the antiviral activities of both IFNs was measured. As 
expected, inhibition of the JAK/STAT signaling pathway fully restores VSV infection to a 
level similar to infected organoids in the absence of IFNs (Figure 22). These results confirm 
that the JAK/STAT signaling pathway is key for both type I and type III IFN activity in primary 
human IECs. Importantly and similar to T84 cells, inhibition of either p38 or JNK signaling 
pathway partially impairs only the type III IFN antiviral activity in human mini-gut organoids 
(Figure 22). No significant effect of MAPK inhibition on type I IFN-mediated antiviral activity 
was observed. The effect of inhibiting ERK-dependent signaling on the antiviral activity of 
both IFNs was not determined (n.d.) since treatment of mini-gut organoids with ERK inhibitor 
induced disruption and death of the organoid culture (Figure 22 and data not shown). 
Altogether, these results corroborate that MAPK signaling pathways participate in the 
establishment of the antiviral state mediated by type III IFN in primary non-transformed 
human IECs.  
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Figure 22. The antiviral activity of type III IFNs strongly dependent on MAPKs in primary 
human intestinal epithelial cells. Human colon organoids were mock treated (black bar) or pre-
incubated with 2 μM Pyridone 6 (pan-JAK inhibitor), 10 μM U0126 (ERK inhibitor), 10 μM M 
SB202190 (p38 inhibitor) and 100 μM SP600125 (JNK inhibitor). One hour post-treatment, organoids 
were mock treated (black bar) or co-treated with type I IFN (β) (2,000 RU/mL equivalent 8 ng/mL) or 
type III IFN (λ1−3) (300 ng/mL) for 2 hours. Organoids were then infected with VSV-Luc (MOI = 1). 8 
hpi, viral replication was assayed by measuring the luciferase activity. Data are normalized to non-
IFN-treated sample for each inhibitor (set to 100). The mean value obtained from three independent 
experiments is plotted. Error bars indicate the SD. ****P < 0.0001, ***P < 0.001, ns, not significant 
(unpaired t-test), n.d. (not determined). The data of this figure was adapted from Pervolaraki et al., 
2017. 
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2.2 Differential induction of interferon stimulated genes between type I 
and type III IFNS is independent of interferon receptor abundance 
The text and figures of part 2.2 have been adapted from Pervolaraki et al. (2018), under 
preparation. This corresponds to a first author manuscript under preparation resulting 
directly from my PhD research project.  
It is currently believed that type I and III IFNs have redundant functions. However, the 
preferential distribution of type III IFN receptor on epithelial cells73-80 suggests functional 
differences at epithelial surfaces. In addition, apart from the spatial restriction of their 
receptors, quantitative differences in the cellular response of type I versus type III IFN 
suggest that type I and type III IFNs establish their antiviral program with distinct kinetics of 
response and magnitude of ISGs induction39,165,189,237,292-295. 
Comparative analysis of the profile of ISGs stimulation with type I and type III IFNs in human 
cells have so far been conducted only in hepatoma cells, lung epithelial cells and 
lymphocytes without including a direct correlation of the antiviral with the transcriptional 
activity of IFNs165,189,237,293-295. In addition, these studies by utilizing traditional experimental 
approaches focused on the signaling cascades downstream of IFN receptor and failed to 
explain the molecular mechanisms leading to this peculiar delayed and reduced induction of 
ISGs upon type III IFN treatment. 
Thus in this part of the presented thesis we followed a systems biology approach and 
combined mathematical modeling with time-resolved experiment data and proposed an 
alternative explanation where type III IFN receptor is expressed at lower levels at the cell 
surface. This lower receptor expression level could provide a biochemical explanation for the 
observed differences in delayed kinetics and weaker amplitude of ISG expression compared 
to type I IFN. In addition by utilizing different human intestinal epithelial cells and primary 
human-mini gut oganoids with functional receptor overexpression approaches we 
investigated whether the observed differences between both IFNs are intrinsic to both 
specific signal transduction pathways and whether they are restricted to some cell types 
(e.g. hepatocytes) or represent a global signaling signature in all cells expressing both IFN 
receptors. 
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2.2.1 Type III IFN-mediated antiviral protection is delayed compared to type I 
IFN.  
We have previously reported that both type I and III IFNs mediate antiviral protection in 
human IECs. To address whether type I and type III IFN have a different profile of antiviral 
activity in IECs, as reported in human lung cells295, we compared the potency of both IFNs in 
our human T84 intestinal epithelial cell model. Cells were pre-treated with increasing 
concentrations of either type I or III IFNs for 2.5 hours and subsequently infected with VSV-
Luc. Viral infection was assayed by bioluminescence and results showed that although both 
IFNs induced an antiviral state in a dose-dependent manner, type III IFNs were more 
efficient in protecting against viral infection at low concentrations, whereas type I IFN was 
more potent at higher concentrations (Figure 23A). The concentration of type I IFN 
necessary to provide 90% of relative antiviral protection (EC90) was significantly lower than 
the one for type III IFN (Figure 23B). Interestingly, at high concentrations, type I IFN could 
almost fully inhibit viral infection while type III IFN was only able to reduce infection to 90% 
(Figure 23A).  
To determine whether type III IFN requires a prolonged treatment to achieve similar antiviral 
protection as observed with type I IFN, we performed a time course experiment in which 
cells were pre-treated for different times with either IFN prior infection with VSV-Luc at 
concentrations which elicited their maximum antiviral activity (Figure 23C). We found that 
approximately 1 h pre-treatment with type I IFN was sufficient to reduce VSV infection by 
90% (10% remaining infection), while type III IFN required around 3.5 hours to achieve a 
90% reduction of infectivity (Figure 23C and 23D). Interestingly, 16 hours of pretreatment 
was necessary for type III IFN to almost completely prevent VSV infection (Figure 23C). 
These results strongly suggest that both type I and type III IFN could have similar potency 
but that type III IFN requires more time to establish an antiviral state. 
We next addressed how long after infection IFN treatment is still able to promote antiviral 
protection. T84 cells were infected with VSV-Luc and treated at different times post-infection 
with either type I or III IFNs. Interestingly, type I IFN could inhibit viral replication even when 
added several hours post-infection. In contrast, type III IFN appeared to require a much 
longer time to establish its antiviral activity, and was unable to efficiently protect cells after 
VSV infection has initiated (Figure 23E and 23F). Importantly, these kinetic differences were 
neither virus nor cell line specific as similar results were observed in T84 cells infected by 
MRV (data not shown) and in the SKCO15 colon carcinoma line (Figure 24). Taken together 
these results demonstrate that while both type I and III IFNs can promote similar antiviral 
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states into target cells, they do so with distinct kinetics. The cytokine-induced antiviral state 
is promoted faster by type I IFN compared to type III IFN. 
  
Figure 23. Kinetics of type I and type III IFN-mediated antiviral activities. (A-B) T84 cells were 
pre-treated with the indicated concentrations of type I IFN (β) or type III IFN (λ1−3) for 2.5 hours prior 
to infection with VSV-Luc using a MOI of 1. Viral replication was assayed by measuring the luciferase 
activity. (A) The relative antiviral protection is expressed as a percentage of total protection in VSV-
infected cells or (B) as the EC90 corresponding to the concentration of type I IFN (β) or type III IFN 
(λ1−3) resulting in 90% inhibition (10% infection) of viral replication. (C-D) T84 cells were treated with 
type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or type III IFN (λ1−3) (100ng/mL each or total 300 
ng/mL equivalent 13.7 nM) for indicated times prior to infection with VSV-Luc. Viral replication was 
assayed by measuring luciferase activity. (C) The relative VSV infection is expressed as the 
percentage of the luciferase activity present in VSV-infected cells without IFN treatment (set to 100). 
(D) Pre-incubation time of type I IFN (β) or type III IFN (λ1−3) required to inhibit VSV infection to 10% 
(90% inhibition). (E-F) Same as (C-D), except T84 cells were treated at the indicated times post-
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infection with VSV-Luc. (F) Delayed-time post-infection for type I IFN (β) or type III IFN (λ1−3) to still 
inhibit VSV infection to 90% (10% inhibition). Data in (A–F) represent the mean values of three 
independent experiments. Error bars indicate the SD. *<P.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001, ns, not significant (unpaired t-test). 
 
Figure 24. Kinetics of type I and type III IFN-mediated antiviral activities in SKCO15 cells. (A-B) 
SKCO15 cells were pre-treated with the indicated concentrations of type I IFN (β) or type III IFN 
(λ1−3) for 2.5 hours prior to infection with VSV-Luc using a MOI of 1. Viral replication was assayed by 
measuring the luciferase activity. (A) The relative antiviral protection is expressed as a percentage of 
total protection in VSV-infected cells or (B) as the EC90 corresponding to the concentration of type I 
IFN (β) or type III IFN (λ1−3) resulting in 90% inhibition (10% infection) of viral replication. (C-D) 
SKCO15 cells were treated with type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or type III IFN 
(λ1−3) (100ng/mL each or total 300 ng/mL equivalent 13.7 nM) for indicated times prior to infection 
with VSV-Luc. Viral replication was assayed by measuring luciferase activity. (C) The relative VSV 
infection is expressed as the percentage of the luciferase activity present in VSV-infected cells without 
IFN treatment (set to 100). (D) Pre-incubation time of type I IFN (β) or type III IFN (λ1−3) required to 
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inhibit VSV infection to 10% (90% inhibition). (E-F) Same as (C-D), except SKCO15 cells were treated 
at the indicated times post-infection with VSV-Luc. (F) Delayed-time post-infection for type I IFN (β) or 
type III IFN (λ1−3) to still inhibit VSV infection to 90% (10% inhibition). Data in (A–F) represent the 
mean values of three independent experiments. Error bars indicate the SD. *<P.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001, ns, not significant (unpaired t-test). 
2.2.2 Type I and III IFNs induce different amplitudes and kinetics of ISG 
expression.  
To understand how type I and type III IFNs promote an antiviral state in cells but with 
different kinetics, we analyzed the magnitude of ISG expression over time upon IFN 
treatment. T84 IECs were treated with increasing concentrations of either type I or type III 
IFN and the expression levels of two representative ISGs (IFIT1 and Viperin) were assayed 
at different times post-IFN treatment. Results revealed that type I IFN ultimately leads to a 
significantly higher induction of both IFIT1 and Viperin compared to type III IFN (Figure 25A 
and 25B). This difference in the magnitude of ISG stimulation was independent of both the 
duration of IFN treatment (Figure 25A and 25B) and the cell line used as similar results were 
obtained in the colon carcinoma derived SKCO15 and Caco2 cells and in non-transformed 
IECs using human mini-gut organoids (Figure 26A and 26B). To determine if this pattern of 
expression applies to other ISGs, we treated T84 cells with either type I or type III IFN over a 
24-hour time course, and analyzed the mRNA levels of 132 different ISGs and transcription 
factors involved in IFN signaling (see complete list of genes and corresponding primers in 
S1 and S2 Table) (Figure 25C and 25D). Differential expression analysis revealed that both 
type I and type III IFNs induce almost the same set of ISGs and that most of the genes 
significantly induced by type III IFN were also induced by type I IFN (Figure 25C). However, 
similar to IFIT1 and Viperin (Figure 25A and 25B), we found that the magnitude of ISG 
expression was always greater for type I IFN compared to type III IFN (Figure 25D). To 
ensure that type III IFN induces globally a lower transcriptional response in primary non-
transformed human IECs, the expression of the above set of 132 ISGs was analyzed in 
human mini-gut organoids upon stimulation with either type I or type III IFN over a 24-hour 
time course. Importantly, and similar to T84 cells, results revealed the weaker transcriptional 
activity of type III IFN compared to type I (Figure 26C and 26D). 
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Figure 25. Type III IFNs have a lower transcriptional activity compared to type I IFNs. (A-B) T84 
cells were stimulated with indicated concentrations of type I (β) or III IFN (λ1−3) for indicated times 
and the transcript levels of the ISGs IFIT1 and Viperin were analyzed by qRT-PCR. Data are 
normalized to TBP and HPRT1 and are expressed relative to untreated cells at each time point. A 
representative experiment with technical triplicates, out of three independent experiments is shown. 
Mean values and SD are shown. (C) T84 cells were treated with type I IFN (β) (2,000 RU/mL 
equivalent 0.33 nM) or type III IFN (λ1−3) (300 ng/mL equivalent 13.7 nM) for the indicated times and 
identification of the IFN-induced ISGs was performed by qRT-PCR. A total of 70 out of 132 ISGs 
tested were found to be significantly induced more than 2-fold compared with a baseline (mean of 
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untreated controls at the particular time points) for at least one time point by at least one IFN 
treatment. Data are normalized to TBP and HPRT1 and visualized in a heatmap using R after sorting 
the fold change of expression in response to type I IFN (β) in decreasing order. (D) Comparison of 
expression values (log2 (Fold Change)) for all genes induced at the indicated times with type I IFN (β) 
versus type III IFN (λ1−3). Solid line indicates equivalent expression. 
 
 
Figure 26. Type III IFNs have a lower transcriptional activity compared to type I IFNs in multiple 
intestinal epithelial cell lines. (A-B) SKCO15, Caco2 and primary IECs from human mini-gut 
organoids were stimulated with indicated concentrations of type I (β) or III IFN (λ1−3) for 6 hours and 
the transcript levels of the ISGs IFIT1 and VIPERIN were analyzed by qRT-PCR. Data are normalized 
to TBP and HPRT1 and are expressed relative to untreated cells. A representative experiment with 
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technical triplicates, out of three independent experiments is shown. Mean values and SD are shown. 
(C) Human mini-gut organoids were treated with type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or 
type III IFN (λ1−3) (300 ng/mL equivalent 13.7 nM) for the indicated times and identification of the 
IFN-induced ISGs was performed by qRT-PCR. A total of 65 out of 132 ISGs tested were found to be 
significantly induced more than 2-fold compared with a baseline (mean of untreated controls at the 
particular time points) for at least one time point by at least one IFN treatment. Data are normalized to 
TBP and HPRT1 and visualized in a heatmap using R after sorting the fold change of expression in 
response to type I IFN (β) in decreasing order. (D) Comparison of expression values (log2 (Fold 
Change)) for all genes induced at the indicated times with type I IFN (β) versus type III IFN (λ1−3). 
Solid line indicates equivalent expression. 
 
To address whether there is any correlation between the different antiviral protection kinetics 
conferred by type I and III IFNs (Figure 23) and the kinetics of ISG expression, we analyzed 
the temporal expression of ISGs upon IFN treatment. Hierarchical clustering analysis of all 
ISGs up-regulated upon type I or type III IFN treatment defined four distinct expression 
profiles based on the time of their maximum induction (Figure 27A-C). Group 1 are ISGs 
whose expression peaks 3 hours post-IFN treatment. The expression of ISGs in group 2 and 
3 peaks at 6 and 12 hours post-treatment, respectively. Group 4 corresponds to ISGs with a 
continuous increase in expression over time (Figure 27A and 27B). Under type I IFN 
treatment, ISGs were nearly equally distributed in all four expression groups (Figure 27A, 
27C, and 27D). By contrast, although the same ISGs were induced by type III IFN, they 
almost all belong to the expression group 4, being expressed late after IFN treatment (Figure 
27B-D). To exclude cell line specific effects, we analyzed the kinetic profiles of ISG 
expression in primary human intestinal epithelial cells. In line with our findings in T84 cells, 
by utilizing human mini-gut organoids, we could clearly demonstrate that type I and type III 
IFNs stimulate ISGs with very distinct kinetics in intestinal epithelial cells, with type III IFN 
inducing a more delayed transcriptional response (Figure 28A-D). 
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Figure 27. Type III IFNs present delayed transcriptional activity compared to type I IFNs in 
intestinal epithelial cells. (A-D) T84 cells were treated with type I IFN (β) (2,000 RU/mL equivalent 
0.33 nM) or type III IFN (λ1−3) (300 ng/mL equivalent 13.7 nM) for 3, 6, 12 or 24 hours and the kinetic 
pattern of expression of the 70 significantly up-regulated ISGs were analyzed by qRT-PCR in 
triplicates. Data are normalized to TBP and HPRT1 and are expressed relative to untreated cells at 
each time point. Hierarchical clustering analysis of these genes produced four distinct temporal 
expression patterns (Groups 1-4) based on the time-point of the maximum induction in response to 
type I IFN (β) or type III IFN (λ1−3). Color codes have been used to visualize the induction peak per 
group. (A-B) Gray lines show the normalized kinetic expression of each gene for each group upon 
treatment with (A) type I IFN (β) or (B) type III IFN (λ1−3). The colored lines are the average of the 
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kinetic profiles for the genes of each group. (C) Gene expression heat map showing the genes 
clustered in their respective temporal expression patterns groups in response to type I IFN (β) or type 
III IFN (λ1−3). The genes per group are sorted in decreasing order on the basis of their fold change of 
expression in response to type I IFN (β) or type III IFN (λ1−3) and only showing the highest expressed 
values within the temporal groups omitting all other values for visualization. (D) Number of genes 
belonging to each group. 
 
Figure 28. Type III IFNs present delayed transcriptional activity compared to type I IFNs in 
human mini-gut organoids. (A-D) Human mini-gut organoids were treated with type I IFN (β) (2,000 
RU/mL equivalent 0.33 nM) or type III IFN (λ1−3) (300 ng/mL equivalent 13.7 nM) for 3, 6, 12 or 24 
hours and the kinetic pattern of expression of the 65 significantly up-regulated ISGs were analyzed by 
qRT-PCR in triplicates. Data are normalized to TBP and HPRT1 and are expressed relative to 
untreated cells at each time point. Hierarchical clustering analysis of these genes produced four 
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distinct temporal expression patterns (Groups 1-4) based on the time-point of the maximum induction 
in response to type I IFN (β) or type III IFN (λ1−3). Color codes have been used to visualize the 
induction peak per group. (A-B) Gray lines show the normalized kinetic expression of each gene for 
each group upon treatment with (A) type I IFN (β) or (B) type III IFN (λ1−3). The colored lines are the 
average of the kinetic profiles for the genes of each group. (C) Gene expression heat map showing 
the genes clustered in their respective temporal expression patterns groups in response to type I IFN 
(β) or type III IFN (λ1−3). The genes per group are sorted in decreasing order on the basis of their fold 
change of expression in response to type I IFN (β) or type III IFN (λ1−3) and only showing the highest 
expressed values within the temporal groups omitting all other values for visualization. (D) Number of 
genes belonging to each group. 
 
To control that the differences in ISG expression kinetics between type I and III IFNs are not 
only true at the transcriptional level but also at the protein level, we checked the protein 
expression of three ISGs (IRF1, IFIT1, MXA) over time post-IFN treatment. We found that 
the difference in the kinetics of ISG expression between both type I and type III IFNs is also 
present at the protein level (Figure 29A-C). 
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Figure 29. Temporal differences of ISG expression induced by type I and type III IFNs. (A-C) 
T84 cells were stimulated with type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or type III IFN (λ1−3) 
(300 ng/mL equivalent 13.7 nM) for the indicated times. (A) The transcript levels of the ISGs IRF1, 
IFIT1 and MXA were assessed by qRT-PCR. Data were normalized to HPRT1 and are expressed 
relative to untreated cells of each time point. The mean value obtained from three independent 
experiments is shown. Error bars indicate the SD. (B) The protein levels of the ISGs IRF1, IFIT1 and 
MXA are analyzed by Western blot. EF-2 was used as a loading control. A representative immunoblot 
is shown. (C) Quantification of ISGs levels from Western blot in (B). Quantification is expressed 
relative to untreated cells and normalized using EF-2 as loading control. Data represent the mean 
values of two independent experiments. Error bars indicate the SD. 
 
We next wanted to control that our observed differences in the kinetics of ISGs expression 
induced by both cytokines were independent of IFN concentration. T84 cells were treated 
with increasing amounts of type I or type III IFNs and the transcriptional up-regulation of 
representative ISGs belonging to each of the expression profile groups (group 1-4, Figure 
27) was measured over time. Consistent with our previous results, the temporal expression 
patterns of the representative ISGs were independent of the IFN concentration and the ISG 
expression kinetic signature was specific to each IFN (Figure 30A-D). Altogether, our results 
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strongly suggest that although both type I and type III IFNs induce a similar set of ISGs in 
hIECs, type III IFN induces globally a lower amplitude and a delayed ISG expression 
compared to type I IFN.  
 
Figure 30. Validation of the unique kinetic patterns of ISG expression upon type I versus type 
III IFN treatment. (A-D) T84 cells were stimulated with increasing concentrations of type I IFN (β) or 
III IFN (λ1−3) for indicated times and the kinetic pattern of expression of one representative ISG from 
each temporal expression patterns groups 1-4 was analyzed by qRT-PCR, (left column) type I IFN 
(β), (right column) type III IFN (λ1−3) treated cells. Data are normalized to HPRT1 and are expressed 
relative to untreated cells at each time point. A representative experiment with technical triplicates, out 
of three independent experiments is shown. Mean values and SD are shown. 
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2.2.3 Mathematical modeling reveals that IFN receptor abundance modulates 
the magnitude of ISG response while its kinetic profile is largely 
preserved  
Our data show remarkable differences in the magnitude and kinetics of ISGs induced by 
type I versus type III IFN (Figure 25-28), and in the subsequent induction of a differential 
antiviral state (Figure 23-24). To investigate the mechanisms underlying these differences, 
we developed a data-driven mathematical model of both IFNs. The model describes the 
dynamics of receptor activation and inactivation, STAT1/2 phosphorylation and STAT-
dependent activation of ISG expression (Figure 31A). The model was implemented as a 
system of ordinary differential equations and fitted to the time-resolved data for the 
prototypical ISG, Viperin, measured with different doses of type I or type III IFNs (S1 Table). 
The model accounted for both the dose-response and the different Viperin expression 
kinetics triggered by type I or type III IFN, group 3 and group 4 expression kinetics 
respectively (Figure 31B-C). Using our mathematical model, we could predict that at low IFN 
concentrations, Viperin is induced almost equally by both IFNs whereas at higher 
concentrations, type I IFN induces a stronger transcriptional up-regulation of Viperin (Figure 
31D). These predictions are in good agreement with our experimental data (Figure 31B, right 
panel). 
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Figure 31. Mathematical modeling of type I and type III IFN responses. (A) Scheme of the 
mathematical model. The empty set sign “∅” represents sink. (B-C) The mathematical model 
reproduces the Viperin expression dynamics upon treatment with different concentrations of (B) type I 
IFN (β) and (C) type III IFN (λ1−3). In (B) and (C), the solid lines represent the best fits and the 
shaded areas are approximate 95% confidence intervals. (D) Simulation of the maximum Viperin 
induction upon treatment with equal concentrations of type I IFN (β) or type III IFN (λ1−3). (E-F) The 
mathematical model shows the effect of IFNAR1 and IFNLR1 overexpression up to 5-fold 
(5×IFNAR1wt and 5×IFNLR1wt) on Viperin activation upon treatment with representative 
concentrations of type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or type III IFN (λ1−3) (300 ng/mL 
equivalent 13.7 nM), respectively. Modeling has been performed by Soheil Rastgou Talemi, 
Heidelberg University and German Cancer Research Center (DKFZ). 
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Both type I and type III IFN receptor complexes mediate STAT-driven ISG expression but 
they do so at different rates. The components that are specific to each IFN pathway are the 
receptors38,39 and therefore we assume that the activation and inactivation of type I and III 
IFN receptor complexes may be differentially regulated. The simulations of the 
parameterized model show transient activity of type I IFN receptor (IFNAR) complex and 
sustained activity of type III IFN receptor (IFNLR) complex (Figure 32). The model suggests 
that the sustained activity of IFNLR complex is mainly due to its longer half-life compared to 
IFNAR complex. This prediction is further supported by statistical analysis of the estimated 
model parameters, showing that the confidence bounds of the estimated inactivation rates of 
the two receptors do not overlap (S1 Figure). Altogether, our data-based mathematical 
model shows that the differential kinetics of the ISG responses to type I and type III IFNs 
could be explained by the different activation and inactivation kinetics of the respective 
receptors. 
 
Figure 32. Comparative simulation of type I and type III IFN receptor complex activation. 
Cellular concentration of the activated type I or type III IFN receptor complex, upon treatment with 0.1 
nM of IFNs, are simulated using the calibrated model. Modeling has been performed by Soheil 
Rastgou Talemi, Heidelberg University and German Cancer Research Center (DKFZ). 
 
Additionally, according to our model the density of IFN receptors at the cell surface 
represents a critical determinant for the activity exhibited by the two IFNs. In particular, our 
model stimulation predicts that if we increase the receptor level, we increase the 
transcriptional potency of IFNs but the kinetic profiles of ISGs induction is largely preserved 
(Figure 31E-F). To experimentally validate the model predictions, IFNAR1 and IFNLR1 were 
overexpressed in T84 cells. Overexpression of the respective IFN receptor chain was 
confirmed by qRT-PCR (Figure 33A-C). 
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Figure 33. Expression levels of IFN receptors in T84 cells. (A) T84 wild-type cells, (B) T84 cells 
overexpressing rIFNAR1 (WT+rIFNAR1) and (C) T84 cells overexpressing rIFNLR1 (WT+rIFNLR1) 
were analyzed by qRT-PCR to quantify the transcript levels of IFNAR1, IFNAR2, IFNLR1 and IL10RB 
(IFNLR2). Data are normalized to HPRT1. The mean value obtained from three independent 
experiments is shown. Error bars indicate the SD. *<P.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 
ns, not significant (unpaired t-test). 
 
 To ensure the functionality of both IFN receptors, IFNAR1 or IFNLR1 were expressed in our 
previously characterized knockout T84 cell lines deficient for either the IFN alpha receptor 1 
(IFNAR1-/-) or the IFN lambda receptor 1 (IFNLR1-/-)100 (Figure 34A and 34F). Our results 
show that overexpression of IFNAR1 in our IFNAR1-/- T84 cells (IFNAR1-/-+rIFNAR1) 
restores their antiviral activity, their ability to phosphorylate STAT1 and their production of 
the ISGs IFIT1 and Viperin in the presence of type I IFN (Figure 34B-E). Similarly, although 
IFNLR1-/- cells were insensitive to type III IFN treatment, overexpression of IFNLR1 
(IFNLR1-/-+rIFNLR1) restored their antiviral activity, pSTAT1 and ISG induction after 
addition of type III IFN (Figure 34G-J). These results demonstrate the functionality of both 
IFN receptors and validate our overexpression approach as a mean to increase IFNAR1 and 
IFNLR1 levels at the cell surface. 
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Figure 34. Type I and type III IFN receptors are functional when overexpressed into cells. (A-E) 
T84 IFNAR1-/- cells were rescued by stable expression of a cleavage resistant mutant of rIFNAR1 
(see methods for details) (T84 IFNAR1-/- + rIFNAR1). (B-E) T84 IFNAR1-/-, T84 IFNAR1-/- + 
rIFNAR1 cells and control T84 cells scramble gRNA (SCR) were pre-treated with type I IFN (β) (2,000 
RU/mL equivalent 0.33 nM) or type III IFN (λ1−3) (300 ng/mL equivalent 13.7 nM). (B) 2.5 h post-
treatment, T84 cells were infected with VSV-Luc (MOI = 1). Viral replication was assayed by 
measuring the luciferase activity. For each sample luciferase activity was measured in triplicates and 
is expressed as the percentage of the luciferase signal in VSV-infected cells without IFN treatment 
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(set to 100) for each cell lines. (C) 1h post IFN treatment, IFN signaling was measured by 
immunoblotting for pSTAT1 Y701. Actin was used as a loading control. A representative immunoblot 
out of three independent experiments is shown. (D-E) same as (B), except that induction of IFN-
stimulated genes was monitored by relative qRT-PCR quantification of IFIT1 and Viperin at the 
indicated times post-IFN treatment. (F-J) same as (A-E) except that T84 IFNLR1-/- were rescued by 
stable expression of a cleavage resistant mutant of rIFNLR1 (T84 IFNLR1-/- + rIFNLR1). Data were 
normalized to HPRT1 and are expressed relative to untreated cells of each time point. The mean 
value obtained from three independent experiments is shown. Error bars indicate the SD.  
 
Wild-type T84 cells overexpressing type I IFN receptor (WT+rIFNAR1) were treated with 
increasing concentrations of type I IFN. Our results show elevated levels of STAT1 
phosphorylation and ISG induction in response to stimulation with type I IFN compared to 
wild-type cells (Figure 35A-C). Importantly, the response of T84 cells overexpressing type I 
IFN receptor to type III IFN remained unchanged, indicating a selective enhancement of the 
type I IFN signaling pathway. Similarly, overexpression of type III IFN receptor 
(WT+rIFNLR1) shows a significant increase in phosphorylated STAT1 and ISG expression 
compared to wild-type cells upon type III IFN stimulation, while no difference was observed 
upon type I IFN treatment (Figure 35D-F). Altogether, our experimental data are consistent 
with the modeling predictions and confirm the crucial impact of surface receptor levels for 
regulating the magnitude of type I and III IFN response. 
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Figure 35. Overexpression of type I and type III IFN receptor increases the transcriptional 
activity of both cytokines. Wild-type T84 cells were transduced with rIFNAR1 or rIFNLR1 to create 
stable lines overexpressing either IFN receptors. (A) T84 wild-type cells (WT) and T84 cells 
overexpressing rIFNAR1 (WT+rIFNAR1) were treated with type I IFN (β) (2,000 RU/mL equivalent 
0.33 nM) or type III IFN (λ1−3) (300 ng/mL equivalent 13.7 nM) for 1 hour and IFN signaling was 
measured by immunoblotting for pSTAT1 Y701. Actin was used as a loading control. A representative 
immunoblot out of three independent experiments is shown and the quantification of pSTAT1 levels. 
(B-C) T84 wild type cells (WT) and T84 cells overexpressing rIFNAR1 (WT+rIFNAR1) were treated 
with increasing concentrations of type I IFN (β) for 12 hours or type III IFN (λ1−3) for 24 hours and the 
transcript levels of the ISGs IFIT1 and VIPERIN were analyzed by qRT-PCR. Data are normalized to 
HPRT1 and are expressed relative to untreated cells at each time point. (D-F) Same as (A-C), except 
T84 cells overexpressing rIFNLR1 (WT+IFNLR1) were used. The mean value obtained from three 
independent experiments is shown. Error bars indicate the SD. *<P.05, **P < 0.01, ***P < 0.001, ****P 
< 0.0001, ns, not significant (unpaired t-test). 
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We next addressed whether this increase of ISG expression in cells overexpressing either 
the type I or type III IFN receptor was associated with an improved antiviral activity. Wild-
type T84 cells overexpressing type I IFN receptor (WT+rIFNAR1) were treated with type I 
IFN at different time points prior to infection with VSV-Luc virus and their antiviral activity 
was compared to wild-type T84 cells. Our results showed that the potency and the kinetics 
of the antiviral activity of cells overexpressing type I IFN receptor does not present any 
significant change upon type I IFN treatment (Figure 36A-B). Similarly, there is no difference 
in the antiviral activity when cells overexpressing type I IFN receptor were treated with type I 
IFN at different time points post-infection (Figure 37A-B). The response of T84 cells 
overexpressing type I IFN receptor to type III IFN remained also unchanged (Figure 36C-D 
and 37C-D). However, overexpression of type III IFN receptor (WT+rIFNLR1) shows a 
modest but significant enhancement in type III IFN antiviral potency in the earlier time points 
of pre-treatment (between 30 minutes and 2 hours) compared to wild-type cells upon type III 
IFN stimulation (Figure 36G), while they responded similarly to wild-type cells upon type I 
IFN treatment (Figure 36E-F). Consistent with this, cells overexpressing type III IFN receptor 
are more protected than wild-type cells when type III IFN was added post-infection for the 
early time points (Figure 37G), while they responded similarly to wild-type cells upon type I 
IFN treatment (Figure 37E-F).  
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Figure 36. Establishment of an antiviral state in cells overexpressing the IFN receptors and 
treated with IFNs. Wild-type T84 cells were transduced with rIFNAR1 or rIFNLR1 to create stable 
lines overexpressing either receptor.  (A-D) T84 wild-type cells (WT) and T84 cells overexpressing the 
IFNAR1 (WT+rIFNAR1) were treated with (A-B) type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or 
(C-D) type III IFN (λ1−3) (100ng/mL each =300 ng/mL equivalent 13.7 nM) at the indicated times prior 
to infection with VSV-Luc. Viral replication was assayed by measuring the luciferase activity. (A, C) 
The relative VSV infection is expressed as the percentage of the luciferase activity present in VSV-
infected cells without IFN treatment (set to 100). (B, D) Pre-incubation time of type I IFN (β) or type III 
IFN (λ1−3) required to inhibit VSV infection to 10% (90% inhibition). (E-H) same as (A-D), but T84 
wild-type cells (WT) and T84 cells overexpressing the IFNLR1 (WT+rIFNLR1) were treated with (E-F) 
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type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or (G-H) type III IFN (λ1−3) (100ng/mL each =300 
ng/mL equivalent 13.7 nM) at the indicated times prior to infection with VSV-Luc. Data represent the 
mean values of three independent experiments. Error bars indicate the SD. *<P.05, **P < 0.01, ns, 
not significant (unpaired t-test). 
 
Figure 37. Establishment of an antiviral state in cells overexpressing the IFN receptors and 
treated with IFNs post-infection. Wild-type T84 cells were transduced with rIFNAR1 or rIFNLR1 to 
create stable lines overexpressing either receptor. (A-D) T84 wild-type cells (WT) and T84 cells 
overexpressing the IFNAR1 (WT+rIFNAR1) were treated with (A-B) type I IFN (β) (2,000 RU/mL 
equivalent 0.33 nM) or (C-D) type III IFN (λ1−3) (100ng/mL each =300 ng/mL equivalent 13.7 nM) at 
the indicated times post-infection with VSV-Luc. Viral replication was assayed by measuring the 
luciferase activity. (A, C) The relative VSV infection is expressed as the percentage of the luciferase 
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activity present in VSV-infected cells without IFN treatment (set to 100). (B, D) Delayed-time post-
infection for type I IFN (β) or type III IFN (λ1−3) to still inhibit VSV infection to 90% (10% inhibition) is 
shown. (E-H) same as (A-D), but T84 wild-type cells (WT) and T84 cells overexpressing the IFNLR1 
(WT+rIFNLR1) were treated with (E-F) type I IFN (β) (2,000 RU/mL equivalent 0.33 nM) or (G-H) type 
III IFN (λ1−3) (100ng/mL each =300 ng/mL equivalent 13.7 nM) at the indicated times post-infection 
with VSV-Luc. Data represent the mean values of three independent experiments. Error bars indicate 
the SD. *<P.05, ns, not significant (unpaired t-test). 
 
Finally, to experimentally validate the limited impact of the IFN receptors abundance on the 
kinetic profile of ISG expression, as predicted by the model (Figure 31E-F), wild-type T84 
cells overexpressing either of the IFN receptors were treated with increasing doses of type I 
or type III IFNs and the expression of ISGs was analyzed over time (Figure 38). The 
experimental data shows that the amplitude of IFIT1 and Viperin expression was dependent 
on both the dose of IFNs used to stimulate the cells and on the expression levels of the IFN 
receptors (Figure 38). Importantly, the kinetic profile of Viperin expression was similar 
between WT cells and cells overexpressing the IFNAR1 (WT+rIFNAR1), independent of the 
applied IFN type I dose (Figure 38A-B). Similarly, wild-type cells overexpressing the IFNLR1 
(WT+rIFNLR1) showed no change in the kinetic profile of ISG induction upon type III IFN 
stimulation (Figure 38C-D). Moreover, we found that the model reproduced the kinetic dose-
response data when the IFNAR1 and IFNLR1 expression levels were increased ~3 and ~1.6 
fold, respectively, while all other parameters were held constant (Figure 39A). The relative 
magnitude of IFNAR1 versus IFNLR1 overexpression predicted by the model was confirmed 
by the transcriptional expression level of IFNAR1 versus IFNLR1 in overexpressing versus 
wild-type cells (Figures 39B and 34B-C). 
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Figure 38. Expression kinetics of ISGs are independent of the IFN receptor levels. Wild-type 
T84 cells were transduced with rIFNAR1 or rIFNLR1 to create stable lines overexpressing either 
receptor. (A-B) T84 wild-type cells (WT) and T84 cells overexpressing the IFNAR1 (WT+rIFNAR1) 
were treated with increasing concentrations of type I IFN (β) for the indicated times and the 
expression kinetics of the ISGs IFIT1 (A) and VIPERIN (B) were analyzed by qRT-PCR. Data are 
normalized to HPRT1 and are expressed relative to untreated cells at each time point. (C-D) Same as 
(A-B), except T84 cells overexpressing the IFNLR1 (WT+IFNLR1) were used and treated with 
increasing concentrations of type III IFN (λ1−3). A representative experiment with technical triplicates, 
out of three independent experiments is shown. Mean values and SD are shown. 
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Figure 39. The mathematical model predicts the effect of IFNAR1 and IFNLR1 overexpression 
on ISGs activation. (A) The IFNAR1 and IFNLR1 levels were increased ~3 and ~1.6 fold, 
respectively, while all other parameters were held constant and the mathematical model predicts the 
Viperin activation upon treatment with different concentrations of type I IFN (β) and type III IFN 
(λ1−3). The solid lines are the best fits and the shaded areas are approximate 95% confidence 
intervals. (B) The mathematical model predicts the IFNAR1 versus IFNLR1 overexpression, 
measured experimentally by qRT-PCR. Modeling has been performed by Soheil Rastgou Talemi, 
Heidelberg University and German Cancer Research Center (DKFZ). 
 
Altogether, our results demonstrate that type I and type III IFNs both induce an antiviral state 
in hIECs but with different kinetics. We could show that although both cytokines induce 
similar ISGs, type III IFN does it with slower kinetics and lower amplitude of individual ISG 
expression compared to type I IFN. Importantly, coupling mathematical modeling of both 
type I and type III IFN-mediated signaling and overexpression of functional IFN receptors 
approaches allowed us to demonstrate that these kinetic differences in type I and type III 
IFN ISG expression are not due to different expression levels of the respective IFN receptors 
but are intrinsic to type I and type III IFN signaling pathways. 
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3 Discussion 
The text of the following paragraphs (3.1) and (3.3) has been adapted from Pervolaraki et al. 
(2017)100. This corresponds to a co-first author published manuscript resulting directly from 
my PhD research project.  
3.1 Type I and type III IFNs display a different dependency on mitogen-
activated protein kinases (MAPK) to mount an antiviral state in the 
human gut 
In recent years, there has been a large interest in uncovering the specific roles of type III 
IFNs in epithelial cells including lung epithelium, gastrointestinal tract epithelium and in 
hepatocytes. In addition, taking into account that the majority of these studies have utilized 
in vivo mouse models, it is of great importance to evaluate the epitheliotropic nature of type 
III IFNs in the human host. In this work, by exploiting human mini-gut organoids, we 
performed a functional characterization of both type I and type III IFNs in a human primary 
intestinal cell context. We found that, upon viral infection, human IECs strongly upregulate 
both type I and type III IFNs at the transcriptional level. Although only type III IFN was found 
to be secreted by IECs, we demonstrated that either type I or type III IFNs induce the 
production of ISGs and that this production is associated with the establishment of an 
antiviral state that efficiently protects IECs from viral infection. Importantly, we revealed that 
type III IFN-mediated signaling allows for efficient protection against viral infection while 
limiting ISG production. We propose that this represents a mechanism to limit inflammation 
in the gut while remaining responsive to pathogens.  
Additionally, genetic ablation of IFN signaling using CRISPR/ Cas9-mediated KO of IFN 
receptors further demonstrated that type I and III IFNs independently mediate an antiviral 
activity. Comparative analyses revealed that both IFNs induce the same set of ISGs and that 
both antiviral states depend on the JAK/STAT signaling pathway. Importantly, we discovered 
that the type III IFN-mediated, but not the type I IFN-mediated antiviral activity depends on 
MAPK signaling pathways. This work establishes that both type I and III IFNs provide potent 
antiviral protection in the human gut, and identifies, for the first time, fundamental differences 
in the mechanism by which these two IFN types establish the antiviral state in primary 
hIECs.  
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3.1.1 Both type I and type III IFNs establish an antiviral state in primary human 
IECs 
In the past, a number of different human intestinal cell lines have been established to 
evaluate the response of the gastrointestinal tract epithelium to infection120,207,300,301. 
However, clonal expansion of a specific intestinal cell population does not reflect the 
complex multicellular composition of the GI tract and the transformed nature of the 
immortalized cell lines could potentially mask subtle but important differences in primary 
non-transformed cell responses. In addition, maintenance of human primary intestinal 
epithelial cells for in vitro culture has been restricted due to fast decline in cell viability4,302. 
For this, the implementation of organoid cultures has open new perspectives for functional 
analysis of the human intestinal responses and has gained substantial and increasing 
interest in the fields of cellular biology and medicine303,304. Even more interestingly, this 
system creates the unique opportunity to evaluate host responses from different individuals 
(different age, genetic background and disease state) and also from different parts of the GI 
tract.  More recently, these organoids have been also used to study and describe infectious 
diseases and gave researches the chance to overcome the limitation of studying human 
pathogens in vivo (Foulke-Abel et al., 2014). Up to now, being the most cutting edge tool to 
investigate host-pathogen interactions in the GI tract, mini-gut organoids have been proven 
a precious model to study infection with different enteric bacteria and viruses such as 
Salmonella Typhimurium, Helicobacter pylori, norovirus, rotavirus and reovirus100,305–308. 
In the present study, we have exploited organoids not only to describe the response of 
hIECs upon pathogen challenges but even more importantly to perform a functional 
characterization of both type I and type III IFNs in the context of human primary non-
transformed IECs. In contrast to data upon viral infection of the mouse GI tract, our results 
demonstrate that hIECs can mount an antiviral state in response to either type I or type III 
IFN treatment. Similar observations, have been made in human organoid cultures upon 
rotavirous infection in combination with exogenous stimulation with either type I or type III 
IFN98.  
Species specific differences in IFN system between mice and humans have been suggested 
as an explanation for the discrepancy between the in vivo murine studies in adult animals, 
where mouse intestinal epithelial cells respond mainly to type III IFN, while type I IFN act on 
endothelial and immune cells75,77–80,96,97, and the ex vivo human intestinal organoid 
cultures98,100. However, this argument remains controversial as further experiments 
demonstrated that isolated murine IECs respond to both IFNs when they are cultured ex 
vivo, pointing out the subcellular localization of type I IFN receptor at the apical side of 
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polarized IECs as a possible explanation for the limitation in type I IFN response in vivo 
upon viral infection or parenteral administration of IFNs79. In line with these observations, 
recent studies have shown murine intestinal organoids to be fully responsive to both 
IFNs309,310. Down-regulation of type I IFN receptor level in vivo, triggered by immune or 
microbial factors, has been proposed as an explanation for this differential 
responsiveness44,80. However, the exact mechanism remains to be elucidated and although 
it is of great importance to unravel the subcellular localization of type I and type III IFN 
receptors and directly compare their cellular ratio at the protein level, these studies have 
been hindered for years by the lack of appropriate reagents such as specific antibodies 
against type I and type III IFN receptor.  
 Another potential explanation for the in vivo versus the in vitro responsiveness of IECs to 
IFN stimulation, might be the specific type I IFN subtypes utilized, which may present 
differential antiviral sensitivity154,311. In particular, IFN-α was utilized in the above-mentioned 
in vivo studies in the mouse GI tract79,80, while murine and human organoids were 
exogenously treated with IFN-β98,100,309,310. Last but not least, another level of complexity has 
been added by a recent study describing age dependent responsiveness of murine IECs to 
type I IFN in vivo, where neonatal IECs respond and are protected by both IFNs, whereas 
adult IECs have a significantly limited responsiveness to type I IFN97. 
As far as the epithelium of other mucosal surfaces is concerned, in vivo and in vitro studies 
of mouse and human lung epithelial cells as well as human hepatoma cells are in 
accordance with our observations, where both type I and type III IFNs participate in the 
protection against viral infection. In particular, respiratory epithelial cells express both type I 
and III IFN receptors and respond to both IFNs, which explains the degree of redundancy 
shown between the two IFN systems in their activity against respiratory viruses76,77,90,93,312. 
Moreover, in concert with our data in human intestinal organoids, although mouse 
hepatocytes are less responsive to type III IFN, both IFNs contribute to the establishment of 
an antiviral state in human hepatoma cells and primary untransformed 
hepatocytes165,189,293,294. 
3.1.2 Type III IFN is predominantly produced in human IECs during viral 
infection 
Our functional characterizations performed in both mini-gut organoids and colon carcinoma-
derived cell lines revealed that although these cells transcriptionally upregulate both type I 
and III IFNs, they secrete very little to no type I IFN. A favored type III IFN response over 
type I IFN has been observed in other epithelial cells stimulated with various viruses and 
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pathogen-associated molecular patterns. Particularly, it was shown that although both IFNs 
can protect airway epithelial cells against viral infection, type III IFNs were preferentially 
made in response to respiratory viruses74,92,93,99,313. Similarly intestinal epithelial cells 
preferentially produce type III IFN rather than type I IFN in mouse GI tract79,80,97,283. However, 
in the above in vivo studies the induction of IFNs has been exclusively assessed at the 
transcript level. Interestingly, in agreement with our results, it has been described that upon 
stimulation of human intestinal organoids with the double strand RNA structural analog poly-
inosinic:cytidylic acid (poly I:C), only type III IFN was secreted by the cells although both 
type I and III IFNs were upregulated at the transcriptional level98. Additionally, a preferential 
induction of type III IFNs has been reported upon HBV and HCV infection in 
hepatocytes314,315. Consequently, favoring type III IFN signaling appears to be a common 
strategy developed at epithelial surfaces (airway, hepatocytes, intestinal tract) to mount an 
antiviral response.  
Despite the high importance of this ‘’pan-epithelial’’ preferential type III IFN induction, the 
molecular mechanisms that predispose type III IFN production by epithelial cells have not 
been unraveled, raising the possibility that it is regulated at differential levels from 
transcription to translation and secretion. At the transcriptional level, the production of both 
type I and type III IFNs has been shown to be triggered by similar stimuli and a set of 
overlapping and distinct transcriptional factors, mainly members of the IRF, the NF-kB and 
the MAP kinase pathway. Interestingly, while IFN-β induction requires simultaneous 
activation of all the transcriptional pathways134–136, type III IFNs can be induced by either 
IRFs or NF-kB142,316, which not only might explain the higher inducibility of type III IFNs in 
epithelial cells, but also may be beneficial in case of pathogen-mediated IRF or NF-kB 
inhibition143.  
Another difference in type I versus type III IFN production, is based on the differential 
contribution of peroxisomal MAVs, downstream the RIG-I-like receptors activation. Apart 
from mitochondrial-associated MAVs which induce the production of both type I and type III 
IFNs, it has been described that peroxisomal-bound MAVs induce only type III IFN 
expression in response to intracellular ligands without stimulating type I IFN production114,296. 
Moreover, while downstream of peroxisomal MAVs, type III IFN induction is mediated 
through IRF3, IRF7, NF-kB and IRF-1, type I IFN up-regulation has been shown to rely on a 
different combination of transcriptional factors downstream mitochondrial-bound MAVs 
including IRF3, IRF-7, NF-kB and AP-1114,316,317. Even more interestingly, it has been 
demonstrated that the abundance of cellular peroxisomes is directly associated with the 
differential induction of IFNs. In other words, an increase in the number of peroxisomes via 
polarization of epithelial cells has been reported to enhance type III IFN-mediated antiviral 
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responses114 and has been proposed as an epithelial specific mechanism for explaining the 
favoring of type III IFN production in mucosal surfaces. However, taking into account that 
comparable contribution from both mitochondrial and peroxisomal MAVs in type III IFN 
induction has been shown in a recent study, further work is required to clarify the 
involvement of peroxisomal MAVs in the mechanism of type I versus type III IFN 
induction318. 
Recently, additional transcriptional factors related only to type III IFN production have been 
identified. For instance, a member of the Mediator complex Med23, has been shown to 
specifically interact with IRF7 and augment type III IFN up-regulation319. In addition, a 
specific binding of the transcriptional repressors ZEB1 and BLIMP1 in IFNL1 promoter has 
been described, which displaces IRF1 and specifically leads to down-regulation of type III 
IFN transcription in lung and intestinal epithelial cells316,319.  
Furthermore, yet unidentified tissue-specific transcriptional factors, present at epithelial 
tissues might be responsible for preferential production of type III IFN upon infection of 
barrier surfaces. In addition, it is notable that IFN genes behave also as ISGs and a 
functional interrelationship between the two IFN systems has been proposed, since type I 
IFN priming of hepatocytes and immune cells has been shown to enhance type III IFN 
production upon viral infection112,320. Priming of type I IFN induction by type III IFNs remains 
still controversial among different cell lines44.  
Downstream from the transcriptional regulation, the fact that, contrary to the intron-less type 
I IFN genes, type III IFN genes are composed of multiple exons and introns reflecting the 
possibility of post-transcriptional modification, which might differentially regulate type III IFN 
production60. In addition to this, it remains unclear whether translation or secretion of type I 
IFN is restricted in human IECs. To date, very little is known about the mechanisms that lead 
to type I and III IFN secretion. It has been shown that signaling downstream of 
mitochondrial-associated MAVS induces the secretion of type I IFN that can be inhibited by 
brefeldin A. On the contrary, the antiviral activity generated following activation of 
peroxisomal-associated MAVS was insensitive to brefeldin A296. It was later demonstrated 
that this brefeldin A-insensitive antiviral state was mediated by type III IFN, which was 
secreted following activation of peroxisomal MAVS114. These observations strongly suggest 
that type I and III IFNs are secreted from cells by two distinct mechanisms.  
It is not known whether hIECS can protect themselves against viral infection by secreting 
and responding to their own IFNs. It was proposed that, during rotavirus infection, IFNs are 
produced by immune cells and not by epithelial cells98. Indeed, during rotavirus infection of 
hIECs, multiple strategies are developed by the virus to inhibit innate immune response 
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particularly the inhibition of both type I and III IFNs production321. Additionally, blocking IFN 
signaling in hIECs does not lead to an increased rotavirus replication98. Our data clearly 
show, for the first time, that when primary hIECs are infected with viruses that do not block 
IFN synthesis, hIECs produce and secrete at least type III IFN (maybe some type I IFN but 
under the detection limit of our ELISA assay) in order to protect themselves. 
Complementarily, KO of IFNLR renders hIECs more susceptible to viral infection (Figure 16).  
3.1.3 Favored type III IFN response in human IECs 
Although type III IFN stimulation of hIECs results in significantly less induction of ISGs 
compared to type I IFN (Figures 11 and 14), we found that type III IFN was only slightly less 
potent in protecting the cells against viral infection (Figures 11 and 15). This lower induction 
of ISGs is not cell type specific as recent publications addressing the role of these IFNs in 
human hepatocytes and Burkitt's lymphoma derived B (Raji) cells also reported that type III 
IFN induces less ISGs compared to type I IFN165,189,237. However, in these studies, the 
antiviral potency of both IFNs was not addressed side-by-side. As such, type III IFN could be 
considered a milder IFN favored at epithelial surfaces (at least intestinal epithelium) due to 
its ability to confer an antiviral state without inducing excessive amounts of ISGs, which 
might result in the induction of local pro-inflammatory signals.  
3.1.4 MAP Kinase signaling pathways are required for type III but not type I 
IFN based antiviral protection in human IECs 
Functional characterization of type III IFN in comparison to type I IFN suggests that both 
cytokines are functionally redundant by mainly activating the same signaling cascade, 
leading to the up-regulation of the same pool of ISGs93,97,165,189,237,293,294. However, the 
restriction of type III IFN receptor to epithelial cells and the preferential type III IFN 
production at mucosal surfaces suggest that type III IFN might have unique functions or 
provide specific advantages at epithelial surfaces. Several studies have tried to unravel 
functional differences both in human (hepatocytes)165,189,293,294 and in murine model systems 
(lung and intestinal tract)76,79,80,93,97. In the liver, since the discovery of type III IFNs, extensive 
work has revealed that human hepatocytes can quickly become refractive to type I IFN, 
while maintaining their responsiveness to type III IFN322. Interestingly, two recent studies 
provide some new evidence for distinct roles of the type III IFN defense system also in the 
respiratory tract. First of all, Galani et al. have showed that upon influenza infection type III 
IFNs are the first IFNs produced to inhibit viral spread and if infection progresses, then type I 
IFNs come into play to reinforce viral inhibition by inducing pro-inflammatory responses99. In 
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addition, a preferential contribution of type III IFN system in the blockade of viral 
dissemination from the upper respiratory compartment to the lower (lungs) and in viral 
transmission among different animals has been described323  
However, as far as the GI tract is concerned, up to date the main difference between both 
IFNs has been explained by the spatial restriction of type III IFN receptor at IECs. In this 
work, we demonstrate that type III IFN induces less ISGs compared to type I IFN. Most 
importantly, we unravel, for the first time, fundamental differences in the molecular 
mechanisms by which both IFNs mount the antiviral state in hIECs. We demonstrate that the 
antiviral activity of type III IFN partially depends on MAPKs, which is not the case for type I 
IFN.  
Although, in recent years many studies have focused on defining the role of the MAP kinase 
pathway on the antiviral activity of type I IFNs, the results are controversial and their precise 
contribution is still under scrutiny. In particular, in human cell lines including hepatocytes, 
cervix epithelial cells and fibrosarcoma cells and in mouse embryonic cells a p38-dependent 
inhibition of virus replication upon HCV or EMCV infection in combination with IFN-α 
stimulation has been documented239,241. Similarly, p38-dependent IFN-β mediated blockade 
in influenza virus replication has been observed in human airway epithelial cells in vitro and 
in murine respiratory tract242. Nevertheless, it remains puzzling and needs to be further 
investigated not only the cell type specificity of the p38-dependent type I IFN antiviral 
activity, but also in which species (human or mouse) and cellular context this is true for the 
different subtypes of type I IFNs and the other members of the MAP Kinase family (ERK, 
JNK). In addition, taking into account that at least to our knowledge, the critical role of MAP 
kinase pathway on type III IFN antiviral activity has not been assessed in other studies, it is 
of great importance to be addressed in future reports whether the dependency of type III IFN 
for MAPKs is specific only for intestinal epithelial cells or for all epithelial surfaces. 
Furthermore, in our experimental model of human IECs or human mini-gut organoids, 
despite the preferential contribution of MAP kinases on the antiviral outcome of type III IFNs, 
we observed a significant activation of MAPKs with both IFNs. This is in line with recent 
publications addressing the activation status of MAPKs in human lymphoma cells, 
fibroblasts, keratinocytes and intestinal epithelial cells, also reported that MAPKs are 
activated upon stimulation with type I or type III IFN104,207,237. However, based on the above 
limited reports on type III IFN, it is speculated that different members of the MAPK family 
(p38, ERK or JNK) might be activated downstream type I or type III IFN in a cell dependent 
manner. In addition, taking into account that IFNs are pleiotropic cytokines, the type I IFN 
mediated MAPK activation may contribute to other functions of type I IFN apart from their 
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antiviral activity. In line, a role of p38 on the growth inhibitory function of type I IFN has been 
reported240. 
Moreover, the molecular mechanisms, which couple the activation of MAPKs with the IFN 
receptor are still unclear. For type I IFNs, the small GTPase RAC1 has been reported to 
serve as a crucial mediator324. Upon type I IFN treatment, JAKs activate VAV, which acts as 
a guanine-nucleotide-exchange (GEF) factor for RAC1325. Taking into account that VAV is 
expressed only in hematopoietic cells, it remains to be determined whether other cell 
specific GEFs serve as RAC1 activators and whether other molecular elements lead to 
MAPK activation downstream of type I IFN receptor in epithelial cell lines. In addition, as the 
above studies have focused only on type I IFNs, comparative analysis of MAPK activation 
downstream type I and type III IFN receptors needs to be conducted.  
In addition to the above open questions, the downstream targets of MAPKs, responsible for 
the antiviral activity of type III IFNs need to be identified. In our study, we demonstrated that 
the MAPK pathway acts independently of the JAK/STAT pathway upon type I or type III IFN 
stimulation. This is in agreement with publications showing that the MAPKs function in a 
STAT independent mechanism downstream type I IFN receptor236,241,324,326,327. However, an 
interaction between ERK2 and STAT1 upon type I IFN treatment has been reported in 
lymphocytes and it remains controversial, whether MAPKs can also induce STAT1 
phosphorylation on Ser727239,242. Various downstream targets of p38 such as MAPK-
activated protein kinase 2 (MAPKAPK2), MAPKAPK3, mitogen- and stress-activated kinase 
1 (MSK1), MSK2 and MAPK-interacting protein kinase 1 (MNK1) have been shown to be 
activated and might play important role in type I IFN responses328.  
Contrary to previous publications, in our experiments, it was difficult to draw a clear 
conclusion on the influence of MAPK inhibition on IFIT1 and Viperin expression, as it 
seemed to be dependent on the dose of the IFN used. Previous studies demonstrated a 
regulatory effect of MAPKs on the transcriptional activity of both IFNs, by showing a 
significant decrease in the expression levels of ISGs237. However, a possible explanation for 
this discrepancy might be a cell type or ISG dependent effect. Even more interestingly, 
Alase et al, reported an inhibitory effect of p38 or ERK blockade on ISG expression only in 
protein level104. As such, it remains an important task for future work to dissect how signaling 
downstream of MAPKs participates in the antiviral activity of type III IFN only.  
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3.2 Differential induction of interferon stimulated genes between type I 
and type III IFNs is independent of interferon receptor abundance 
The text of the following paragraph (3.2) has been adapted from Pervolaraki et al. (2018), 
under preparation. This corresponds to a first author manuscript under preparation resulting 
directly from my PhD research project.  
In this work, we have for the first time, performed a parallel study of the role of type I and III 
IFN in human IECs and mini-gut organoids. Our results demonstrate that type I and III IFNs 
are unique in their magnitude and kinetics of ISG induction. Type I IFN signaling is 
characterized by a relatively strong expression of ISGs and confers to cells a fast antiviral 
protection. On the contrary, the slow acting type III IFN mediated antiviral protection is 
characterized by a weak induction of ISGs in a delayed manner compared to type I IFN. Our 
results are in line with previous studies which also demonstrated that type III IFN is less 
potent than its type I IFN counterpart39,165,189,237,292–294,309. Additionally, we have confirmed 
that the delayed ISG induction seen upon type III IFN treatment of hepatocytes165,189,293,294  is 
not tissue specific but likely represents a global pattern of action of this cytokine in cells 
expressing the type III IFN receptor (i.e. human epithelial cells). In other words, the different 
kinetics of ISG expression induced by type I and type III IFNs are specific and intrinsic to 
each IFN signaling pathway. 
3.2.1 Mathematical modeling characterizes key differences of ISG response to 
type I versus type III IFNs 
In the current work, we have employed, a data-driven mathematical modeling approach to 
explain signal transduction kinetic differences downstream type I and type III IFN receptors. 
While type I IFN-mediated signaling has been previously modeled329,330, type III IFN has not. 
Our model predicted that the receptor levels directly influence the magnitude of ISG 
expression however, the kinetics of ISG expression appear to be intrinsic to each IFN-
signaling pathway and is largely preserved under receptor overexpression. This prediction 
was experimentally validated by studying the response of wild-type and IFN receptor 
overexpressing cells to different doses of IFN (Fig 38 and 39). We propose that these 
phenotypic differences reflect functional differences, which are important for mounting a 
well-tailored antiviral innate immune response at mucosal surfaces where type III IFN 
receptors are expressed.  
We also compared the kinetic properties of the active IFNAR1 versus IFNLR1. Our model 
suggested less potency of the IFNLR1 compared to the IFNAR1 that was supported by the 
  Discussion 
 89 
well identified and bounded confidence bounds of the IFNLR1 efficacy factor (S1A Figure). 
The model also suggests that the IFNLR1 has longer half-life compared to the IFNAR1 
which may explain its ability to induce a sustained ISG activation. By computing the 
confidence bounds of the IFNAR1 and IFNLR1 inactivation rate we show that this is a 
statistically significant prediction. Finally, the model predictions about the IFNAR1 and 
IFNLR1 become more credible when we show that our model is also able to explain the 
relative overexpression of the IFNAR1 versus IFNLR1 in the receptor-overexpression 
experiments (Figure 39). Altogether, this data-driven mathematical modeling and 
experimental validation approach provides strong evidence that the fundamental differences 
between IFNAR1 versus IFNLR1 mediated ISG expression cannot be explained only by 
changing the IFN receptor abundance. This suggests that the kinetic differences in the ISG 
induction are intrinsic to each IFN signaling pathway. 
3.2.2 IFN receptor level affects the magnitude of ISG response 
 Both type I and III IFNs have unique and independent receptors which are structurally 
unrelated. These receptors are likely expressed at different levels on individual cells and 
their relative expression to each other might also be cell type specific75,80. To address 
whether the unique ISG and antiviral expression kinetics shown by each IFN were not due to 
differences in their expression levels, we overexpressed into cells functional type I 
(rIFNAR1) and type III IFN (rIFNLR1) receptors. Our results from IFNAR1 overexpressing 
cells (Figures 35 and 38) are in line with previous studies showing a direct relationship 
between the surface levels of type I IFN receptors and the magnitude of ISG induction331,332. 
Interestingly, we could demonstrate a similar relationship when overexpressing IFNLR1 
(Figures 35 and 38), which was also associated with an increase of type III IFN antiviral 
potency (Figure 36G). These findings are in agreement with previous experiments which 
show that overexpression of IFNLR1 in cells which normally do not express this IFN receptor 
rescues both type III IFN-mediated signaling and IFN-mediated antiviral protection 39,237. In 
line, a linear relationship between the endogenous transcript levels of type III IFN receptors 
and type III IFN-mediated responses in different cell lines has been illustrated75,237,292,333,334. 
Interestingly, there are two recent studies demonstrating that the endogenous type III IFN 
receptor levels can be elevated through blockade of histone deacetylases (HDACs) in a cell 
type specific manner or by induction of cell polarization in mouse IECs, promoting in turn the 
responsiveness of cells only to type III FNs309,335. Although, these are interesting observation 
and indicate the previously unrecognized importance of cellular epigenetic status in IFN 
receptor expression regulation, there are not in agreement with our results in human ICEs 
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and mini-gut organoids (data not shown) and further investigation is required to conclude 
whether these observations are species or cell specific.  
Apart from the expression levels of IFN receptors, lower binding affinity towards their 
respective receptors could be an alternative explanation for the differential potencies of both 
type I and type III IFNs145. Multiple studies have tried to affect the binding affinity of type I 
IFNs with their receptors however; results suggest that wild-type I IFNs exert their antiviral 
activities already at maximum potency. Modifications leading to an increased affinity for their 
receptors do not lead to improvement of antiviral potency151,181,332,336,337. To address whether 
the weaker activity of type III IFN could be the result of its weaker affinity for its receptor, 
Mendoza et al, engineered a IFNλ3 variant with higher-affinity for the type III IFN receptor. 
They showed increased IFN signaling and antiviral activity in comparison with the wild-type 
IFNλ3. However, the engineered variant of IFNλ3 was still acting with weaker efficacy 
compared to type I IFNs181. This is similar to our results, where although we observed a 
significant increase of the amplitude of ISG expression and of the antiviral activity of type III 
IFNs in IFNLR1 overexpressing cells, the overall potency of type III IFN does not reach that 
of type I IFN. 
3.2.3 Temporal differences between type I and type III IFN mediated 
responses are not influenced by the IFN receptor level  
As far as the comparative analysis of type I versus type III mediated kinetic patterns of ISGs 
expression is concerned, our results indicate a model were inherent temporal differences 
exist between type I and type III IFNs signaling. Our IFN receptor overexpression approach 
in combination with mathematical modeling demonstrate that these differences are not the 
result of differential surface expression of the receptors but is the result of distinct signaling 
cascades from the receptors to the nucleus or within regulatory mechanisms of gene 
expressions. 
While few studies have focused on the endocytosis and inactivation of IFNAR1, there is no 
information about how these processes occur for IFNLR1. It has been shown that the ternary 
IFNAR complex is internalized by clathrin-mediated endocytosis167,168. Additionally, IFNAR1 
has been shown to serve as the critical player in the mechanism of internalization and 
degradation of the ternary IFNAR complex167–170. Our data-driven mathematical modeling 
approach suggests a longer half-life of the activated IFNLR1 compared to the IFNAR1 
receptor (Figure 32). Therefore, further studies investigating trafficking of IFNLR1 will be 
important and may show that subtle changes in the time course of receptors internalization, 
recycling or degradation can have profound effect on kinetics of IFN activity.  
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Apart from receptor internalization and degradation, several molecular mechanisms leading 
to IFN receptor inactivation have been described, such as de-phosphorylation182,183, or by 
negatively targeting the interaction of IFNAR1 with downstream signaling elements of the 
JAK/STAT signaling, for instance ubiquitin-specific protease USP18185  and members of the 
suppressor of cytokine signaling protein (SOCS) family191–193. However limited information is 
available for negative regulators of IFNLR receptor complex162,195,207. Additionally, there is a 
lack of direct and temporal comparisons of these negative regulatory mechanisms in type I 
versus type III IFN signaling activity.  
In the canonical type I and III IFN signaling pathway the next downstream players from the 
IFN receptors are the JAKs, STAT1, STAT2 and IRF9, which are all regulated on the level of 
expression and activation. Data not shown and previous studies could not explain the major 
differences in the kinetics of type I versus type III IFNs activity by focusing on the time 
course of phosphorylation of STAT1 and STAT2189,293. However, apart from the ISGF3 
complex (STAT1:STAT2:IRF9), not only homodimers of STAT1 or STAT2  but also 
heterodimers of  STAT1 or STAT2  with the other members of the STAT family (STAT3 , 
STAT4, STAT5 and STAT6), have been reported to participate in type I IFN signaling in a 
cell type dependent manner203,208,328. In addition, alternative modifications of STATs (e.g. 
phosphorylation on alternative residues, acetylation, methylation and sumoylation patterns 
or un-phosphorylated forms) have been proposed to contribute to the activity of type I 
IFNs165,215,226–228,338 it might be possible that new modifiers of STAT activity may determine 
the kinetic pattern of action of type I versus type III IFNs. For instance, type I and type III IFN 
induced formation of the un-phosphorylated ISGF3 (U-ISGF3) complex, containing un-
phosphorylated STAT1 and STAT2 together with IRF9, has been shown to mediate 
prolonged expression of a set of ISGs339–341. In addition, apart from the JAK/STAT axis, there 
is accumulating evidence which correlates ISG transcription upon IFN treatment with a 
plethora of JAK-STAT independent pathways, such as members of the CRK208,209,235 and 
MAPKinase family100,104,207,236,237, which might also temporally coordinate IFNs kinetic profile 
of action.  
The next step in the classical type I and type III IFN signaling cascade takes place in the 
nucleus and involves the interaction of the ISGF3 complex with promoter elements of 
hundreds of ISGs, responsible for the IFN activity. Currently, an emerging field in the 
regulation of IFN responses focuses on epigenetic modifications. Importantly, by 
investigating the regulation of type I IFN response in the nucleus, recent studies have 
identified a number of different chromatin modifiers, which interact with the promoters of 
ISGs247,250,252,257,259 together with the coordinated activity of multiple other transcriptional 
factors224,269,270. However, there is no information available for chromatin remodeling and 
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epigenetic modification downstream the type III IFN receptor signaling cascade in human 
epithelial cells. For this, further work in this area is necessary to understand the sequence of 
events shaping the type I IFN signaling cascade in the nucleus and compare it with type III 
IFNs qualitatively and quantitatively. Last but not least, apart from the differences in the 
signaling cascade of type I versus type III IFNs, an explanation for their differential kinetics 
of action might stem from the physiology of the different cell types. For example, in a recent 
study Bhushal et al. reported that polarization of mouse intestinal epithelial cells eliminates 
the kinetic differences between type I and type III IFNs, by accelerating type III IFN 
responses309,310.  
3.2.4 Functional advantages for the differential pattern of ISG induction 
between type I and type III IFNs 
Several studies describing the transcriptional activities of both type I and type III IFNs have 
reported that very similar sets of ISGs are produced upon both type I and type III IFN 
stimulation93,97,165,189,237,293,294, while only few ISGs appear to be predominantly expressed 
upon type III IFN treatment in murine IECs310. Here, we confirmed that almost the same 
ISGs are induced with both IFNs, but there are significant quantitative differences in the 
amplitude and the kinetic pattern of the establishment of the transcriptional activity of type I 
versus type III IFN. We believe that there are several functional advantages for adopting a 
lower and slower activity, like the profile of action of type III IFN, in the antiviral protection of 
epithelial tissues. The differences in the temporal expression of ISGs could create unique 
antiviral environments for each IFN. Many ISGs function as pro-inflammatory factors342–344. 
By stimulating ISGs production in high magnitude, an excessive amount of antiviral and pro-
inflammatory signals could be produced which on the one hand will eliminate efficiently viral 
spreading but on the other hand may cause local exacerbated inflammation and irreversible 
tissue damage, leading to chronic inflammation in mucosal surfaces.  
In addition, the expression of different functional groups of ISGs at early and at late time 
points (Figures 27 and 28) might allow cells to create two distinct phases within the antiviral 
response. At early time points, minimum levels of ISGs may act to protect the host against 
viral infection. Antiviral ISGs will be responsible for fighting the pathogens and pro-
inflammatory ISGs will stimulate members of the adaptive immune system to assist the 
antiviral protection. Our results show that very low levels of ISG transcriptional up-regulation 
is sufficient to fight pathogens in human IECs and show that type III IFN confers similar or 
even better protection against viruses at low concentration compared to type I IFN (Figure 
23A and data not shown). However, the produced ISGs at later time points, may be involved 
in anti-inflammatory processes, such as resolving of inflammation and tissue healing and 
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repair104,107. To exert this anti-inflammatory role, ISGs may need to be produced in higher 
levels, as they might act more paracrine and spread through the tissue to balance again the 
tissue homeostasis after the viral attack.  
Apart from the well-known pro-inflammatory aspects and the systemic side effects related to 
type I IFNs342,345,346, a new unique role for type III IFN in shaping the immune responses has 
recently been emerging109,343. Significant immune-modulatory properties for type III IFN have 
been already demonstrated in mucosal surfaces (e.g. skin, lung, GI tract and liver) and 
involve not only the production and secretion of anti-inflammatory factors, which in turn act 
directly on the epithelium but also, as an indirect phenomenon, the establishment and 
promotion of an intercommunication between epithelial cells and tissue specific immune 
cells86,87,107,342,347. This is clearly illustrated by the characteristic example of neutrophils in the 
lung and the intestinal tissue89,99. These recent studies have paved the way for the discovery 
of the unique involvement of type III IFNs in the resolution phase of inflammation and 
maintenance of the barrier functions of mucosal tissues89,99,104,107,348. This is of great 
importance for the complex environment at mucosal sites, where a wide range of different 
highly specialized cell types (e.g. epithelial cells, goblet cells, neuroendocrinocytes, stem 
cells, tissue specific immune cells and cells of lamina propria) co-exist together with a variety 
of micro-organisms (commensal bacteria, viruses, fungi and pathogenic microorganisms) in 
a fine-tuned balance. 
In conclusion, we propose that type III IFN-mediated signaling is not only set to act 
predominantly at epithelium surfaces due to the restriction of its receptor but also is 
specifically tailored to mount a distinct immune state compared to other IFNs which is critical 
for mucosal surfaces that face the challenge. 
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3.3 General conclusions and perspectives 
It is currently believed that type I and III IFNs have redundant functions. However, the 
preferential distribution of type III IFN receptor on epithelial cells suggests functional 
differences at epithelial surfaces. Here, we utilized human mini-gut organoid cultures to 
delve into the antiviral properties of type I versus type III IFNs in the human gut. We reported 
that although primary human IECs produce transcript levels for both IFNs, they secrete only 
type III IFNs upon viral infection. However human IECs respond to both IFNs, by 
independently establishing a differential antiviral state. First of all, contrary to type I IFN, the 
antiviral activity induced by type III IFNs is strongly dependent on the MAPK signaling 
pathway. In addition, we showed that while type I IFN signaling is characterized by an acute 
strong induction of ISGs and confers fast antiviral protection, type III IFN mediated antiviral 
protection is based on a slow weak induction of ISGs. Combining data-driven mathematical 
modeling with experimental validation, we demonstrated that these kinetic differences are 
intrinsic to each signaling pathway and not due to different expression levels of the 
corresponding IFN receptors. 
Considering our results that only type III IFN is secreted by hIECs and based on the distinct 
antiviral environment that type III IFN creates, it is tempting to propose that IECs have 
evolved to favor type III IFN over type I, as it allows for efficient protection against pathogens 
while limiting production of ISGs. From the perspective of an epithelium, which is always 
exposed to the extracellular environment and commensal challenges, this might represent a 
“smart strategy” to regulate the immune response in order to achieve the balance between 
responsiveness to pathogens versus tolerance of commensals. Restricting signaling to type 
III IFNs allows for spatial segregation of the response ,as type III IFN signaling is restricted 
mostly to epithelial cells75,77–80,97, thereby limiting systematic inflammation. 
In perspective, from our findings in epithelial cells of the gastrointestinal tract, we can 
speculate that the first response to pathogen threats will be generated by hIECs. This 
response will be mediated by type III IFNs, characterized by a moderate and delayed peak 
of transcriptional activity, leading to limiting ISGs and pro-inflammatory cytokine production. 
This first wave response of type III IFN produced by IECs, alone might be enough to clear 
enteric virus infection80,99,287. A second wave response might be generated through 
recruitment of immune cells at the site of epithelium infection, which in turn will produce 
various cytokines including type I IFN. This IFN will then mediate a fast and strong induction 
of ISGs and pro-inflammatory signals to powerfully combat pathogen at the infected mucosa 
and also will provide systemic protection. This uniquely tailored response would be 
fundamental for the maintenance of human gut homeostasis.  
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Figure 40. Fine tuning of type I versus type III IFN response in epithelial cells of the 
gastrointestinal tract. Upon infection of the intestinal epithelial cells, type III IFNs are produced by 
human IECs and induce a moderate and delayed induction of ISGs, responsible for eliminating viral 
replication without causing excessive production of pro-inflammatory cytokines. This first line of type 
III IFN dependent defense is mediated through the JAK/STAT and the MAPkinases signaling 
cascade. A second line of antiviral protection is generated by type I IFNs, induced mainly by immune 
cells. In turn type I IFNs act on epithelial cells generating a fast and strong ISG response, responsible 
for eliminating viral replication but also for causing immunopathology. Adapted from Andreakos et al 
(2017)
343
. 
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4 Materials and methods 
4.1 Materials 
4.1.1 General chemicals, media, enzymes and reagents 
Chemicals and reagents not listed below are described at the methods part (4.2) together 
with the methods for which they were used. 
Table 2: List of chemicals, media, enzymes and reagents 
Name Manufacturer 
30% Acrylamide/Bis-acrylamide solution (37.5:1) Carl Roth 
Agarose Standard Carl Roth 
Albumin Standard Thermo Scientific 
Ammonium Persulfate (APS) Carl Roth 
Ampicillin (100 mg/mL) Carl Roth 
Antibiotic-Antimycotic (Anti-Anti) Gibco
TM
/Invitrogen 
Avidin-HRP 1000x BioLegend 
A-83-01 Tocris 
β-Mercaptoethanol Sigma-Aldrich 
Bovine Serum Albumin New England Biolabs
TM
 
BsmbI New England Biolabs
TM
 
Bromophenol Blue AppliChem 
B-27 Invitrogen 
Collagen (from rat tail) Sigma-Aldrich 
Complete protease inhibitor cocktail EDTA-free Roche 
DAPI Sigma 
DC Protein Assay Kit I Bio-Rad 
dNTP set (100 mM) Thermo Fisher Scientific 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco
TM
/Invitrogen 
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F-12) (1:1) (1X) 
Gibco
TM
/Invitrogen 
DMSO (Dimethyl Sulfoxide), anhydrous Life Technologies 
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Enhanced chemiluminescence (ECL) film 
(Amersham Hyperfilm ECL) 
GE Healthcare 
Enhanced chemiluminescence (ECL) Western Blotting 
reagents 
GE Healthcare 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Ethanol Thermo Fisher Scientific 
Ethidium bromide solution (10 mg/mL) Carl Roth 
Fetal Bovine Serum (FBS) Superior Biochrom AG 
Gateway BP-Clonase Enzyme Mix II Thermo Fisher Scientific 
Gateway LR-Clonase Enzyme Mix II Thermo Fisher Scientific 
Gel Loading Dye, purple, 6x New England Biolabs
TM
 
GlutaMax Gibco
TM
/Invitrogen 
HEPES Invitrogen 
Human IL-6 ELISA MAX
TM
 Standard Sets BioLegend 
Human recombinant R-spondin Produced in HEK293 cells 
Human recombinant IFN-beta1a (IFNβ) Biomol 
Human recombinant IFNλ1 (IL-29) Peprotech 
Human recombinant IFNλ2 (IL28A) Peprotech 
Human recombinant IFNλ3 (IL-28B) Cell signaling 
Iscove’s Modified Dulbecco’s Medium (IMDM) Gibco
TM
/Invitrogen 
Isopropanol Carl Roth 
Kanamycin (50 mg/mL) Carl Roth 
LB agar and medium powder Carl Roth 
[Leu15]-Gastrin I Sigma-Aldrich 
Matrigen BD-bioscience 
Methanol Sigma-Aldrich 
Mouse recombinat Epidermal Growth Factor (EGF) Invitrogen 
Mouse recombinat Noggin Peprotech 
NEBuffer 3.1 New England Biolabs
TM
 
Nicotinamide Sigma-Aldrich 
Nitrocellulose membrane (Amersham Hybond ECL) GE Healthcare 
  Materials and methods 
 98 
Non-Essential Amino Acids (NEAA) Gibco 
Non-fat dried milk powder AppliChem 
N-acetyl-cysteine Sigma-Aldrich 
N-2 Invitrogen 
PenStrep (Penicillin Streptomycin) Gibco
TM
/Invitrogen 
Phosphate buffered saline (PBS) Sigma-Aldrich 
PhosphoSTOP phospatase inhibitor coctail Roche 
Phusion HF buffer (5x) Thermo Fisher Scientific 
Phusion hot start II DNA polymerase Thermo Fisher Scientific 
Proteinase K Thermo Fisher Scientific 
Precision Plus Protein Dual Colour Bio-rad 
ProLong Gold Antifade Mountain with DAPI Molecular Probes 
2-Propanol Sigma 
Puromycin (10 mg/ml) Sigma 
Pyridone-6 (pJAKi) Calbiochem 
Quick-Load 1 kb DNA ladder New England Biolabs
TM
 
SB202190 (p38i) Tocris 
SOC Outgrowth medium New England Biolabs
TM
 
Sodium chloride Carl Roth 
Sodium dodecyl sulfate (SDS) Carl Roth 
SP600125 (JNKi) Tocris 
SsoAdvanced Universal SYBR Green Bio-Rad 
TEMED Carl Roth 
TMB High Sensitivity Substrate Solution BioLegend 
Trypsin – EDTA 0,25% and 0,05% Gibco by Life Technologies, 
T4 DNA Ligase Reaction Buffer, 10x New England Biolabs
TM
 
Tris base Sigma-Aldrich 
TritonX-100 Sigma-Aldrich 
Tween 20 MP Biomedical 
U0126 (ERKi) Cell Signaling 
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Western Bright Chemiluminescent Substrate Sirius Biozym 
Wnt3A Produced in L929 cells 
Y27632 Sigma-Aldrich 
β-mercapoethanol Sigma-Aldrich 
 
4.1.2 4.1.2 Media and buffers 
Table 3: List of media and buffers 
Name Composition 
Advanced Dulbecco’s Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F-12)(1:1) 
for organoid media 
Advanced DMEM/Ham’s F-12 
10 mM HEPES 
1 x GlutaMAX 
1% (v/v) PenStrep 
Blocking solution (western blot) I Nonfat dried milk powder 5% (w/v) 
1 x TBS-T  
Blocking solution (western blot) II BSA 5% (w/v) 
1 x TBS-T  
Blotting buffer (western blot) 25 mM Tris base, 
190 mM Glycine 
Culture medium for HEK293T human embryonic kidney 
cells cells 
IMDM, 
1°% (v/v) FBS 
1% (v/v) 100 U/mL PenStrep 
Culture medium for T84 coloncarcinoma cells DMEM/F-12 
10% (v/v) FBS 
1% (v/v) PenStrep 
Basal Culture medium for human intestinal & colon 
organoids 
Advanced DMEM/F-12 
50% (v/v) Wnt3a conditioned media 
20% (v/v) R-Spondin conditioned media 
1 x B-27 
1 x N-2 
500 nM A-83-1 
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50 ngr/ml EGF 
10 nM Gastrin 
2 mM GlutaMAX 
10 mM HEPES 
1 mM N-acetyl-cystein 
10 mM Nicotinamide 
100 ngr/ml Noggin  
1 x PenStrep 
10 μM Sb202190 
ELISA coating buffer 8.4 g NaHCO3 
3.56 g Na2CO3 
in 1L H2O 
ELISA reagent diluent/block 1% BSA 
1x PBS 
ELISA stop solution 2N (1M) H2SO4 
ELISA wash buffer 0,05% Tween 20 
1x PBS 
Laemmli buffer (4x) 200 mM Tris base (pH 6.8) 
8% (w/v) SDS 
40% (v/v) glycerol 
4% (v/v) β-mercapoethanol 
0.08% (v/v) bromphenol blue 
LB agar (pH 7.0) 10 g LB agar powder 
150 mL H2O 
LB medium (pH 7.0) 12,5 g LB medium powder 
500 mL H2O 
Phosphate buffered saline (PBS) 10x 137 mM NaCl 
2,7 mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4 
in H2O 
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RIPA 150 mM sodium chloride 
1% (v/v) Triton X-100 
0.5% (w/v) sodium deoxycholate 
0.1% (w/v) SDS 
50 mM Tris base (pH 8.0) 
Complete protease inhibitor  
PhosphoSTOP phospatase inhibitor  
SDS-Tris-Glycine buffer (1x) 
 
25 mM Tris base 
200 mM Glycine 
0.1% (w/v) SDS 
SDS-PAGE seperation gel buffer (4x) 1.5 M Tris base (pH 8.8) 
0.4% (w/v) SDS 
SDS-PAGE seperation gel (12%) 3.6 ml 30% Acrylamide/Bis-acrylamide 
solution  
3.15 ml millipore H2O 
2.25 ml running gel buffer 
75 ul APS (10% w/v) 
15 ul TEMED 
SDS-PAGE stacking gel buffer (4x) 0.5 M tris base (pH 8.8) 
0.4% (w/v) SDS 
SDS-PAGE stacking gel (5%) 0.5 ml 30% Acrylamide/Bis-acrylamide 
solution  
1.75 ml millipore H2O 
0.75 ml seperation gel buffer 
25 ul APS (10% w/v) 
5 ul TEMED 
SOC medium 2.66% (w/v) SOB-medium powder 
20 mM D-(+)-Glucose 
TBE buffer (0.5%) 50 mM Tris-base 
50 mM Boric-acid 
1 mM EDTA-Na2 
TBS 50 mM Tri-HCL, pH 7.5 
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150 mM NaCL 
TBS-T 50 mM Tri-HCL, pH 7.5 
150 mM NaCL 
0.1% Tween 
Transfer buffer 20 mM Tris-base 
160 mM Glycine 
20% methanol 
Tris-borate EDTA (TBE) running buffer 5x (agarose gel 
electrophoresis) 
60,5 g Tris base 
31 g H3BO3 
3,7 g EDTA 
in H2O 
 
4.1.3 Antibodies 
Table 4: List of primary antibodies 
Antibody Source Species Application 
Anti-β actin Sigma (#A5441) monoclonal mouse WB: 1:5,000 
Anti-E-cadherin BD (#610181) monoclonal mouse IF: 1:100 
Anti-EF2 Santa Cruz (# sc-13004) polyclonal goat WB: 1:3,000 
Anti-ERK Cell signaling (#4695) polyclonal rabbit WB: 1:1,000 
Anti-IFIT1 Abnova (#H00003434-DO1) polyclonal rabbit WB: 1:1,000 
Anti-IRF1 Cell signaling (#8478) polyclonal rabbit WB: 1:1,000 
Anti-Mucin-2 Santa Cruz (#sc-15334) polyclonal rabbit IF: 1:100 
Anti-MxA 
Georg Kochs-Freiburg, 
Germany 
monoclonal mouse WB: 1:1,000 
Anti-p38 Cell signaling (#8690) polyclonal rabbit WB: 1:1,000 
Anti-phospho p38 Cell signaling (#4511) polyclonal rabbit WB: 1:1,000 
Anti-phospho ERK1/2 Cell signaling (#4370) polyclonal rabbit WB: 1:1,000 
Anti-phospho-SAPK/JNK Cell signaling (#4668) polyclonal rabbit WB: 1:1,000 
Anti-phospho-STAT1 BD (#612233) monoclonal mouse WB: 1:1,000 
Anti-SAPK/JNK Cell signaling (#9258) polyclonal rabbit WB: 1:1,000 
Anti-STAT1 BD (#610115) monoclonal mouse WB: 1:1,000 
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Anti-Syn Santa Cruz (#sc-17750) monoclonal mouse IF: 1:100 
Anti-ZOI Invitrogen (#339100) monoclonal mouse IF: 1:100 
Anti-μNS GenScript, USA monoclonal mouse WB, IF: 1:1,000 
 
Table 5: List of secondary antibodies 
Antibody Source Species Application 
anti-mouse IgG Alexa Fluor 568 Invitrogen 
(A-11004) 
polyclonal goat IF: 1:1,000 
anti-mouse IgG Alexa Fluor 647  Invitrogen 
(A-21235) 
polyclonal goat IF: 1:1,000 
anti-rabbit IgG Alexa Fluor 568 Invitrogen 
(A-11011) 
polyclonal goat IF: 1:1,000 
anti-rabbit IgG Alexa Fluor 647  Invitrogen 
(A-21244) 
polyclonal goat IF: 1:1,000 
ECL anti-goat IgG HRP Jackson 
(#705-035-
147) 
polyclonal donkey WB: 1:5,000 
ECL anti-mouse IgG HRP GE-
Healthcare 
(NA931) 
polyclonal sheep WB: 1:5,000 
ECL anti-rabbit IgG HRP GE-
Healthcare 
(NA934) 
polyclonal donkey WB: 1:5,000 
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4.1.4 Primer 
Table 6: List of primer sequences used for qRT-PCR analysi 
 Gene 
Symbol 
Forward primer (5’-3’) Reverse primer (5’-3’) 
#1 ARID3A CCACGGCGACTGGACTTA GCTGAACAAGTCATCCAGGAAT 
#2 BLZF1 CATTAACAAATCACAAGTTGGCAAA TGCAGAATTCAACTGTTGATGG 
#3 CBFB GCGAGTGTGAGATTAAGT AGAGACAGATTGGTTCCT 
#4 CEBPD ACTTACCACCACTAAACTGC TGTACCTTAGCTGCATCAAC 
#5 CREB3L3 TTTAGCTGCTGGAAAGATGG TCCACGTGTCTCAGGATG 
#6 CSDA TTCTCGCCACCAAAGTCCTTG TTCTTCTTGATGGCAGTCTGATGT 
#7 CXCL10 TGAAATTATTCCTGCAAGCCAA GACATCTCTTCTCACCCTTCTTT 
#8 DRAP1 ACATCCCACCTGAAGCAG ATCCATGTGGTTGTCTTCC 
#9 EGR1 CAGCACCTTCAACCCTCAG AGCGGCCAGTATAGGTGATG 
#10 EGR2 GCTGACACGGCACATCC ACAGTAGTCACAGGCGAAGG 
#11 ELF1 TGTCATGCTGCAGTCACAAA ACTGCGAGGAGAAAAGGTCA 
#12 ELK4 CTGGTGCCAAGACCTCTAGC TCGGCTGGATTCTCAGTCTT 
#13 ETS2 TCTGCCTCAATAAGCCAACC TAAACTCCCATCCGTCTCCA 
#14 ETV6 AAGCCCATCAACCTCTCTCA CCATCGGATGAAGTTTTCGT 
#15 ETV7 AAGAACCGGGTGAACATGAC TTGTCCTGGACCATCTTTCC 
#16 EWSR1 TAGGATATGGACAGAGTAAC GTAGAGGAATAGCTGGTAG 
#17 FUBP1 ACGCTTTCAAAGATGCACTG TTTTTGTCCCCCATAACCAT 
#18 GBP1 CTATGAGGAACCGAG CACGTTCCACTTCAATCTCC 
#19 HDAC2 AGCATCAGGATTCTGTTACGTTAATGA CAACACCATCACCATGATGAATATCT 
#20 HIF1A GCTATTTGCGTGTGAGGAAAC CACCATCATCTGTGAGAACCA 
#21 HPRT1 CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA 
#22 IFIT1 AAAAGCCCACATTTGAGGTG  GAAATTCCTGAAACCGACCA 
#23 IFITM3 GATGTGGATCACGGTGGAC AGATGCTCAAGGAGGAGCAC 
#24 IFNAR1 CACTGACTGTATATTGTGTGAAAGCCA
GAG 
CATCTATACTGGAAGAAGGTTTAAGTGATG 
#25 IFNAR2 ATTTCCGGTCCATCTTATCAT ACTGAACAACGTTGTGTTCC 
#26 IFN-β GCCGCATTGACCATCTAT GTCTCATTCCAGCCAGTG 
#27 IFN-λ2/3 GCCACATAGCCCAGTTCAAG  TGGGAGAGGATATGGTGCAG 
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#28 IL10RB TTGCTGTGGTGCGTTTACAAG CTTTCAGGTGCTGTGGAAGAGA 
#29 IFNLR1 ACCTATTTTGTGGCCTATCAGAGC CGGCTCCACTTCAAAAAGGTAAT 
#30 IRF1 CCAAGAGGAAGTCATGTG TAGCCTGGAACTGTGTAG 
#31 IRF4 ATCACAGCTCACGTAGAA ATAGAGGAATGGCGGATA 
#32 IRF8 GGCATTCTCGGAGGAGTAGA GTTACAGCATCCAGGCCATC 
#33 JUN GAGGACCGGAGACAAGTG CCTTCTTCTCTTGCGTGG 
#34 JUNB CATACACAGCTACGGGATAC TTTGAGACTCCGGTAGGG 
#35 MAFB GACGCAGCTCATTCAGCAG CCGGAGTTGGCGAGTTTCT 
#36 MAFF GATTGAGAGATACAGAGCCG CTAGCTTTGAATCCTGGGAG 
#37 MAX AACCGAGGTTTCAATCTGC GGGATGCCTTCTCTCCTTG 
#38 MYC GATTCTCTGCTCTCCTCGAC CTTGTTCCTCCTCAGAGTC 
#39 MXA GAGCTGTTCTCCTGCACCTC CTCCCACTCCCTGAAATCTG 
#40 NFIL3 AATGCAGACCGTCAAAAAGG AGCAGCTCCTCACCTGTTGT 
#41 NFE2 AGCTGCAGGGTCTGAATG CAGAATCTGGGTGGATTGAG 
#42 NPAS2 AGGAGCTGGCTCTGGAAGAC CCGAGGTTCCAGGCTTGAG 
#43 RASD1 CAAGACCGGGGAGAATACCTG GCGAGAATGTCCAAATACTCACC  
#44 REO (μ2) GTGTACACCACGACGGACAG TCAACCCCACTCATGACAAA 
#45 RELA TATCAGTCAGCGCATCCAGACCAA AGAGTTTCGGTTCACTCGGCAGAT 
#46 SMAD3 AGCAATATTCCAGAGACC GCAGGTCCAAGTTATTATG 
#47 SMAD4 TTACCATCATAACAGCACTA CAAGCTCATTGTGAACAG 
#48 SOCS3 GCGAGGATCCTGGTGACA CCAGGATGGTTCCCTTCAG 
#49 SREBF1 ACTTCTGGAGGCATCGCAAGCA AGGTTCCAGAGGAGGCTACAAG 
#50 TBP TGCACAGGAGCCAAGAGTGAA CACATCACAGCTCCCCACCA 
#51 TCF7L2 CATATGGTCCCACCACATCA CACTCTGGGACGATTCCTGT 
#52 TEAD4 ATGATCATCACCTGCTCCAC GTCCATTCTCATAGCGAGCA 
#53 TLR3 TTGTCTTCTGCACGAACCTGCGC  AACGCAAGGATTTTATT  
#54 TRIM21 TGGAGACCTTTAGGGGGTTT TGAGCGGAAACTGAAAGTGA 
#55 TRIM22 GGATGCCAGCACGCTCATCTCAG TTCAGCATCACGTCCACCCAGTAGT 
#56 TRIM25 AACATCTCTCAAGGCCAAGGT AGATGCCTACCCCACAGAAGT 
#57 USP18 ATGTGAGCCAGGCACGAT TCCCGACGTGGAACTCAG 
#58 VIPERIN GAGAGCCATTTCTTCAAGACC  CTATAATCCCTACACCACCTCC  
#59 ZFP36L2 CTTGATAGTTAGCCCTCAGC CCAAGTAACCAGTATGGACC 
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Table 7: List of primers used in predesigned 384 well assay qRT-PCR 
  Gene 
Symbol 
RefSeq Accession No   Gene 
Symbol 
RefSeq Accession No 
#1 ADAR NC_000001.10, NG_011844.1, NT_004487.19  #45 IL15 NC_000004.11, NT_016354.19  
#2 B2M NC_000015.9, NG_012920.1, NT_010194.17  #46 IL6 NC_000007.13, NG_011640.1, NT_007819.17  
#3 BAG3 NC_000010.10, NG_016125.1, NT_030059.13  #47 IRF1 NC_000005.9, NG_011450.1, NT_034772.6  
#4 BST2 NC_000019.9, NT_011295.11  #48 IRF2 NC_000004.11, NT_016354.19  
#5 CASP1 NC_000011.9, NT_033899.8  #49 IRF3 NC_000019.9, NT_011109.16  
#6 CAV1 NC_000007.13, NT_007933.15, NG_012051.1  #50 IRF5 NC_000007.13, NT_007933.15, NG_012306.1  
#7 CCL2 NC_000017.10, NG_012123.1, NT_010799.15  #51 IRF7 NC_000011.9, NT_009237.18  
#8 CCL5 NC_000017.10, NG_015990.1, NT_010799.15  #52 IRF9 NC_000014.8, NT_026437.12  
#9 CD70 NC_000019.9, NT_011255.14  #53 ISG15 NC_000001.10, NT_004350.19  
#10 CD80 NC_000003.11, NT_005612.16  #54 ISG20 NC_000015.9, NT_010274.17  
#11 CD86 NC_000003.11, NT_005612.16  #55 JAK1 NC_000001.10, NG_023402.1, NT_032977.9  
#12 CDKN1B NC_000012.11, NG_016341.1, NT_009714.17  #56 JAK2 NC_000009.11, NG_009904.1, NT_008413.18  
#13 CIITA NC_000016.9, NG_009628.1, NT_010393.16  #57 MAL NC_000002.11, NT_022171.15  
#14 CRP NC_000001.10, NG_013007.1, NT_004487.19  #58 MET NC_000007.13, NT_007933.15, NG_008996.1  
#15 CXCL10 NC_000004.11, NT_016354.19  #59 MNDA NC_000001.10, NT_004487.19  
#16 DDX58 NC_000009.11, NT_008413.18  #60 MX1 NC_000021.8, NG_027788.1, NT_011512.11  
#17 EIF2AK2 NC_000002.11, NT_022184.15  #61 MX2 NC_000021.8, NT_011512.11  
#18 GBP1 NC_000001.10, NT_032977.9  #62 MYD88 NC_000003.11, NG_023225.1, NT_022517.18, 
NG_016964.1  
#19 GUSB NC_000007.13, NG_016197.1, NT_007933.15  #63 NMI NC_000002.11, NT_005403.17  
#20 HLA-A NC_000006.11, NT_007592.15, NT_113891.2, 
NT_167244.1  
#64 NOS2 NC_000017.10, NG_011470.1, NT_010799.15  
#21 HLA-B NC_000006.11, NG_002397.2, NG_023187.1, 
NT_007592.15, NT_113891.2,  
#65 OAS1 NC_000012.11, NT_009775.17, NG_011530.1 
    NT_167246.1, NT_167247.1, NT_167248.1, 
NT_167249.1  
#66 OAS2 NC_000012.11, NT_009775.17  
#22 HLA-E NC_000006.11, NT_007592.15, NT_113891.2, 
NT_167245.1, NT_167246.1, 
#67 PML NC_000015.9, NT_010194.17  
     NT_167247.1, NT_167248.1, NT_167249.1  #68 PRKCZ NC_000001.10, NT_004350.19  
#23 HLA-G NC_000006.11, NT_007592.15, NT_113891.2, 
NT_167245.1, NT_167246.1,  
#69 PSME2 NC_000014.8, NT_026437.12  
    NT_167247.1, NT_167248.1, NT_167249.1  #70 RPLP0 NC_000012.11, NT_009775.17  
#24 HPRT1 NC_000023.10, NG_012329.1, NT_011786.16 #71 SH2D1A NC_000023.10, NT_011786.16, NG_007464.1  
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#25 IFI16 NC_000001.10, NT_004487.19  #72 SHB NC_000009.11, NT_008413.18  
#26 IFI27 NC_000014.8, NT_026437.12  #73 SOCS1 NC_000016.9, NT_010393.16  
#27 IFI30 NC_000019.9, NT_011295.11  #74 STAT1 NC_000002.11, NG_008294.1, NT_005403.17  
#28 IFI6 NC_000001.10, NT_004610.19  #75 STAT2 NC_000012.11, NT_029419.12  
#29 IFIH1 NC_000002.11, NG_011495.1, NT_005403.17  #76 STAT3 NC_000017.10, NT_010783.15, NG_007370.1  
#30 IFIT1 NC_000010.10, NT_030059.13  #77 TAP1 NC_000006.11, NG_011759.1, NG_028165.1, 
NT_007592.15, NT_113891.2, NT_167244.1,  
#31 IFIT2 NC_000010.10, NT_030059.13      NT_167245.1, NT_167246.1, NT_167247.1, 
NT_167248.1, NT_167249.1  
#32 IFIT3 NC_000010.10, NT_030059.13  #78 TBP1 NC_000006.11, NT_025741.15, NG_008165.1 
#33 IFITM1 NC_000011.9, NT_009237.18  #79 TICAM1 NC_000019.9, NT_011255.14  
#34 IFITM2 NC_000011.9, NT_009237.18  #80 TIMP1 NC_000023.10, NG_008437.1, NG_012533.1, 
NT_079573.4  
#35 IFITM3 NC_000011.9, NT_009237.18  #81 TLR3 NC_000004.11, NG_007278.1, NT_016354.19  
#36 IFNA1 NC_000009.11, NT_008413.18  #82 TLR7 NC_000023.10, NG_012569.1, NT_167197.1  
#37 IFNA2 NC_000009.11, NT_008413.18  #83 TLR8 NC_000023.10, NG_012882.1, NT_167197.1  
#38 IFNA4 NC_000009.11, NT_008413.18  #84 TLR9 NC_000003.11, NT_022517.18  
#39 IFNAR1 NC_000021.8, NT_011512.11  #85 TMEM1
73 
NC_000005.9, NT_029289.11  
#40 IFNAR2 NC_000021.8, NG_012089.1, NT_011512.11, 
NG_016003.1  
#86 TNFSF1
0 
NC_000003.11, NT_005612.16  
#41 IFNB1 NC_000009.11, NT_008413.18  #87 TRAF3 NC_000014.8, NT_026437.12, NG_027973.1  
#42 IFNE NC_000009.11, NT_008413.18  #88 TYK2 NC_000019.9, NG_007872.1, NT_011295.11  
#43 IFNW1 NC_000009.11, NT_008413.18  #89 VEGFA NC_000006.11, NG_008732.1, NT_007592.15  
#44 IL10 NC_000001.10, NG_012088.1, NT_167186.1     
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4.2 Methods 
The text of part 4.2 has been adapted from Pervolaraki et al. (2017)100 and from Pervolaraki 
et al. (2018), under preparation.  
4.2.1 Cell culture, viruses and viral infection 
4.2.1.1 Culture of human cell lines 
T84 human colon adenocarcinoma cells (ATCC CCL-248) were maintained in a 1:1 nutrient 
mixture of Dulbecco’s modified Eagle’s medium (DMEM) and F-12 supplemented with 10% 
fetal bovine serum (FBS) and 1% (100 U/ml) penicillin and 1% (100 μg/mL) streptomycin. 
SKCO15 human colon adenocarcinoma cells were a kind gift from Prof. Asma Nusrat, 
Department of Pathology, University of Michigan and maintained in DMEM with 10% FBS, 
1% penicillin/streptomycin, 15 mM HEPES and 1% Non-Essential Amino Acids (NEAA). 
Caco2 human colon adenocarcinoma cells (ATCC HTB 37) were maintained in DMEM with 
10% fetal bovine serum and 1% penicillin/streptomycin. T84, SKCO15 and Caco2 cells were 
cultured in collagen coated T25 flasks and split in 1:2 ratio every 3-4 days by treatment with 
0.25% Trypsin/EDTA. HEK293T human embryonic kidney cells (ATCC) were cultured in T75 
cell culture flasks using Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 
10% FBS and 1% penicillin/streptomycin. All mammalian cells were cultured at 37oC and 5% 
CO2. 
4.2.1.2 Culture of human colon and intestinal mini-gut organoids 
Human colon and intestinal tissue was received from colon resections from the University 
Hospital Heidelberg, Germany and human ileum and jejunum were purchased from Baylor 
University, USA. The resected tissue was washed several times with ice-cold PBS 
containing 1 x Antibiotic-Antimycotic (Anti-Anti) and stem cells containing crypts were 
isolated following 2 mM EDTA dissociation of tissue sample for 1 hour at 4°C, with rocking. 
Crypts were spun and washed in ice-cold PBS. Fractions enriched in crypts were 
resuspended in Matrigel and maintained in Advanced DMEM/F-12, supplemented with 
penicillin/streptomycin, HEPES, Wnt3A, B-27, N-2, GlutaMax, EGF, R-Spondin, Noggin, 
Gastrin, N-acetyl-cysteine, nicotinamide and A-83-01 (basal organoid medium). 24 hours 
post-isolation, the open crypts were resealed and round organoid structures were apparent. 
Medium was changed every 2-3 days and for the first two days post isolation, the Rho–
associated coiled-coil containing protein kinase (ROCK) inhibitor Y-27632 (10 μM) was 
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added to the basal organoid culture medium. Organoids were split every 7-10 days by 
passaging the Matrigel containing organoids through a 271⁄2 gauge needle several times. 
Differentiation media is the same as above except without Wnt3A, nicotinamide and 50% 
reduced levels of R-Spondin and Noggin24,349,350.  
Ethics Statement 
Human gut tissue was received from colon and small intestine resection from the University 
Hospital Heidelberg, Germany. All subjects gave written informed consent in accordance 
with the Declaration of Helsinki. All samples were received and maintained in an 
anonymized manner. The protocol was approved by the “Ethic commission of University 
Hospital Heidelberg” under the approved study protocol S-443/2017. Human ileum and 
jejunum were purchased from Baylor University, USA and transferred by signed MTA. 
4.2.1.3 Viruses and viral infection 
VSV-Luc was a kind gift from Sean Whelan (Harvard Medical School) and was produced as 
previously described351. An MOI of 1 was used to infect T84 cells and organoids. Titers were 
determined as previously described352. Reovirus MRV strains Type 3 clone 9 derived from 
stocks originally obtained from Bernard N. Fields were grown and purified by standard 
protocols120. For T84 cell MRV infections, MRV was purified on CsCl-gradient and stocks 
were titred by fluorescence foci forming assay (expressed in FFU) in T84 cells. Titers were 
calculated by determining the 50% tissue culture infective dose and expressed in FFU/mL. 
T84 cells were infected as previously described120. The MOI was determined as the ratio of 
infected cells (determined by fluorescence foci forming assay)/total number of cells. An MOI 
of 1 was used in T84 based experiments resulting in about 50–60% of infected as 
determined by fluorescence assay. For mini-gut organoids MRV infection, organoids were 
removed from Matrigel by adding cold-PBS for 5 min, liquefied Matrigel and organoids were 
separated by centrifugation (400xg 5 min), the total number of cells per organoid samples 
was measured using an haematocytometer. Organoids were resuspended in culture medium 
containing or not MRV. When using an MOI of 1 (as determined in T84 cells) to infect mini-
gut organoids, very few infected cells were detected per organoid. This discrepancy between 
T84 and organoid infectivity might be due to the 3-dimensional nature of the organoids and 
to residual Matrigel that might absorb and neutralize MRV. As such MRV stocks were titred 
directly in organoids by serial dilution infection and subsequent immunostaining. The MOI 
was calculated by the ratio of the number of infected/total number of cells/organoid. An MOI 
of 0.5 was used to infect organoids.  
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4.2.2 Cloning and generation of stable cells lines 
4.2.2.1 Cloning and generation of IFN receptor KO cell lines  
Knockouts of IFNAR1 and IFNLR1 in T84 cells were achieved by using the CRISPR/Cas9 
system. Three different single-guide RNAs (sgRNAs) per gene were used to target the 
coding region of IFNAR1 and IFNLR1 and inserted into the lentiviral vector lentiCRISPR v2 
(Addgene #52961) also encoding the Cas9 nuclease. The following sgRNAs were used: 
IFNAR1 (#1) 5′ GCGGCTGCGGACAACACCCA 3′, (#2) 5′ GACCCTAGT- GCTCGTCGCCG 
3′, (#3) 5′CTAGGGTCGTCGCGCCCAGG3′,IFNLR1(#1) 5′ACTGGATCTGAAGTATGAGG3′, 
(#2) 5′CC TGGTGCTCACCCAGACGG3′ (#3) 5′ TGAGGTGGCATTCTG GAAGG 3′. 
Lentiviruses were produced and T84 cells were transduced two times using 1:2 diluted 
stocks of lentiviral particles encoding sgRNA #1, 2 or 3. Data at Figure 16 were obtained by 
using a cell clone treated with the sgRNA #2 for IFNAR1 and IFNLR1 and analogous results 
were obtained with cell clones generated with the other sgRNAs (Figure 17). 36 hours post-
transduction, transduced cells were selected for using puromycin for 2-3 weeks and then 
used for experiments. To establish IFNAR1 and IFNLR1 KO cells, clonal selection was 
performed via single-cell dilution in a 96-well plate. KOs were confirmed by sequencing and 
functional tests. 
4.2.2.2 Cloning and generation of IFN receptor overexpressing cell lines 
For back-compensation of the IFN receptor KO cell lines and for generation of wild-type T84 
cells overexpressing the IFNAR1 and IFNLR1, plasmids containing the cDNA of IFNAR1 
and IFNLR1 were obtained from a gateway compatible ORF bank (pENTRY221-IFNAR1) 
and from GE Healthcare (pCR_XL_TOPO_IFNLR1, #MHS6278-213246004), respectively. 
Caspase-cleavage resistant IFNAR1 and IFNLR1 were generated using the Quick Change II 
XL site directed mutagenesis kit (Agilent Technologies, Germany), following manufacturer’s 
instructions. Point mutations were controlled by plasmid sequencing. The expression vectors 
were generated by inserting the respective constructs into the lentiviral vector pDest GW35 
by using the Gateway cloning technology (Life Technologies, Germany) according to 
manufacturer’s instructions. Lentiviruses were produced and T84 cells were transduced two 
times using concentrated stocks of lentiviral particles encoding the cleavage resistant 
IFNAR1 and IFNLR1. 36 hours post-transduction, transduced cells were selected for using 
blasticidin. 
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4.2.2.3 Production and use of lentiviral vectors  
Hek293T cells with a low passage number were cultured in 10 cm dishes until 80-90% 
confluence. After reaching the appropriate confluence, medium was changed and the cells 
were transfected with a transfection mixture of 4 μg pMDG.2, 4 μg psPAX2 and 8 μg of the 
expression vector containing the construct of interest using polyethylenimine (PEI). The 
Transfection mixture was added dropwise to cells and culture medium was exchanged the 
next day. After three days, virus containing supernatant was harvested, centrifuged at 
4,000xg for 10 minutes and filtered (Millex-HA, 0.45μm, Millipore, SLHA033SS). Purified 
virus was concentrated by ultracentrifugation at 134,000 rcf in an SW40 Ti rotor (Beckman-
Counter) at 4oC  for 2 hours and stored at -80 °C.  
For transduction of T84 cells with lentivirus, 300,000 cells per well were seeded in a 6-well 
plate and 20-40 μl of the concentrated lentivirus stock was added in 3 ml of cell culture 
medium together with 10 μg/ml polybrene. After two days, cells were transduced for second 
time with the same mixture of lentivirus stock and polybrene and two days later, the medium 
was replaces with selection medium containing the appropriate antibiotic (10 μgr/ml 
puromycin or blasticidin). Cells were cultured in selection medium for 2-3 weeks, before 
being used for experiments. 
4.2.3 Cell biology techniques and protein biochemistry 
4.2.3.1 Protein extraction 
At time of harvest, media was removed, cells or mini-gut organoids were rinsed one time 
with 1 x cold PBS and lysed with 1 x RIPA buffer. Cells were incubated at 4oC for 20 
minutes. Afterwards, lysates were collected and centrifuged at 12,000xg  for 20 minutes at 
4oC. Supernatant was transferred to a new tube and protein concentration was determined 
using the DC Protein Assay Kit I (Biorad), according to the manufacture’s instructions. 
Absorption was measured at a wavelength of 750 nm using the Biorad iMark microplate 
reader and protein concentration was calculated by using the BSA standard curve. 
4.2.3.2 Western blot (WB) 
Lysates of equal protein amounts (6-12 μg, depending on the experiment) were 
supplemented with Laemmli buffer, boiled at 95oC for 10 minutes, spun down at 12,000xg for 
1 minute and separated by Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). Proteins were separated according to their electrophoretic mobility in 8-12% 
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SDS-PAGE gels at 100V. For immunoblotting, proteins were transferred to a nitrocellulose 
blotting membrane with 0.45 μm pore size (GE Healthcare) by wet-blotting at 100V for 1.5 
hour in pre-cooled transfer buffer by using the Bio-Rad Tank blot system. After blotting, 
membranes were blocked for 1-2 hours shaking at room temperature in TBS containing 
0.1% Tween 20 (TBS-T) with 5% milk or 5% BSA, when the phospho antibodies were used.  
Primary antibodies were diluted in blocking buffer and incubated overnight at 4°C. 
Membranes were washed 4 x in TBS-T for 15 minutes at RT. Secondary antibodies were 
diluted in blocking buffer and incubated at RT for 1 hour with rocking. Membranes were 
washed 4 x in TBS-T for 15 minutes at RT. For protein visualization, HRP detection reagent 
(ECL Western Blotting Detection Reagents or Western Bright Chemiluminescent Substrate 
Sirius) was mixed 1:1 and incubated at RT for 3-5 minutes. Membranes were exposed to 
high performance chemiluminescence films (GE healthcare) and developed. Quantitative 
immunoblot analysis was performed using Fiji. 
4.2.3.3 Indirect Immunofluorescence (IF) assay  
T84 cells were seeded in a 24-well plate were fixed in 2% paraformaldehyde for 20 minutes 
at RT, washed with PBS and permeabilized using 0.5% Triton X-100 for 15 minutes. After 
blocking with 3% BSA in PBS for 1 hour at RT, cells were incubated with primary antibodies 
in 3% BSA for 1 hour at RT. After washing with PBS, cells were stained with secondary 
antibodies in 3% BSA for 45 minutes at RT. To stain human mini-guts, organoids were 
embedded in optimal cutting temperature (OCT) compound (Tissue-Tek) and cryosectioned 
using the Leica CM1950 (Leica) cyrostat. 10 μm cryosections were fixed in 80% ethanol for 
10 minutes at RT, followed by a 2 minute incubation in ice-cold acetone. After blocking in 5% 
goat serum in PBS containing 1% Triton for 1 hour at RT, sections were incubated with 
primary antibodies in blocking solution for 2 hours at RT or overnight at 4°C. After washing in 
PBS, sections were stained with secondary antibodies in 1% BSA in PBS containing 0.5% 
Triton for 2 hours at RT. Nuclear DNA was stained with ProLong Gold DAPI. Slides were 
imaged by epifluorescence using a Nikon Eclipse Ti-S (Nikon) microscope or by confocal tile 
scans on a Zeiss LSM 780 (Zeiss) microscope. Image processing was performed using the 
Fiji software. For infection experiments, the percentage of infected cells was determined by 
counting at least 600–1,000 cells detected in 10 fields of view for each condition.  
4.2.3.4 VSV luciferase assay 
Luciferase activity was measured as read out for VSV-Luc replication.  T84 cells were 
seeded in a white F-bottom 96-well plate (Greiner bio-one) 1 day prior experiment. Cells or 
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organoids were pre-treated prior to infection or treated post-infection as indicated with 
increasing concentrations of type I or type III IFNs. VSV-Luc was added to the wells and the 
infection was allowed to proceed for 8 hours. At the end of the infection, media was 
removed, cells and organoids were washed 1 x with PBS and lysed with luciferase cell Lysis 
Buffer (Promega) at RT for 20 minutes. A 1:1 dilution of Steady Glo (Promega) and Lysis 
Buffer were added to the cells and organoids and incubated at RT for 15 minutes. 
Luminescence was measured using an Omega microplate Luminometer reader (BMG-
Labtech). 
4.2.3.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
Supernatant from cells and organoids was collected at the indicative time points and 
centrifuged at 12,000xg at RT to remove cellular debris. IFNβ contained in the supernatant 
was quantified by using the human IFN-beta ELISA kit (PBL-Interferon Source) according to 
manufacturer’s instructions. IFN-λ 2/3 was analyzed by using the VeriKine-DIYTM human 
IFN-λ 2/3 (IL-28A/28B) ELISA kit (Pestka Biomedical Laboratories) and all volumes were 
adjusted to fit to a half-area assay plate. Briefly, the plate was incubated over night with the 
capture antibody (2 μg/ml anti-IFNλ in reagent diluent at 4°C) and blocked at room 
temperature for 1 hour with vertical shaking at 200 rpm. 50 μl of cytokine standards and 
samples were loaded on the plate and incubated at RT for 2 hours with vertical shaking at 
200 rpm. The biotinylated detection antibody was diluted to 100 ng/ml in reagent diluent and 
incubated at RT for 2 hours with shaking at 200 rpm. After incubation with Avidin-HRP 
(diluted 1:1000, BioLegend) was performed for 20 minutes. Between each step, three 
washes with ELISA washing buffer were performed. Lastly, 50 μl of mixed A and B (1:1) 
TMD substrate solutions (BioLegend) were added to each well, the plate was incubated in 
the dark until the standard curve was clearly visible in blue and the reaction was stopped by 
adding 20 μl of 2 N Sulfuric acid (H2SO4). The final absorbance was measured at 450 nm 
on a Bio-Rad iMark microplate reader. 
4.2.4 mRNA analysis 
4.2.4.1 RNA purification and cDNA-synthesis  
Purification of total RNA from cells or mini-gut organoids was performed using the 
NucleoSpin RNA extraction kit (Macherey-Nagel) as per manufacturer’s instructions. In 
summary, cell lysates were passed through a DNA elimination column and the flow through 
was mixed with 70% ethanol, added to a RNeasy spin column, allowing RNA binding to the 
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membrane. Columns were washed with two buffers of decreasing salt concentration and 
RNA samples were eluted in 40-60 μl nuclease free water and stored at -80oC for further 
analysis. RNA concentration was determined by measuring the absorbance at 260 nm with 
the NanoDrop Lite spectrophotometer (Thermo Scientific). For cDNA generation, 50-200 ng 
of total RNA was reverse transcribed using the iScriptTM cDNA Synthesis kit (BioRad) 
according to the manufacture’s instructions using the following reaction: 
Table 8: Components of cDNA synthesis reaction 
Component  Volume (μl) 
iScript reaction buffer 4 
Reverse transcriptase 1 
RNA template  15 
 
Components were mixed together and reverse transcription was performed according to the 
following program using the thermal cycler (Biorad): 
Table 9: Thermal cycler program for cDNA synthesis 
Step Temperature (°C) Time (min) 
Priming 25 5 
Reverse transcription 42 30 
Reverse transcription 
termination/Termination 
85 5 
 
4.2.4.2 Quantitative real time polymerase chain reaction (qRT-PCR) 
Following cDNA-synthesis, the resulting cDNA was diluted 1:1 with nuclease free water 
before proceeding to the quantitative real time polymerase chain reaction (qRT-PCR). qRT-
PCR was performed in 96-well format using Sso Advanced Universal SYBR Green 
Supermix (Bio-Rad) with the following reaction per well: 
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Table 10: Components of the qRT-PCR reaction 
Component  Volume (μl) 
SsoAdvanced Universal SYBR Green 
Supermix 
7,5 
Primer reverse (2 μM) 1,9 
Primer forward (2 μM) 1,9 
Millipore H2O 1,7 
cDNA (1:2 diluted) 2 
 
The reaction was performed using the Bio-Rad CFX96 Real-Time PCR Detection System 
with the following settings: 
 
Table 11: Program for qRT-PCR 
Step Temperature (°C) Time Number of 
cycles 
Activation 95 30”  
Melting 95 5” 40 
Primer annealing and 
Elongation 
60 30” 40 
Plateread    
Melting curve 
generation 
    65       5”  
+0,5°C/cycle to 95°C 
 
The obtained data were then analyzed with the Bio-Rad CFX Manager 3.0 using HPRT1 
and/or TBP as housekeeping genes to normalize mRNA expression. The data obtained by 
qRT-PCT were calculated as relative expression levels (ΔΔCq) normalized to input mock 
sample of initial time point. 
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4.2.4.3 Gene expression analysis of interferon stimulating genes 
T84 cells and mini-gut organoids were treated with 2000 RU/ml of type I IFN (β) or 100 ng/ml 
-treatment 
as described above. For the gene expression analysis of interferon stimulated genes (ISGs), 
qRT-PCR was performed using the predesigned 384-well assay of type I IFN response for 
use with SYBR Green assaying the expression of 87 ISGs (Biorad # 10034592). The 
expression of 45 additional ISGs and transcriptional factors was analyzed by qRT-PCR with 
primer sets obtained as previously described353. The complete gene list monitored in this 
study and the primers used to amplify each gene are available in Table 5 and 6. Differential 
expression analysis of each treatment was performed by comparing the baseline expression 
of genes in an untreated control at each time point. Only genes which were either induced or 
reduced more than 2-fold in any of the samples were considered to be significantly 
regulated. These genes were either analyzed using scatterplots or visualized by a heatmap 
after sorting the fold change of expression in response to type I IFN (β) in decreasing order. 
All fold change values above 20 and below 0.05 were replaced with 20 and 0.05 respectively 
to center the heatmap around 0 (white) and to avoid errors in logarithmic calculations. When 
visualizing the expression peaks, only the highest value is shown per time point for each 
gene. All analyses were performed using R version 3.3.0 and 3.3.3 including the packages 
gplots and ggplot2. 
4.2.4.4 Microarray  
Total RNA was purified as described above from T84 cells treated with 2,000 RU/mL of type 
I IFN (β) or 100 ng/mL of each type III IFN (λ1−3) for 6 hours. Microarray data were 
processed using the software package R. Differentially expressed probe sets were 
determined by comparing the triplicate stimulated samples with the three unstimulated 
samples. Significance was defined by a minimum absolute of 2-fold change in expression 
and a q-value (false discovery rate) <0.05.  
4.2.5 Mathematical modeling  
Mathematical modeling has been performed by Soheil Rastgou Talemi, Heidelberg 
University and German Cancer Research Center (DKFZ). 
4.2.5.1 Model simulation and parameter estimation 
The mathematical model was implemented in terms of ordinary differential equations (ODEs) 
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in MATLAB 2016b (S1 Table). The numerical simulations were conducted using the 
CVODES, a module from SUNDIALS numerical simulation package, in the MATLB 
environment. The model was initially set to a steady state condition and most of the initial 
conditions were set (S2 Table). Only, the IFNLR efficacy factor was estimated using time-
resolved ISG expression data that we measured with different doses of type I IFN (β) or III 
IFN (λ1−3). All of the ISG expression data for the IFNAR1 and IFNLR1 overexpression 
experiments were reproduced only by fitting new initial values of IFNAR1 and IFNLR1 (S3 
Table). 
Parameter estimation was conducted by minimizing the weighted nonlinear least squares,  
wSSR = ∑ (
1
𝐴𝑣𝑒𝑟𝑎𝑔𝑒(yobserved_i)
) ∑ (ysimulation_i,j  −  yobserved_i,j)
2M
j=1
N
i=1 , 
of model simulations versus data points, j = 1, … , M, of different experiments, i = 1, … , N. 
The inverse of the average of every time-resolved experimental data was used as a 
weighting factor for fitting the corresponding data.  
4.2.5.2 Profile-likelihood analysis 
To assess the uncertainty in the estimated parameter values, we used the profile-likelihood 
method354. In this method, the parameter confidence bounds are calculated based on their 
contribution to the likelihoods, or in another word, the objective function (wSSR). This 
computational approach is conducted in a stepwise manner. In every step, the respective 
parameter is fixed at a new value distant from the optimum estimated one. Then, the new 
maximum likelihood is calculated (wSSRmin(θ)). Using this approach, we can calculate the 
profile of the maximum likelihoods over different values of the considered parameter. Then a 
threshold, Δα,  
 
∆𝜒2 = wSSRmin(θ) − wSSRmin(θoptimum), 
{θ|∆𝜒2 < ∆α}, 
 
is used to define the confidence bounds for the respective parameter. The threshold, Δα, is 
the α quantile of the chi-squared distribution.  
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4.2.5.3 Approximate 95% confidence bands calculation 
To investigate the effect of the parameter uncertainty on model predictions we calculated 
approximate 95% confidence bands, as explained in Seber and Wild355.  
 
Approx 95% confidence bands =  ysimulated  ±  tinvN−P
α ∙ √MSE ∙ (1 + S ∙ (S ∙ S)−1 ∙ S)
1
2 
 
where “tinvN−P
α ” is the α quantile of student's t distribution, “N” is the number of data points 
and “P” is the number of estimated model parameters, “MSE” is the mean standard error and 
“S" is the sensitivity matrix of the respective simulated observable.  
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6 Appendix 
6.1 List of abbreviations 
AP-1 activator protein-1 
BSA bovine serum albumin 
CARD caspase activation and recruitment domain 
cDC conventional dendritic cells 
CRISPR clustered regularly interspaced short palindromic repeats 
E-cad E-cadherin 
EGF epidermal growth factor 
ERK extracellular signal-regulated kinase 
FAE follicle-associated epithelium 
FBS fetal bovin serum 
GAS IFN-γ activated site 
GEF guanine nucleotide exchange factor 
HAT histone acetyltransferase 
HCV hepatitis C virus 
HDAC histone deacetylase 
HPRT hypoxanthine-guanine phosphoribosyltransferase 
IEC intestinal epithelial cells 
IEL intraepithelial lymphocyte 
IF immunofluorecence 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 
IFN interferon 
IFNR interferon recetor 
IL interleukin 
IRF interferon regulatory factor 
ISG interferon-stimulated gene 
ISGF3 interferon-stimulated gene factor 3 
ISRE interferon-stimulated response element 
JAK Janus kinase 
JNK c-Jun N-terminal kinase 
LB Lysogeny broth 
LGP2 laboratory of genetics and physiology 2 
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MALT mucosa-associated lymphoid tissue 
MAPK mitogen-activated protein kinase 
MAVS mitochondrial antiviral-signaling protein 
MDA5 melanoma differentiation-associated protein 5 
MNoV murine norovirus 
MOI multiplicity of infection 
MRV mammalian reovirus 
MXA  mx dynamin like GTPase 1 
MyD88 myeloid differentiation factor 88 
ng nanogram 
NFKB nuclear factor kappa-light-chain-enhancer of activated B cells 
NLR nucleotide-binding oligomerization domain-like receptors 
nM nanomolar 
OCT optimal-cutting-temperature 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffer saline 
pDC plasmacytoid dendritic cell 
PEI polyethylenimine 
PFA paraformaldehyde 
PIAS protein inhibitors of activated STAT 
PI3K phosphatidyl-inositol 3-kinase 
poly I:C poly-inosinic:cytidylic acid 
PRR pattern-recognition receptor 
PTP1B protein-tyrosine phosphatase 1B 
P38-MAPK p38-mitogen activated protein kinase 
qRT-PCR quantitative real-time Polymerase chain reactions 
RCF relative centrifuge force 
RIG-1 retinoic acid-inducible gene 1 
RLR retinoic acid-inducible gene-I-like receptor 
RNA ribonucleic acid 
Rpm round per minutes 
RT room temperature 
RU reactive units 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SHP-2 Src Homology phosphatase 2 
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SOC suppressor of cytokine signaling 
STAT signal transducer and activator of transcription 
Syn synaptophysin 
TAD transactivation domain 
TBP TATA-binding protein 
TBS Tris buffer saline 
TBK1 TANK-binding kinase 1 
TCPTP T cell protein-tyrosine phosphatase 
TLR toll-like receptor 
TRIF toll/interleukin 1-domain-containing adaptor-molecule 1 
TYK2 tyrosine kinase 2 
USP18 ubiquitin-specific protease 
VIPERIN virus inhibitory protein, endoplasmic reticulum associated, interferon-inducible 
VSV vesicular stomatitis virus 
WB Western blot 
WT wild type 
ZO-1 zonula occludens-1 
μNS reovirus non-structural protein 
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6.2 Supplementary figure 
 
 
Figure S1. Profile likelihoods of model parameters. The uncertainty of the estimated model 
parameters is calculated using profile likelihood method. (A) The solid blue line is the change in the 
weighted sum of squared residuals (∆𝛘𝟐), the filled circle indicates optimum parameter value and the 
solid red line indicates the 95% threshold calculated using 𝛘𝟐 distribution. (B) The 95% confidence 
bounds of type I or type III IFN receptor complex inactivation rate constants are calculated using 
profile likelihood method. Our calculations show that the type III IFN receptor complex inactivation 
rate constant (k4) is significantly less than the corresponding value of type I IFN receptor complex 
(k3). Modeling has been performed by Soheil Rastgou Talemi, Heidelberg University and German 
Cancer Research Center (DKFZ) 
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6.3 Supplementary tables 
The supplementary tables S1-S3 have been produced by Soheil Rastgou Talemi, 
Heidelberg University and German Cancer Research Center (DKFZ). 
 
S1 Table. Mathematical formulation of the model. 
ODEs model biological system dynamics Explanation 
d[RI]
dt
=  −Area ∙ k1 ∙ IFNβ ∙ RI IFNAR dynamics 
d[RI
∗]
dt
= Area ∙ k1 ∙ IFNβ ∙ RI − k3 ∙ RI
∗ ∙ ISG 
Activated IFNAR 
dynamics 
d[RIII]
dt
=  −Area ∙ k2 ∙ IFNλ ∙ RIII IFNLR dynamics 
d[RIII
∗]
dt
=  Area ∙ k2 ∙ IFNλ ∙ RIII − k4 ∙ RIII
∗ ∙ ISG 
Activated IFNLR 
dynamics 
d[pST]
dt
=  k5 ∙ (RI
∗ + RIII
∗) ∙ (1 − pST) − k6 ∙ pST 
Activated  STAT1/2  
dynamics 
d[ISG]
dt
=  k7 + k8 ∙ pST − k7 ∙ ISG 
ISG activation dynamics 
(Viperin) 
d[IFNβ]
dt
=  −k9 ∙ IFNβ IFN-β dynamics 
d[IFNλ]
dt
=  −k9 ∙ IFNλ IFN-λ dynamics 
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S2 Table. State variables and initial values. 
State variable Initial value Explanation 
IFN-β 8.30×10-7-0.33 nM Interferon beta 
IFN-λ 4.56×10-6-13.70 nM Interferon lambda 
RI 8.3×10
-4 nM 
Cellular IFNAR 
concentration1 
RI
* 0 nM 
Activated IFNAR 
concentration 
RIII EFIFNLR・RI-0 nM 
Cellular IFNLR 
concentration 2 
RIII
* 0 nM Activated IFNLR 
pST 0 #pST 
Activated/Phospho 
STAT1/2 (relative value 
between 0-1) 
ISG 1 #ISG 
Interferon stimulated 
Gene (relative value) 
 
1-The initial value is calculated assuming 103 IFNAR molecule per cell.  
2-The initial IFNLR value is calculated relative to the initial IFNAR level using the estimated 
IFNLR efficacy factor (EFIFNLR). 
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S3 Table. Estimated parameter values. 
Estimated 
parameters 
Estimated 
value 
Parameter 
bounds 
Dimension 
Respective 
reaction 
k1 8.45×10
3 
4.84×103 (cm2・min・
nM)-1 
IFNAR activation 
1.69×104 
k2 2.79×10
5 
6.89×103 (cm2・min・
nM)-1 
IFNLR activation 
2.24×106 
k3 0.051 
0.023 
min-1 IFNAR inactivation 
0.087 
k4 4.9×10
-4 
1.58×10-4 
min-1 IFNLR inactivation 
2.0×10-3 
k5 569.98 
389.30 
(min・nM)-1 STAT1/2 activation 
915.72 
k6 1.4×10
-3 
1.0×10-3 
min-1 STAT1/2 inactivation 
1.7×10-3 
k7 1.2×10
-3 
8.55×10-4 
min-1 Basal ISG activation 
1. 5×10-3 
k8 0.20 
0.17 #ISG・(#pST・
min)-1 
STAT mediated ISG 
activation 0.22 
k9 0.08 
0.04 
min-1 IFN inactivation 
0.14 
EFIFNLR 1.1×10
-3 
5.26×10-4 
# 
IFNLR efficacy 
factor (relative 
value) 1.9×10
-3 
OEIFNAR 3.05 - # 
IFNAR over-
expression factor 
OEIFNLR 1.67 - # 
IFNLR over-
expression factor 
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